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ABSTRACT 
DEFINING THE ROLE OF NEUROPILIN-2 IN TUMOR ASSOCIATED 
MACROPHAGES: IMPLICATIONS IN PANCREATIC CANCER 
SOHINI ROY 
University of Nebraska Medical Center, 2017 
 
Advisor: Kaustubh Datta, PhD. 
Macrophages are extremely heterogeneous and highly plastic hematopoietic cells that 
reside in all tissues and act as a bridge between the innate and adaptive arms of the 
immune responses. Besides, they undertake a wide array of housekeeping functions like, 
clearance of cellular debris that arise due to regular turnover in tissues, iron homeostasis, 
immune surveillance as well as tissue repair processes post inflammation. They are also 
causally associated with several clinical conditions, including cancer where the infiltration 
of macrophages contribute to disease progression, metastasis and therapy resistance, 
and thereby poor clinical outcome.  
Neuropilins (NRPs) are non-tyrosine kinase cell surface glycoproteins expressed in all 
vertebrates and widely conserved across species. The two isoforms, NRP1 and NRP2 are 
mainly known for their role as co-receptors for class III Semaphorins and for members of 
the vascular endothelial growth factor (VEGF) family of molecules. Both NRP1 and NRP2 
are overexpressed in many cancers, exert pleiotropic effects in various aspects of cancer 
pathobiology and correlate with the stage and grade of the disease and poor survival. 
Intriguingly, additional immunoregulatory roles for NRPs have been reported in myeloid 
and lymphoid cells, in normal physiological as well as different pathological conditions, 
including cancer, various immunological disorders, and bone diseases. In comparison to 
NRP1, the overall comprehensive function of NRP2 in macrophages and factors that 
govern those functions is not well known. Therefore, the enveloping goal of this 
dissertation is to comprehensively understand the role and function of NRP2 in 
macrophages and their implication in tumor associated macrophages in solid tumor. 
In the first part of the dissertation, we primarily investigated the expression pattern of 
NRP2 during the differentiation of macrophages under inflammatory (M1) and 
immunosuppressive (M2) polarizing conditions. We observed although NRP2 is not 
expressed at a detectable level in monocytes, its expression is upregulated during the 
differentiation of monocytes precursors to either M1 or M2 type mature macrophages. We 
identified a novel function of NRP2 in regulating phagocytosis in macrophages by 
modulating the levels of Rab5+ early phagosomes and Rab7+ late phagosomes. In NRP2 
depleted macrophages clearance of bacteria or yeast components was delayed and these 
cells exhibited elevated number or early phagosomes and decreased number of late 
phagosomes.  
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Since pancreatic cancer (PC) typifies the complex architecture of a tumor stroma and 
tumor associated macrophages are abundantly present here, the second part of the 
dissertation is aimed at elucidating the implication of NRP2 regulated phagocytosis in 
TAMs in this lethal disease. The expression NRP2 in TAMs in human and mouse PC 
tissues was assessed. Due to nutrient limiting conditions and rapid proliferation of tumor 
cells in the TME, many of the cancer cells undergo apoptosis. TAMs efferocytose these 
dying tumor cells, an event that polarizes them further to pro-tumoral type and contribute 
to relapse and therapy resistance. We observed that in the absence of NRP2, clearance 
of apoptotic cells was delayed. The implication of this observation in PC progression was 
tested using a subcutaneous tumor model. Upon depletion of NRP2 in TAMs, tumors were 
smaller. Of note, NRP2 depletion did not affect TAM recruitment to, or angiogenesis but 
recruited and activated anti-tumor CD8 cells into the TME. Further, RNA-Seq analysis of 
CD11b+ TAMs isolated from tumors indicated that many genes associated with either 
endosomal/phagosomal maturation, recycling and exocytosis, immune modulation and 
leukocyte recruitment and activation are deregulated following NRP2 depletion. Further, 
NRP2 depletion downregulated many of the immunosuppressive genes and cytokines in 
macrophages that may be important for either suppression of T cell response or induce 
Treg formation. The data further suggested that NRP2 is important for efferocytosis and 
maintaining TAM-like phenotype in intratumoral macrophages, thus helping to create a 
tumorigenic immunosuppressive environment in the TME.  
Taken together, studies in this dissertation document a requirement for NRP2 in 
macrophage phagocytosis. Further, regulation of efferocytosis in TAMs by NRP2 have 
implications in TAM functions and tumor progression. Hence, targeting NRP2 axis in TAMs 
may help re-engineer the immunosuppressive stroma in the TME and emerge as potential 
therapy in combination with chemotherapy or other adjuvant therapies.  
 
 
 
 
 
 
 
  
vii 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
Acknowledgement 
First and foremost, I want to express my heartfelt gratitude towards my mentor, Dr. 
Kaustubh Datta, who is one of my greatest inspirations. I cannot thank him enough 
for keeping faith in me and for believing that I can successfully complete my 
project. Training under his mentorship and learning to critically analyze and 
evaluate experiments under his guidance was one of the best things that happened 
in my scientific career. He also instilled in me the qualities to become a humble 
and polite human being. I hope all the training and qualities imbibed from him will 
help me go a long way in my life and I can become a passionate scientist and a 
fine human being like him. 
I would like to extend my gratitude to all my current and former lab members, for 
being so patient and supportive. I thoroughly enjoyed the scientific discussions that 
I often had with my lab members, and they helped me hone my scientific aptitude. 
I consider myself fortunate to be able to spend five years in a lab that felt like my 
second home. I want to thank Navatha for being a great friend and confidante. We 
have survived the highs and lows of graduate student life together and it helped 
make our bond stronger. I would also like to thank the former members of our 
neighboring lab, Dr. Michael Upchurch and Jana Opavska for being great friends.  
I want to specially thank all my supervisory committee members, Dr. Surinder K 
Batra, Dr. Rakesh Singh and Dr. Michael A. Hollingsworth. I am indebted to them 
for their precious time, constructive criticisms and positive inputs during my entire 
graduate studies. They have always motivated me to remain enthusiastic about 
my work and encouraged my ideas and opinions. It has been a privilege to train 
ix 
 
under fine scientific minds as them. I want to specially thank Dr. Singh for teaching 
us how to perform orthotopic pancreatic surgery in mouse. He was always 
available for scientific discussions and I learnt a great deal about animal 
experiments from him. Words are not enough to express my gratitude to Dr. James 
E. Talmadge. He introduced me to the intricacies of immunology and helped me 
with all the aspects of my projects. I also want to extend my thanks to my 
comprehensive examination committee members, Dr. Justin Mott, Dr. Parminder 
Mehta and Dr. Jixin Dong. They helped me improve my scientific writing skills and 
thinking. It was a great learning experience for me.  
I want to thank my family for their love, constant support and motivation. I want to 
start by thanking my husband. Mr. Rahul Bhattacharjee, who is also pursuing his 
PhD, in Kent State University, Ohio. He was always by my side during my 
professional and personal challenges. He always motivated me by saying that PhD 
is my dream and I must make it come true, no matter what challenges come our 
way. All the sacrifices he made, and all the little things he did for me, brought me 
closer to my goal. I want to thank him for being a part of this journey with me. 
Words are not enough to express my gratitude to my former lab member and my 
best friend and family, Dr. Arup K. Bag, for being a rock in my life. He has given 
unconditional support to me during all the tough times I encountered. He constantly 
pushed me to bring out the best in me. I want to thank him deeply for training and 
teaching me scientific skills and how to think critically. I thoroughly enjoyed the 
numerous though provoking scientific discussions I had with him. I never realized 
science could be so much fun until I worked with him. He has instilled in me a great 
x 
 
sense of professionalism and other qualities that helped me become a better 
human being. I want to thank my close friend and sister-in-law, Suranjana 
Goswami, for her unreserved love and support to me and my family. I want to thank 
my parents, Mr. Gour Roy and Mrs. Shelly Roy, for their unconditional love and 
support. This journey would not have been possible without their sacrifice, to 
provide me higher education, so that I can fulfil my dreams. I sincerely thank them 
for all the little things they have done for me. I hope I can continue to make them 
proud. I also want to express my gratitude towards my father-in-law, Mr. Amitava 
Bhattacharjee, and my mother-in-law, Mrs. Jharna Bhattacharjee, for their 
constant love and support. They have never failed to be my side in testing times, 
always infusing in me positive attitude and praying for my well-being.  A special 
thank you to my sister-in-law, Oindrila Bhattacharjee, for being more than a sister 
and bringing comic relief in our lives. All of them have made unconditional 
sacrifices to help make my dream come true and see me smile. I thank them with 
all my heart and soul; they are the reason I could finish my dissertation. I owe them 
for what I am today and it is only right that I share this credit with everyone who 
were a part of my journey. 
Last, but not the least, I want to thank one of my closest friends here, in Omaha, 
Dr. Kriti Bahl and her husband, Dr. Suprit Gupta. Kriti and I started our graduate 
life together, here, at UNMC. She could relate to all the highs and lows I went 
through and was always there whenever I needed her. I want to deeply thank her 
for giving me so many warm and fond memories, and that I am going to cherish all 
xi 
 
of them forever. This journey would not have been possible without her positive 
attitude and pep-talks.   
xii 
 
 
 
 
List of Figures 
 
Chapter I          Page 
Fig 1.1. Neuropilin (NRP) domain structure and splice variants                    22 
Fig. 1.2. Origin of monocytes in the bone marrow                                         24 
Fig. 1.3. Human monocyte subsets and their functions                                 26 
Fig.1.4. Mouse monocyte subsets and their functions                                   28 
Fig.1.5. Stimuli for M1/M2 type polarization of macrophages                        30 
 and the pathways associated 
Fig.1.6. Marker panel for M2 macrophages                                                   32 
Fig.1.7. Marker panel for M1 macrophages                                                   34 
Fig.1.8. Physiological roles of macrophages                                                            36 
Fig.1.9. Role of NRP2 in macrophages                                                         38 
Fig. 2.1. Origin of tumor associated macrophages                                        52 
Fig. 2.2. TAMs promote immune suppression in the                                     54 
tumor microenvironment 
Fig. 2.3. TAMs promote tumor cell intravasation                                           56 
Fig. 2.4. TAMs promote tumor metastasis                                                     58 
Fig. 2.5. Brief summary of different clinical trials to target TAMs                   60  
Fig. 2.6. TAMs are double-edged swords in cancer therapies                       62 
Fig. 2.7. TAMs after chemotherapy as predictor for patient outcome            64 
Fig. 2.8. Different approaches to target TAMs                                               66 
Fig. 2.9. Anatomy of the pancreas                                                                 85 
Fig. 2.10. Progression of PanIN lesions to Pancreatic                                   87 
Ductal Adenocarcinoma 
xiii 
 
Fig. 2.11. Different components of the desmoplasia associated with PDAC    89 
Fig. 2.13. Therapeutic agents and strategies to target TAMs                           91 
at different stages of pancreatic cancer pathogenesis 
Fig. 3.1. Find me and Eat me signals during efferocytosis                              108 
Fig.3.2. Phagosomal maturation during efferocytosis                                      110 
Fig.3.3. LC3 associated autophagy (LAP) during efferocytosis                       112 
Fig.3.4. Efferocytosis in cancer                                                                        114 
Chapter III 
Fig. 3.1 Expression of NRP2 in M2 type macrophages                                   160 
Fig. 3.2 Expression of NRP2 in M1 type macrophages                                   162 
Fig. 3.3 NRP2 regulates phagosome maturation in macrophages                  164 
without affecting uptake in human macrophages  
Fig. 3.4 NRP1 does not regulate phagosome maturation in macrophages     166 
Fig. 3.5 NRP2 regulates phagosome maturation in GM-CSF treated     
macrophages                                                                                                    168 
Fig. 3.6 NRP2 does not affect uptake of phagocytic cargo in                           170 
GM-CSF treated macrophages 
Fig. 3.7 Scheme for transgenic mouse generation and knock                          172 
out of NRP2 from macrophages 
Fig. 3.8 NRP2 regulates phagosome maturation in mouse macrophages        174 
Fig. 3.9 NRP2 does not significantly affect the uptake of phagocytic                176 
cargo in mouse macrophages 
Fig. 3.10 Effect of NRP2 depletion on bacterial clearance in vitro                    178 
 by macrophages 
Fig. 3.11 NRP2 affects zymosan clearance in vitro by macrophages               180 
Fig. 3.12 NRP2 inhibits phagosome maturation in human macrophages         182 
Fig. 3.13 NRP2 inhibits phagosome maturation in mouse macrophages          184 
Chapter IV 
Fig. 4.1 NRP2 is expressed by tumor infiltrating macrophages                        219 
xiv 
 
in pancreatic cancer 
Fig. 4.2 Expression of NRP2 in human and mouse TAMs                                221 
 generated in vitro 
Fig. 4.3 NRP2 regulates phagosome maturation in TAMs in vitro                    223 
Fig. 4.4 NRP2 regulates efferocytosis of apoptotic cells in bone                      225 
marrow derived macrophages 
Fig. 4.5 NRP2 regulates efferocytosis of apoptotic cells in                               227 
peritoneal macrophages 
Fig. 4.6 NRP2 regulates the clearance of apoptotic cells in TAMs in vitro        229 
Fig. 4.7 Scheme of subcutaneous tumor growth model                                    231 
Fig. 4.8 NRP2 in macrophages affects tumor progression                                233 
Fig. 4.9 Depletion of NRP2 in macrophages increases the necrotic                  235 
area in tumors 
Fig. 4.10 Effect of macrophage NRP2 depletion on TAM                                  237 
recruitment, angiogenesis and CD8+ T cell infiltration 
Fig. 4.11 NRP2 in macrophages regulates tumor growth                                  239 
Fig. 4.12. Effect of NRP2 depletion in macrophages on TAM                           242 
 recruitment, angiogenesis and α-SMA 
Fig. 4.13 NRP2 depletion in macrophages affects T cell response in tumor     244 
Fig. 4.14 Transcriptome analysis from CD11b+ cells by RNA-                         247 
Sequencing analysis 
Fig. 4.15 Analysis of differentially expressed genes using Ingenuity                249 
Pathway Analysis and DAVID functional annotation bioinformatics  
microarray analysis 
 
 
 
 
1 
 
 
  Chapter I 
  Introduction 
 
 
 
*A part of this chapter has been published under the title “Multifaceted Role of 
Neuropilins in the immune System: Potential Targets for immunotherapy” in 
collaboration with Sohini Roy, Arup K. Bag, Rakesh K. Singh, James E. Talmadge, 
Surinder K. Batra and Kaustubh Datta in Frontiers in Immunology. 
(https://doi.org/10.3389/fimmu.2017.01228). 
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1.1.1. Macrophages: A brief summary 
Macrophages belong to the mononuclear phagocytic system. They are the 
most plastic cell type among the hematopoietic family and extremely diverse in 
functions. Macrophages bridge the innate and adaptive arms of the immune 
response. They are also endowed with a variety of house-keeping functions, like 
clearance of cellular debris through phagocytosis, immune sentinel in tissues and 
priming adaptive responses as well as developmental processes, metabolism and 
homeostasis. Macrophages are also causally associated with various diseases, 
like diabetes, multiple sclerosis, autoimmunity, rheumatoid arthritis, asthma, 
atherosclerosis, as well as cancer. In the following sections, we will briefly 
summarize and discuss the development, different polarization states of 
macrophages and their role and function in normal physiology as well as some 
clinical conditions.  
1.1.2. Origin and different monocyte subsets 
Myelopoiesis starts in the yolk sac 3-4 weeks into gestation in human and 
embryonic day 8 in mice. Myeloid progenitors developing from the primitive 
ectoderm give rise to the embryonic macrophages. The first hematopoietic stem 
cell (HSC) seeds the fetal liver around 5weeks of gestation and expand and mature 
to erythroid, lymphoid and myeloid cells. Extra embryonic hematopoiesis stops at 
around 10-12 weeks into gestation in human and E12 in mice. The liver remains 
the primary site of hematopoiesis until birth in mice and week 20-24 of gestation in 
humans. The HSC from liver gradually colonize the thymus and spleen and finally 
the bone marrow just before birth in mice (and second trimester in human). The 
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HSC gives rise to monocytes through the granulocyte-macrophage progenitor 
(GMP), the macrophage-dendritic cell precursor (MDP) and common monocyte 
progenitor (CMP) intermediates, in a sequential manner (1). There are different 
monocyte populations in both mouse and human. In humans, monocytes can be 
divided into the following groups: a major population called the classical monocytes 
(CD14++CD16-), intermediate monocytes (CD14++CD16+) and a minor population 
called the non-classical monocytes (CD14+CD16++) (2). The classical monocytes 
express significant levels of CCR2 and CD62L, and low levels of CX3CR1 whereas 
the non-classical type expresses a high level of CX3CR1. Extensive transcript 
enrichment analyses have shown homology between Ly6ChiCX3CR1loCCR2hi (in 
mouse) and CD14++CD16- monocytes (in human) and between 
Ly6CloCX3CR1hiCCR2lo (in mouse) and CD16+ monocytes (in human) (3-5). 
During infection or injury, chemokines and pro-inflammatory cytokines released 
from the inflamed tissue induce the egress of monocytes from the bone marrow. 
The classical monocytes are targeted towards the site of infection where they 
differentiate to mature macrophages and either exhibit cell mediated cytotoxicity 
towards infected cells or can even migrate to the lymph nodes to prime DC or naïve 
T cells for adaptive immune responses (6). The non-classical monocytes which 
mainly patrol the endothelium, can also be recruited to sites of infection where they 
secrete TNF and other inflammatory cytokines (7). 
The tissue resident macrophages are heterogeneous, seed different tissues and 
are maintained by self-renewal. They can origin atleast from three different 
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sources: yolk sac derived macrophages, fetal liver monocytes or bone marrow, 
depending on the tissue and the stage of development (8). 
1.1.3. Macrophage polarization states 
 Macrophage polarization refers to the activation state of the cells at a given 
point of time under a certain condition. As mentioned earlier, macrophages are 
highly plastic in nature and respond rapidly to the cues they receive from their 
surroundings. Tissue resident macrophages act as immune sentinels. Following a 
pathogen insult or inflammatory reaction, they get skewed into an activated state. 
Additional monocytes from circulation as are recruited which further differentiate 
to activated inflammatory macrophages. These activated cells, called M1 
macrophages are robust inducers of T cell response and are cytotoxic. They 
secrete a wide variety of inflammatory cytokines and other molecules to eliminate 
the infection. Post infection or inflammation, these cells engage in a tissue repair 
program. At this stage, they are polarized towards an anti-inflammatory or 
alternatively activated state (M2). These M2 macrophages are inducers of 
regulatory T cells, release angiogenic growth factors and molecules and enzymes 
to remodel and repair the damaged tissue. Finally, most of the infiltrating 
macrophages either egress from the site of infection or die at the end of the 
resolution phase.  
Agents for M1 type polarization: Macrophages exposed to G-MCSF and 
TLR agonists, like LPS and IFN-Y and Tumor Necrosis Factor (TNF) are polarized 
to the inflammatory M1 type. Once activated, they produce M1 associated hallmark 
molecules like IL-12, inducible Nitric Oxide Synthase (iNOS), IL-6, IL-1β and 
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reactive oxygen and nitrogen species (ROS and RNS respectively). They also 
activate the helper CD4+ T cells and cytotoxic CD8+ T cells.  
G-MCSF, upon binding to its receptor, triggers JAK2/STAT5 signaling, 
resulting in the activation of ERK and AKT pathways as well as the nuclear 
translocation of NF-κβ and IRF5 (9).  G-MCSF stimulates the macrophages to 
produce inflammatory cytokines like, IL-6, IL-8, G-CSF, M-CSF, TNF, and IL-1β. 
TLR agonists like LPS trigger MyD88 and MaL/Tirap (Toll-interleukin 1 receptor 
domain containing adaptor protein)-dependent pathways that subsequently 
activate the NF-κB, activator protein 1 (AP-1), IRFs, STAT1, and EGR (early 
growth response) family members. LPS induced macrophages produce robust 
inflammatory cytokines like IFN-β, IL-12, TNF, IL-6, IL-1β, chemokines, antigen 
presentation molecules and several co-stimulatory molecules. IFN-Y signals 
through the receptors, IFNGR-1 and IFNGR-2. Following ligand binding, the 
receptors activate the JAK1 and JAK2 proteins which then recruit molecules like 
STAT1, IRF-1 and IRF-8 (10). Although a combination of LPS and IFN-Y is used 
to polarize M1 macrophages in vitro, the gene signature profiles of the combination 
is different from that of macrophages treated with either LPS or IFN-Y alone. This 
highlights the heterogeneity of the macrophage population existing in vivo and 
cautions us to carefully extrapolate our in vivo or in vitro findings.  
Agents for M2 type polarization: M2 macrophages are further classified into 
three groups, based on the polarizing cytokine they are exposed to and the 
signaling pathways that get triggered thereafter. Alternative activation triggered by 
IL-4 or IL-13 was termed as M2a, cells exposed to and polarized by Fc receptors 
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and immune complexes belong to M2b and that by IL-10 and glucocorticoid 
receptors was named M2c subgroup. M-CSF alone can also skew the cells 
towards an anti-inflammatory M2 phenotype. However, in a tissue environment, 
macrophages form a mixed population and it is impossible to distinguish them as 
either M2a or M2b or M2c type. These cells are a potent source of 
immunosuppressive cytokines like IL-10, TGF-β, angiogenic molecules like VEGF 
family of members and tissue remodeling factors like MMPs. They also suppress 
the activation of helper and cytotoxic T cells and induce the formation of Tregs. 
M2 inducers like M-CSF when binds to the cognate receptor, induces the 
dimerization and autophosphorylation of the receptor and subsequent activation of 
ERK, phosphatidylinositol 3-kinase, phospholipase C and finally the nuclear 
translocation of Sp1. IL-4 activates JAK1 and JAK3 which results in the activation 
of STAT6. IL-4 can act through different receptor pairs: IL-4Rα1 can pair with the 
common gamma chain, Yc; or it can heterodimerize with the IL-13Rα1 chain that 
can bind both IL-4 and IL-13. Additionally, IL-13 can signal through a third receptor, 
IL-13Rα2. IL-4 and IL-13-treated macrophages, although similar, exhibit different 
gene signature profiles. In case of M2b macrophages, FcYR represses IL-12, one 
of the hallmark cytokines for M1 state, and induces the production of IL-10 and 
promotes a Th2 response (11, 12). The M2c inducers, IL-10 and glucocorticoids 
signal through entirely different pathways. For example, macrophages metabolize 
glucocorticoids that are secreted by the adrenal glands. These hormones bind to 
the glucocorticoid receptor alpha (GCR) and results in its nuclear transcription, 
where it either alone or by interacting with other transcription factors regulate the 
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expression of genes like, complement component 1 subunit A (C1QA), TSC22 
domain family, member 3 (DSIPI), MRC1, thrombospondin 1 (THBS1), IL-10, 
IL1R2, and CD163 (13). IL-10 on the other hand, signals through the STAT3 
pathway and regulate the expression of several genes like, selected Fc receptors, 
the chemoattractants CXCL13 and CXCL4, the recognition receptors formyl 
peptide receptor 1 (FPR1), TLR1, TLR8, MARCO (14).  
Of note, macrophage polarization is not an absolutely ON/OFF 
phenomenon. For example, both the M1 and M2 types express Arg1, albeit in 
different amounts. Another such pervasive misconception is about IL-10, a robust 
anti-inflammatory cytokine. Although known as a marker for M2 polarized 
macrophages, IL-10 is also secreted by M1 type cells. Surprisingly, macrophages 
stimulated with immune complexes and that are signaling through Fc receptors 
produce significant amount of IL-10. This may be a result of negative feedback 
regulation to avoid excess inflammatory response. Another major concern is that 
most of the studies on macrophages done in vitro use simple polarization 
techniques. This clearly does not mimic the complex overlapping and pleiotropic 
signals that a macrophage is exposed to in a tissue where M1 and M2 signals 
cannot possibly exist alone. Also, the polarization technique varies among different 
laboratories and hence there is a lot of inconsistency in the markers used for each 
subtype. However, some of the classical markers used to identify either M1 or M2 
polarized macrophages is listed in Fig. 1.6 and 1.7.  
The above-mentioned M1/M2 classification of macrophages is over-
simplified and vague. Especially, under conditions of non-resolving inflammation, 
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like cancer, chronic infection or autoimmune disorders, macrophages exhibit much 
more complex molecular profile and gene signatures of M2 as well as M1 type 
macrophages. In the above cases, there is an increased output of monocytes from 
the bone marrow to maintain sustained recruitment to the site of chronic 
inflammation. Also, a non-resolving inflammation like cancer takes years to 
decades to develop, allowing the monocytes/macrophages a lot of time to adapt 
to the wide array of signals they receive. Once inside the tumor, they are exposed 
to inflammatory as well as immunosuppressive factors, as a result of which they 
show a mixed phenotype resembling more of M2 macrophages, but also express 
some genes characteristic of the M1 type cells.  
1.1.4. Functions of macrophages in normal physiology and clinical 
conditions 
Macrophages are indispensable for normal developmental processes. On 
the other hand, they are also causally related to several clinical conditions, like 
autoimmunity, rheumatoid arthritis, atherosclerosis, cancer to name a few. Few of 
these aspects of are discussed briefly below: 
Development: In absence of macrophages, several developmental defects 
have been reported. For example, Csf1 null mice, which lacks macrophages, 
develops osteopetrosis due to loss of osteoclasts. The cavities in bones where 
hematopoiesis occurs are not formed in these mice. However, the mice survive till 
adulthood due to extramedullary hematopoiesis in spleen and liver. Macrophages 
are also important for angiogenesis, proper tissue architecture and patterning in 
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kidney, pancreas, mammary gland, brain as well as stem cell niche maintenance 
and deciding their fate (15).  
Phagocytosis: The primary function of macrophages is phagocytosis. For 
example, during erythropoiesis, macrophages surround the maturing erythroblasts 
and engulf the extruded erythrocyte nuclei (16). Macrophages also phagocytose 
cells not expressing CD47 and hence are critical for deciding erythropoietic egress 
from bone marrow (17). They also maintain hematopoietic steady state by clearing 
neutrophils in spleen and liver (18). Macrophages are also central to clearing 
apoptotic cells arising as part of daily turnover in our body or apoptotic debris 
occurring during infection or injury. The importance of removal of apoptotic cells 
by macrophages is discussed later in the relevant sections.  
Metabolic homeostasis: Macrophages are important for maintenance of 
systemic metabolic homeostasis. For example, in healthy lean individuals, 
macrophages are alternatively activated (express Arg-1, CD206) and comprise 10-
15% of white adipose tissue, which acts as a long-term storage of nutrients. This 
is important for imparting insulin sensitivity in the white adipose tissue. However, 
in obesity, the white adipose tissue is under stress and releases macrophage 
chemoattractants like CCL2, CCL5 and CCL8 and macrophage content increases 
upto 45-60%. These macrophages are inflammatory in nature and contribute to 
insulin resistance in obesity (19-23). Further, high fat feeding causes inflammatory 
macrophage infiltration into the insulin producing islets and augments β-cell 
dysfunction (24, 25). Macrophages also phagocytose aged erythrocytes and 
contribute to iron recycling (26).  
10 
 
Thermogenesis: Brown adipose tissue or brown fat generates heat and 
maintains our body temperature. Alternative activation of macrophages by IL-4 and 
IL-13 induce the production of catecholamines in macrophages that contribute to 
thermogenesis in brown fat. 
Infections: In case of pathogenic infection or inflammation, circulating 
monocytes are rapidly recruited to the site of injury where they polarize to 
classically activated M1 type. These cells secrete pro-inflammatory and cytotoxic 
cytokines, anti-microbial mediators like ROS/NOS and mediate killing of infected 
cells. They also directly or indirectly alert the adaptive immune responses for 
eradicating the invading pathogen. Post injury, macrophages adopt a reparative 
phenotype where they phagocytose and clean up the apoptotic debris that arose 
due to infection or injury and plays a vital role in tissue remodeling, regeneration 
and wound healing process by secreting growth factors, angiogenic molecules, 
and matrix metalloproteinases. However, in cases where the repair process is 
impaired, it results in aberrant healing and fibrosis (scarring). 
Inflammatory diseases: Macrophages are also causally associated with 
several chronic sterile inflammation related diseases, like rheumatoid arthritis 
(RA), inflammatory bowel disease (IBD), asthma, atherosclerosis and fibrosis. For 
example, in RA, IBD and multiple sclerosis, macrophages secrete pro-
inflammatory cytokines like IL-12, IL-18, IL-23, TNF-α and contribute to disease 
pathogenesis and severity. On the other hand, allergic asthma, which arises due 
to airway obstruction and inflammation and lung remodeling, is characterized by 
the abundance of macrophages that secrete Th2 like cytokines and molecules that 
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degrade the tissue and remodel the airway. Macrophages also secrete molecules 
that result in the recruitment of eosinophils, basophils and Th2 type T cells that 
worsen the disease.  
1.2. Neuropilins: A brief introduction 
Neuropilins (NRPs) are multifunctional, transmembrane surface 
glycoproteins that are expressed in all vertebrates and are highly conserved across 
species. They were originally identified for their role in axonal guidance. NRPs are 
well known for their function as co-receptors for Vascular Endothelial Growth 
Factor (VEGF) members and Class III Semaphorins by interacting with VEGF 
receptors and Plexins respectively. However, work over the past decade have 
identified additional role of NRPs in a wide array of physiological processes, like 
development, angiogenesis, immunity as well as clinical conditions like cancer. 
The two isoforms, NRP1 and NRP2 are often over-expressed in different cancers 
and their expression correlates with poor clinical outcome. NRPs are known to aid 
cancer progression by promoting cell survival under therapeutic stress, inducing 
tumor associated angiogenesis and therapy resistance. They are also expressed 
in a variety of immune cells, like, macrophages, dendritic cells, and different T cell 
subsets where they take part in the development, migration and immune 
responses under physiological as well as pathological conditions. NRPs are also 
expressed in bone compartment, namely osteoclast and osteoblast where they 
regulate bone homeostasis. Of the two isoforms, NRP1 is well characterized in 
different T cell subsets and to some extent in myeloid cells (dendritic cells and 
macrophages). NRP2, on the other hand, is poorly characterized in the immune 
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cell subpopulations, and details of its ligands and pathways governing its functions 
not well understood.  
1.2.1. Genomic organization, protein structure and splice variants of 
Neuropilins 
There are two isoforms of NRPs, NRP1 and NRP2. They are encoded by 
distinct genes located on different chromosomes, 10p12 for NRP1 and 2q34 for 
NRP2. The two isoforms arose because of gene duplication and share homology 
in their structure and overlapping sets of ligands and functions. Each gene contains 
17 exons and 16 exons and similarity in exon-intron junctions (27). The general 
domain structure of the NRPs comprises of an N-terminal extracellular region, a 
single pass transmembrane domain followed by a short C-terminal cytosolic part 
(43-44 amino acids). The extracellular portion comprises of two CUB (complement 
binding factors C1r/C1s, Uegf, Bone Morphogenetic protein 1)(a1/a2) domain, two 
Factor V/VIII coagulation factor homology (b1/b2) domain, a b-c linker, followed by 
a MAM (homologous to meprin protease, A5 antigen, receptor tyrosine 
phosphatase µ and κ). The CUB domain interacts with Semaphorin group of 
ligands, the b1/b2 domain is important for binding anionic phospholipids and thus 
mediate cell-cell adhesion. This is also the site for interaction with VEGF ligands. 
The MAM domain is required for homo or heterodimerization with other receptors.  
Several splice variants have been identified for each of NRP1 and NRP2. Both 
NRP1 and NRP2 can exist as membrane bound or soluble splice forms. The latter 
often act as decoy molecules and antagonize the function of the full-length 
receptors. For instance, two such splice forms, 12sNRP1 and 11sNRP1 arise due 
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to pre-mRNA splicing at intron 12 and 11 respectively (27). 12sNRP1 acts as a 
decoy receptor for VEGF165. When 12sNRP1 was overexpressed in rat prostate 
carcinoma cells, this resulted in tumors with increased number of hemorrhaged 
and damaged blood vessels and higher number of apoptotic tumor cells (28). Two 
additional soluble splice forms have been reported for NRP1, namely, sIIINRP1 
and sIVNRP1 and their expression detected in normal condition as well as tumor 
tissues. Both these isoforms act as a ligand trap and regulated breast cancer cell 
migration (29). Another splice variant for NRP1 is reported; it lacks a stretch of 7 
amino acids, two residues downstream of the O-glycosylation site and hence 
undergoes less glycosylation. When overexpressed in prostate cancer cells, it 
reduced tumor cell proliferation and migration and hence slowed tumor growth 
(30).  
Two membrane bound splice variants are known for NRP2, namely NRP2a 
and NRP2b. They differ at the last 100 amino acids in the cytoplasmic tail. NRP2a 
is 44% homologous to NRP1 and may exhibit redundant functions. The 
extracellular domain of NRP2a and NRP2b are identical, but share only 11% 
homology in their transmembrane and cytosolic domains, indicating activation of 
divergent downstream signaling cascades and functions. Indeed, a recent study 
reported opposite function of these two splice variants in non-small cell lung 
carcinoma. NRP2b showed pro-metastatic role whereas NRP2a antagonized 
tumor progression and metastatic burden (31). In humans, two splice variants for 
NRP2a have been identified, namely NRP2a(17) and NRP2a(22). The former 
arises as a result of insertion of insertion of 17 amino acids after position 809, 
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located between the MAM and transmembrane domains. On the other hand, 
NRP2a(22) has an insertion of additional 5 amino acids within the 17 amino acid 
stretch as in NRP2a(17) as a result of alternate splicing. Similarly, NRP2b can also 
exist as two splice forms, NRP2b(0) and NRP2b(5) that is generated by alternate 
splicing between exon 15 and 16b and insertion of 0 or 5 amino acids after residue 
808. NRP2b(0) is more abundantly expressed than NRP2b(5) (27). Of note, 
NRP2a and NRP2b have divergent C terminus, indicating they probably can 
activate distinct signaling pathways and exert non-redundant functions. Therefore, 
to successfully target NRPs, it is crucial to clearly understand why the different 
isoforms or splice variants are expressed, sometime one preferentially over 
another, under different conditions and the differences in their cellular signaling.  
In mice, NRP2 undergoes alternative splicing and gives rise to four splice variants; 
these differ in the insertion of 0, 5, 17 or 22 amino acids after residue 809. The fact 
that these differential insertions occur in the b-c linker and transmembrane domain, 
it may alter the ability of the splice variants to homo or heterodimerize with other 
surface receptors. Hence the splice forms may potentially regulate distinct 
downstream cellular signaling pathways (27).  
A soluble isoform for NRP2 is known, 9sNRP2 (62.5 kDa). Alternate splicing 
results in the inclusion of an intron in the b2 domain of the mRNA and an in frame 
stop codon results in the termination of the translation of the protein. Hence this 
soluble isoform has the a1/a2 domain, the b1 domain but only a part of the b2 
domain, but not the last 48 amino acids of the b2 domain, the b-c linker, the 
transmembrane domain and the cytosolic tail (27). Intriguingly, 9sNRP2 acts as a 
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ligand trap and sequesters VEGFC, impairing the oncogenic VEGFC/NRP2 
signaling axis and growth of prostatospheres in vitro (32).  
1.2.2. Post translational modifications of NRPs 
Both NRP1 and NRP2 undergo various post translational modifications with 
different functional consequences. NRP1 is often modified by the covalent addition 
of Glycosaminoglycan (GAG) to a conserved Serine residue (Ser612) in the b-c 
linker region (33). Structurally, GAGs are a repeating disaccharide unit containing 
N-acetylglucosamine (GlcNac) or N-acetylgalactoseamine (GalNac) and a uronic 
acid or galactose. GAGs can be either Heparan sulfate (HS-GAG) or Chondroitin 
sulfate (CS-GAG), keratin sulfate or hyaluronic acid. In several human tumor cell 
lines, NRP1 exists as N-glycosylated as well as CS-GAG modified fractions. 
Surprisingly, the latter negatively regulated tumor cell invasion (34). CS GAG 
NRP1 is predominantly expressed in the vascular smooth muscle (SMC) cells. In 
HUVEC cells, NRP1 expressed equivalent amount of CS GAG and HS GAG. GAG 
modification on NRP1 enhances its binding to VEGF, however, CS-GAG NRP1 
may act as a decoy receptor under certain circumstances. On the other hand, HS-
GAG NRP1 may bind multiple NRP1 molecules and promote NRP1 clustering. 
Such a cluster can bind VEGFR2 in presence of VEGF and stabilize the complex, 
prevent internalization of VEGFR2, resulting in enhanced signaling (33). In 
contrast, there are no reports for such modification on NRP2. In DCs, NRP2 
undergoes post translational modification by the addition of polysialic acid (PSA) 
chains to mucin type O-linked glycans between the b2 and c domains(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
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36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36. NRP2 polysialylation regulates CCL21 
driven trafficking of DCs to the secondary lymphoid organs and modulates 
interactions between DCs and T lymphocytes (37). NRP1 has also been recently 
reported to undergo polysialylation at a level 50% of that of NRP2, although the 
exact biological implication of this remains unknown (38).  
1.2.3. Ligands for the NRPs 
NRP1 and NRP2 are most well known for their role as co-receptors to VEGF 
family members and Class III Semaphorins. Semaphorins comprise a large family 
of proteins and can be sub-categorized into seven classes. They bind with Plexins 
on the cell surface and activate cellular signaling to affect different aspects of 
developmental biology, immune responses, as well as clinical disorders. Class III 
Semaphorins are secreted from cells and can interact with either NRP1 or NRP2 
at the a1/a2/b1 domain. Together with Plexin A1 or A2, they form a holoreceptor 
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complex. NRP1 and NRP2 exhibit some selectivity in binding to the Semaphorins. 
For instance, the major ligand for NRP1 is Sema3A, although it can also bind 
Sema3F, albeit with lower affinity. NRP2, on the other hand, binds mainly Sema3C 
and Sema3F, but not Sema3A. NRPs also bind VEGF family members with 
differential specificities. For example, NRP1 binds VEGFA, classically VEGFA165 
(39). NRP2 preferentially binds with proteolytically cleaved and activated VEGFC, 
although it can also bind other VEGFA isoforms. Structural studies have delved 
into explaining how NRPs exhibit selectivity in binding different VEGF isoforms. It 
has been shown that a surface groove in the b1 domain binds with linear epitopes 
containing a C-terminal arginine, present in the VEGFA isoforms and 
proteolytically cleaved VEGFC. However, the interactions can be fine-tuned by 
additional side chain interactions in the b1 domain region.  
NRPs are also known to bind several other ligands, where they mainly act 
as co-receptors to enhance the signal. For example, NRPs can bind with 
Transforming Growth Factor beta 1 (TGF-β1) and signal through the canonical 
Smad2/3 pathway to trigger anti-apoptotic and anti-proliferative pathways. They 
also bind to c-Met and platelet derived growth factor (PDGF) and contribute to 
cancer pathogenesis. It is now well established that miRNAs circulate either in 
encapsulated form or bound to protein Argonaute-2 (AGO2) and travel to distant 
sites where they crosstalk with target cells. A recent study showed that NRP1 binds 
AGO2/miRNA complexes and facilitates their cellular internalization process (40). 
miRNAs have now been proven to be causally associated with several clinical 
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disorders, including cancer. miRNA/NRP1 interaction may have impact in different 
pathological conditions.  
1.2.4. Phenotypes of genetically engineered mouse models for NRPs 
The crucial roles of NRP1 and NRP2 in developmental biology began to 
emerge from different genetically engineered mouse models. NRP1 depletion is 
embryonically lethal at E10.5-E13.5. The embryos die of severe cardiac and 
vascular defects (41-43). Transgenic mice with NRP1 overexpression also die in 
utero at E12.5 owing to extensive hemorrhage and had developmental defects in 
the nervous system (44). In contrast, NRP2 knock out mice are viable and proceed 
to adulthood.  However, they have smaller lymphatic vessels and proper 
development of cranial nerves, spinal sensory axons is impaired (45-47). NRP2 
also plays an important role in bone homeostasis. This was evident from the 
significantly lower bone mass of NRP2 knock out mice. The bone loss was 
attributed to reduced number of osteoblasts and increased number of osteoclasts 
in absence of NRP2 (48). Simultaneous depletion of NRP1 and NRP2 is embryonic 
lethal at E8.5; the embryos die due to severe vascular defects (49).  
1.2.5. Role of NRPs in macrophages 
Both NRP1 and NRP2 expression have been reported in macrophages 
under various conditions (50). NRP1 is expressed on tissue resident 
macrophages, like alveolar, bronchial, intravascular, decidual as well as 
microglia/macrophages in the brain. For example, TIE2+ yolk sac derived 
microglia/macrophages that express NRP1 are important during brain 
vascularization. These macrophages are present near the endothelial cells and 
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promote vessel fusion. However, NRP1 has been shown to be dispensable for 
normal vessel growth in brain (51-53). Recently, there have been a lot of focus on 
tumor infiltrating macrophages (TAMs). As discussed later, TAMs comprise a 
unique population of myeloid derived cells in the tumor core and their infiltration 
correlates with disease progression and clinical outcome in many cancers. TAMs 
have been causally associated with various aspects of cancer, like cancer cell 
survival, EMT, migration and invasion, angiogenesis and suppression of immune 
response against the malignant cells (54-57). Recently, it has been shown that 
recruitment of TAMs to the hypoxic core of the tumor is crucial for their attainment 
of pro-tumorigenic properties. Once recruited to the tumor site, NRP1 regulates 
the migration of TAMs to the hypoxic core and its ablation arrests the TAMs in the 
peripheral normoxic region of the tumor, activates anti-tumor immune response 
and reduces tumor burden (58, 59). NRP1 is also expressed in glioma associated 
macrophages (GAM) and promotes their tumorigenic activities. Indeed, depletion 
of NRP1 in GAMs reduced the burden of glioma tumors (60). An immunoregulatory 
role for NRP1 has been documented in several other studies as well.  
NRP2 on the other hand, is not well characterized in the myeloid cell 
compartment. Previous literature as well as work in the current dissertation show 
that NRP2 is not expressed at a detectable level in the monocytes, but its 
expression is induced in inflammatory M1 as well as alternatively activated M2 
macrophages. NRP2 is also detected in tissue macrophages, including alveolar, 
bronchial, peritoneal as well as intravascular macrophages in mice (50). A recent 
study reported that polysialylation is progressively lost in monocytes as the cells 
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migrate towards pulmonary and peritoneal sites of inflammation. Interestingly, 
peritoneal macrophages do not express polysia themselves, however NRP2 is 
modified post-translationally by polysialylation when maintained in culture. Further, 
removal of polysia increased the phagocytosis of bacteria in macrophages. 
However, it is still not clear if this observation could be attributed to polysialylated 
NRP2 (61). It is possible that macrophages lose polysia during bacterial infection 
to enhance phagocytosis, following which it is re-expressed and probably plays a 
part in the interaction with T cells. Polysialylated NRP2 has also been reported in 
microglia, where they mainly remain confined in the golgi compartment. Following 
LPS stimulation, it gets quickly mobilized to the cell surface and is eventually lost. 
Interestingly, polysialylated NRP2 was detected in the cell culture supernatant, 
indicating metalloproteinase mediated cleavage of the protein. Exogenous addition 
of polysia blunted the production of pro-inflammatory cytokines in microglia in 
response to LPS challenge. This indicated a possible role for polysialylated NRP2 
in negative feedback regulation of inflammatory response in macrophages (62, 
63). However, the main concern in this finding is since the addition of exogenous 
polysia abrogated the production of inflammatory cytokines in microglia in 
response to LPS, this effect does not necessarily depend on the polysia carrier. 
Also, it is not clearly known why polysialylated NRP2 is mobilized to the cell surface 
following LPS challenge. 
Expression pattern of NRP2 in TAMs is not well characterized, nor is its 
function in cancer associated macrophages known. Two previous studies have 
reported NRP2 expressing macrophages in patients with lung cancer as well in 
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mouse mammary tumors (50, 64). However, no data exists till date that correlates 
NRP2 expression in TAM with disease progression or clinical outcome and patient 
survival. We have detected NRP2 expression in TAMs in pancreatic cancer. 
Expression of NRP2 in TAMs in pancreatic cancer and its functions and 
implications in tumor progression will be discussed in more detail in the relevant 
sections. 
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Fig 1.1. Neuropilin (NRP) domain structure and splice variants. The general 
domain structure of NRP1 and NRP2 is shown. There is an N-terminal extracellular 
domain for ligand binding, followed by a single pass transmembrane domain and 
a short cytosolic tail. The extracellular domain comprises of two CUB, two b1/b2 
and one MAM domain. The sites for binding different ligands are indicated. Both 
NRP1 and NRP2 can exist as multiple splice variants. Soluble isoforms (sNRP1 
and sNRP2) contain truncated extracellular domain but lack the transmembrane 
and cytosolic regions and can act as decoy receptors to blunt NRP function. NRP2 
can exist as two splice forms, NRP2a and NRP2b, which share only 11% homology 
in their C terminus, therefore, being capable of regulating different signaling 
pathways. The percentage of sequence homology in the different extracellular and 
cytosolic domains of NRP1 and NRP2 as well as between NRP2a and NRP2b are 
indicated. The C termini of both NRP1 and NRP2a contain a PDZ binding motif 
(SEA) that can act as docking site for interacting partners. Red arrowheads 
indicate insertion at residue 808 in NRP2 of five amino acids GENFK giving rise to 
different splice variants of NRP2a and NRP2b.The percentage amino acid 
homologies between the domains of full length NRP1 and NRP2 isoforms and 
between the NRP1 and NRP2a/NRP2b isoforms are indicated. The figure has 
been adapted from Roy et al. “Multifaceted Role of Neuropilins in the Immune 
System: Potential Targets for Immunotherapy”. Front Immunol. 2017. 
doi:  10.3389/fimmu.2017.01228 with permission.  
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Fig. 1.2. Origin of monocytes in the bone marrow. Hematopoietic stem cells 
(HSC) in the bone marrow continuously giving rise to monocytes through 
sequential generation of Granulocyte-Myeloid Progenitor (GMP), Monocyte-
Dendritic Cell Precursor (MDP) and Common Myeloid Progenitor (cMOP) 
intermediates. Monocytes exit bone marrow to enter circulation. The two classes 
of monocyte subsets are shown: classical monocytes and non-classical 
monocytes; in the steady state, the two subsets form a developmental continuum, 
but are functionally distinct. This figure has been adapted from Ginhoux et al. 
“Monocytes and macrophages: developmental pathways and tissue homeostasis.” 
Nat Rev Immunol. 2014. doi: 10.1038/nri3671 with permission. 
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Fig. 1.3. Human monocyte subsets and their functions.  Three different human 
monocyte subsets are indicated: classical (CD14+++CD16-), intermediate 
(CD14++CD16+) and non-classical (CD14+CD16++). In the steady state, the 
different subsets comprise a developmental continuum, although the classical type 
can switch to the intermediate and non-classical types in circulation. Classical 
monocytes display efficient antimicrobial capability due to their enhanced 
phagocytic activity, and secrete ROS/NOS upon LPS stimulus, whereas 
intermediate and non-classical MCs secrete inflammatory cytokines, TNFα and IL-
1β. During inflammation, classical and intermediate subsets infiltrate target tissue, 
mature to M1Mϕ and present self-antigen via MHC-I/II to prime naïve T cells. In 
steady state, non-classical monocytes patrol the endothelium and become M2Mϕ. 
They express CD206, IL-10 and are involved in tissue remodeling, wound healing, 
immunosuppression and are pro-tumorigenic.   During the resolution phase of 
inflammation, M1 Mϕ   can repolarize to M2Mϕ. This figure has been adapted from 
Yang et al. “Monocyte and macrophage differentiation: circulation inflammatory 
monocyte as biomarker for inflammatory diseases.” Biomarker Research. 2014. 
doi.org/10.1186/2050-7771-2-1 with permission.  
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Fig.1.4. Mouse monocyte subsets and their functions. Different monocyte 
subsets in mouse are indicated: classical (Ly6c+) and non-classical (Ly6c-). Ly6C+ 
monocytes leave the bone marrow in a CC-chemokine receptor 2 (CCR2)-
dependent manner. In the steady state, both the subtypes form a developmental 
continuum, and Ly6C+cells can differentiate into Ly6C- type. Ly6C- MCs patrol the 
endothelium are recruited into normal tissue to become tissue resident Mϕ/DCs 
where they clear apoptotic debris and perform other housekeeping functions. 
Ly6C+MCs rapidly respond to inflammation or pathogen invasion, become M1Mϕ 
and exhibit antimicrobial capability, enhanced phagocytosis and secrete ROS, 
TNFα, and IL-1β, present antigens and activate T cells; they are anti-tumorigenic. 
Ly6C- MCs are recruited to tissue and differentiate into M2Mϕ, which secrete anti-
inflammatory cytokine and contribute to tissue repair and are reparative and 
immunosuppressive in nature and are protumorigenic. During the resolution phase 
of inflammation or injury, M1 type can re-polarize to M2 type macrophages. This 
figure has been adapted from Yang et al. “Monocyte and macrophage 
differentiation: circulation inflammatory monocyte as biomarker for inflammatory 
diseases.” Biomarker Research. 2014. doi.org/10.1186/2050-7771-2-1 with 
permission.  
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Fig.1.5. Stimuli for M1/M2 type polarization of macrophages and the 
pathways associated. A. M1-M2 macrophage model, in which M1 is generated 
following exposure to interferon-gamma (IFN-g) + lipopolysaccharide (LPS) or 
tumor necrosis factor (TNF); M1 macrophages are characterized by secretion of 
IL-12, IL-1, IL-23, TNF, IL-6 and MHC-II and low levels of IL-10 and are anti-
microbial, cytotoxic and anti-tumoral. M2 type is further subdivided to M2a (IL-
4/IL-13 induced), M2b (immune complex+ Toll-like receptor (TLR) ligands 
induced), and M2c (IL-10 and glucocorticoids induced). (B) The key signaling 
pathways and downstream mediators behind the M1 and M2 stimuli in 
macrophages are highlighted. The diagram includes granulocyte macrophage 
colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor 
(M-CSF) as M1 and M2 stimuli respectively, in addition to other cytokines 
mentioned. This figure has been adapted from Martinez et al. “The M1 and M2 
paradigm of macrophage activation: time for reassessment.” F1000Prime Rep. 
2014. doi:  10.12703/P6-13 with permission.  
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Fig.1.6. Marker panel for M2 macrophages. This figure has been adapted from 
Murray et al. “Macrophage Polarization.” Annual Review of Physiology. 2016. 
DOI:10.1146/annurev-physiol-022516-034339 with permission.  
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Fig.1.7. Marker panel for M1 macrophages. This figure has been adapted from 
Murray et al. “Macrophage Polarization.” Annual Review of Physiology. 2016. 
DOI:10.1146/annurev-physiol-022516-034339 with permission.  
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Fig.1.8. Physiological roles of macrophages. Macrophage heterogeneity arises 
from their different origins (either yolk sac or bone marrow derived) and their ability 
to detect and rapidly adopt to complex signals in the tissue microenvironment 
(shown on the left). The vast range of physiological roles undertaken by 
macrophages, e.g.  erythropoiesis, metabolic homeostasis (insulin resistance), 
iron recycling, development, tissue regeneration and thermogenesis (shown on the 
right). Macrophages respond to external stimuli through “sensor systems” in the 
form of (a) cell surface and intracellular pattern recognition receptors for detecting 
invading pathogens and damage-associated molecular patterns; (b) receptors for 
recognizing and engulfing apoptotic cells; (c) receptors that promote M1/M2-like 
activation; (d) receptors for neurotransmitters (e) cell surface receptors that 
regulate macrophage activation, e.g. the inhibitory receptors SIRP1-α and 
CD200R. Integrins (f) mediate interaction with macrophages and ECM. 
Macrophages produce numerous molecules that contribute to tissue remodelling 
and inflammation and mediate clearance of apoptotic bodies, cell debris. 
Macrophages rely heavily on efficient phagocytosis and endocytosis for 
maintenance of homeostasis as well as other functions. This figure has been 
adapted from Gordon et al. “Physiological roles of macrophages.” Pflügers Archiv 
- European Journal of Physiology. 2017 with permission.  
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Fig.1.9. Role of NRP2 in macrophages. NRP2 is expressed in microglia, tissue 
resident (M2) and inflammatory M1 type macrophages as well as TAMs. In 
peritoneal macrophages, NRP2 is involved in phagocytosis. In microglia, NRP2 is 
polysialylated and remains confined in the golgi compartment. Following LPS 
challenge, it rapidly translocates to the cell surface and is shed from the cells. The 
role of NRP2 in TAMs is not reported. This figure has been adapted from Roy et 
al. “Multifaceted Role of Neuropilins in the Immune System: Potential Targets for 
Immunotherapy”. Front Immunol. 2017. doi:  10.3389/fimmu.2017.01228 with 
permission.  
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2.1.  Tumor Associated Macrophages: An overview 
The tumor microenvironment (TME) is now considered a complex 
ecosystem, comprising not only of cancer cells, but also other cell types, like 
immune cell infiltrates, stromal cells, endothelial cells and fibroblasts. It is now well 
established that this ecology of cells evolves with and engages in a complex cross 
talk with one another, thereby providing support to the growing tumor. Suppression 
of antitumor adaptive immune response and non-resolving tumor-promoting 
inflammation have now become known as hallmarks of cancer. Of the 
inflammatory immune cell infiltrates, macrophages are the most abundant in the 
ecological niche of cancer and orchestrate the non-resolving cancer related 
inflammation (CRI). There is now substantial evidence to suggest that tumor 
associated macrophages (TAMs) engage in dynamic interplay with cancer cells, 
and other immune and non-immune cells in the TME, adopt a pro-tumoral 
phenotype, both in the primary and metastatic sites and most often correlate with 
poor clinical outcome. Therefore, understanding the ontogeny of TAMs, and the 
molecular pathways that govern their differentiation and functional phenotypes will 
emerge as an important prong in developing effective therapeutic strategies in 
combination with chemotherapy and other immunotherapies in the future.  
2.1.1. Origins of TAMs and their recruitment to the TME 
In neoplastic tissues, cues from malignant cells or other cells of the TME 
that govern the TAM differentiation and functional phenotypes are diverse in nature 
and vary between tumors, or even various parts of the same tumor. Therefore, 
there are varied TAM populations within a single tumor. Of note, most of the time 
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TAMs do not fit into the oversimplified M1/M2 classification mentioned earlier and 
exhibit complex molecular signatures. However, despite the varied intra-tumoral 
and intertumoral phenotypes of TAMs, they are in general polarized towards an 
immunosuppressed type in all cancers. As mentioned earlier, macrophages can 
originate from either yolk-sac derived or bone marrow derived precursors. 
However, the precise ontogeny of TAMs is still not entirely clear. Work over the 
past few decades indicate that TAMs can arise either from circulating blood 
monocytes, monocytic myeloid derived suppressor cells (M-MDSCs) that get 
recruited to the TME or from local resident tissue macrophages of embryonic origin 
(65). For example, in mouse gliomas, TAMs can originate from either blood 
monocytes or tissue resident microglial cells (66). Using genetically engineered 
mouse models, there have been attempts to assess the relative contribution of 
TAMs arising from these various sources in tumor progression. Many recent 
studies have documented that most TAM sub-populations in the TME arise from 
the Ly6C+ circulating blood monocytes that invade the growing tumor in response 
to recruitment cues from the TME, at least in grafted tumors (67), primary mouse 
mammary tumors (68) and in lung metastases (57). Indeed, in mouse glioma, the 
Ly6C+ circulating monocytes that differentiated to TAMs were causally associated 
with increased rate of tumor incidence and shorter disease-free survival. 
Interestingly, there was no significant contribution of TAMs that arose from the 
resident microglial cells (66). Cortez-Retamozo et al. proposed that circulating 
monocytes that give rise to TAMs originate from extramedullary hematopoiesis that 
allows a rapidly mobilizable reservoir of TAMs for the tumor. However, recent 
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lineage tracing studies have shown that bone marrow is the primary source of 
monocytes that differentiate to TAMs, with minimal contribution from the spleen 
(69).In addition, there are conflicting studies to suggest that TAMs arise from the 
non-classical subset of circulating monocytes (70). Hence, it is possible that the 
origin of TAMs depends on the tumor type and the tumor microenvironment. 
Additionally, their origin may also dictate their functions in the tumor (71). Some of 
these aspects have been discussed in more details elsewhere (72). 
The tumor bed secretes a wide array of cytokines and chemokines that act 
as a gradient for recruiting circulating monocytes and differentiate them towards 
TAMs. Among these, CD62L, CX3CL1, CCL2, VEGF-A, CSF-1 are widely 
implicated in TAM recruitment to the TME. For instance, in solid tumors, the 
inflamed endothelium secretes molecules like CD34, podocalyxin, endomucin, 
nepmucin, MAdCAM-1, endoglycan, GlyCAM-1, Spg2000 etc., which act as 
ligands for CD62L expressed on circulating monocytes to recruit them to the TME. 
Also, tumor cells produce CX3CL1, CCL2 and VEGF-A which bind to and act 
through their cognate receptors, CX3CR1, CCR2 and VEGFR1 respectively to 
promote monocyte migration to the TME (73). Additionally, CCL2/3/4/5/22, 
CXCL8, Endothelin, PDGF have also been showed to promote monocyte 
recruitment (74).  
2.1.2. Pro-tumoral role of TAMs  
Tumor infiltrating macrophages assist in tumor progression in many ways. 
It is now well accepted that in addition to mutations acquired in the tumor cells, a 
persistent inflammatory micro-environment can provide necessary support to 
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cancer initiation (75). For example, chronic inflammation caused by Helicobacter 
pylori in the stomach, Crohn’s disease, chronic pancreatitis have all been causally 
associated with cancer initiation (76-78). Macrophages significantly contribute to 
this process by producing molecules like IL-6, TNF-α, IFN-Y (78, 79). For example, 
genetically depleting STAT3 in macrophages results in chronic inflammation in the 
colon and subsequent invasive adenocarcinoma (80). This persistent inflammation 
supports a mutagenic microenvironment for the tumor cells to acquire additional 
mutations (78). Macrophages also produce reactive oxygen and nitrogen species 
which further add to the genetic instability of the cancer cells. The mutated cells 
recruit more inflammatory cells in a vicious cycle which further facilitates tumor 
formation (57, 75, 76).  
During the proliferation phase of the tumor, one of the most well-known and 
well-characterized functions of macrophages is regulation of the ‘angiogenic 
switch’. Macrophage secreted factors induce endothelial cells to produce VEGFA 
resulting in the angiogenic switch (81, 82). Further, TIE2+ macrophages 
physically associate with endothelial cells of blood vessels through ANG2 and 
blockade of this association reduced angiogenesis in several tumor models (83, 
84). Intriguingly, recent reports indicate macrophages can transdifferentiate to 
lymphatic endothelial cell precursors and contribute to lymphangiogenesis (85). 
Metastatic cancers, before spreading to distant sites, first colonize the draining 
lymph nodes. Thus, by inducing lymphangiogenesis, macrophages facilitate 
cancer cell metastasis. Another important criterion for cancer cell metastasis is 
acquirement of EMT phenotype (86). With the advancement of cancer, tumor cells 
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suppress the epithelial markers like E-Cadherin and upregulate mesenchymal 
markers like Snail and Slug. Macrophages can induce EMT in cancer cells in 
multiple cancers, including pancreatic, lung, hepatocellular and breast cancers 
(87-89). Macrophages also release a variety of molecules like Osteonectin, MMPs, 
cathepsin proteases that help remodel the surrounding extra cellular matrix and 
facilitate cancer cell invasion and migration (90, 91). TIE2+ macrophages can 
further facilitate tumor cell intravasation into blood vessels (92). Recently. an 
anatomical structure comprising tumor cell, macrophages and endothelial cells in 
histological sections of primary human breast cancers has been reported. These 
“Tumor microenvironment for metastasis (TMEM)” structures are predictive of 
metastasis. Macrophages and tumor cells engage in a paracrine interaction and 
get aligned along blood vessels in ‘lock step’ fashion with the former eventually 
facilitating the escape of the latter into circulation (92-94).  
One of the most principal factors contributing to tumor advancement and 
therapy failure is suppression of the adaptive immune response against the 
malignant cells in the TME. Once the recruited monocytes enter the TME, tumor 
cell derived factors efficiently re-educate them towards an immunosuppressive 
TAM phenotype. The latter, in addition to the myriad functions described earlier, 
potentially suppress helper T effector cell activation against the tumor by secreting 
elevated levels of immunosuppressive molecules like TGF-β and IL-10 and skew 
them towards Th2 phenotype. These molecules not only blunt helper and cytotoxic 
T cell response against the tumor, but also induce the development of Tregs 
(56, 95, 96). Also, in the TME, TAMs undergo metabolic reprograming. They 
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produce Arginase-1 and other metabolites via the indoleamine 2,3-dioxygenase 
(IDO) pathway which results in the starvation of T cells and their inactivation. L-
Arginine is metabolized by inducible Nitric Oxide Synthase (iNOS) or Arginase-1, 
depending upon the M1 or M2 state of macrophages (95). TAMs secrete Arginase-
1 and hence consumes L-Arginine from the TME to produce urea and L-ornithine 
(97, 98). Non-availability of L-Arginine restricts T cell activation (99). The Th2 cells, 
eosinophils and basophils in the TME also produce ample amount of IL-4, IL-10, 
IL-13 which elicit TAM polarization of macrophages (100-102). Tumor cells 
themselves secrete molecules like M-CSF and TGF-β to cause a phenotypic shift 
in the infiltrating macrophages (103). Most importantly, intratumoral macrophages 
are known to express immune checkpoint inhibitor molecules like PDL-1, PDL-
2 and ligands for CTLA-4 in various cancers. Upon binding with their cognate 
ligands, these molecules potentially restrict T cell receptor (TCR) and B cell 
receptor (BCR) signaling and restricts their activation and proliferation (56). 
Enhanced expression of these checkpoint inhibitors on TAMs is one of the key 
factors why most of the therapies fail in the clinic or show poor benefit. Another 
important function of TAMs is to remove cellular debris to maintain growth 
permissive environment for cancer cells. In the TME, apoptotic index is usually 
high, either due to nutrient limitation or rapid proliferation of cancer cells. TAMs 
phagocytose the cellular debris and facilitate their clearance. This process of 
efferocytosis skews the macrophages more towards TAMs and establishes further 
immunosuppression in the microenvironment (104). This aspect will be discussed 
in more details in the relevant section. 
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Finally, macrophages are essential for the formation of pre-metastatic niche 
where disseminated cancer cells seed and colonize. Once tumor cells arrive at the 
target tissue, they form micro-clots with associated platelets and get arrested in 
tissue vessels (105). Tumor cells then secrete CCL2 and recruit circulating 
monocytes via CCR2 (56, 106, 107). These recruited monocytes, called 
metastasis associated macrophages (MAM) facilitate extravasation of cancer cells 
by increasing vascular permeability.  
2.1.3. Approaches to target TAMs 
Immunotherapy has gained a lot of focus in the treatment of several cancers 
lately. With increasing amount of evidences establishing a crucial role for TAMs in 
tumor progression, metastasis and recurrence post therapy, several macrophage 
centered strategies to target TAMs are currently being explored. The approaches 
mostly aim at either inhibiting the recruitment of macrophages and thus dampening 
their protumorigenic activities, or re-educate TAMs and activate them towards an 
inflammatory phenotype that can trigger cytotoxic responses towards cancer cells 
or activate T cells. A few of the various strategies employed are listed below: 
Inhibiting the CSF-1/CSF-1R axis: CSF-1 is one of the most crucial 
molecules for myeloid cell differentiation. The ligand is overexpressed by 
many cancer cells, as a means to recruit and differentiate TAMs (56, 108) 
and their expression correlates with poor prognosis (109, 110). A number 
of small molecule inhibitors or antibody antagonists have been tested in 
multiple preclinical models (111-114). For instance, emactuzumab 
(RG7155), a humanized monoclonal antibody against CSF-1R decreased 
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TAM densities and increased CD8+ T cells in the tumor (114). It showed 
similar results in patients with several solid tumors enrolled in a phase I 
clinical trial, as part of the same study. Another similar inhibitor, Pexidartinib 
(PLX3397) induced regression in patients with tenosynovial giant cell 
tumors (115), but did not increase 6-month progression free survival in a 
phase II clinical trial with patients diagnosed with recurrent glioblastoma 
(116).  In addition to this, few other CSF-1R inhibitors, namely, BZL945, 
GW2580 have shown positive results in mouse preclinical models, either 
alone or when used in combination with gemcitabine or paclitaxel based 
chemotherapy or other inhibitors (111, 117-119).  
Re-educating TAMs towards an activated phenotype: Many of the 
studies aimed at depleting monocyte/macrophage recruitment into the 
tumor bed resulted in failure and eventual disease relapse. This is primarily 
because macrophages are crucial for eliciting antitumor adaptive 
responses. One of the most important strategies currently being explored is 
to re-educate the immunosuppressed TAMs and activate them towards an 
inflammatory M1 phenotype and prime them for triggering cytotoxicity or 
recruiting and activating cytotoxic T cells. IFN-γ has been tested in 
advanced ovarian cancer patients for its ability to induce macrophage driven 
cytotoxicity (120, 121). One of the most important molecules in this regard 
is CD40 agonist. This when administered, resulted in a shift towards M1 
type macrophages, upregulated their antigen presentation ability and 
activated T cell responses (122). Based on these findings, a fully humanized 
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CD40 agonist, CP-870,893, was tested in a phase I trial in combination with 
chemotherapy to treat advanced stage pancreatic cancer patients. The 
combination therapy showed partial responses in 4 out of 22 patients and 
correlated with improved survival (123). Another strategy that is currently 
under clinical evaluation is ibrutinib, in combination with gemcitabine-nab-
paclitaxel in advanced stage pancreatic cancer patients. This drug prevents 
the crosstalk between M2-like TAMs and B cells via the PI3Kγ-BTK pathway 
and re-polarized TAMs towards M1 type and triggered T cell responses 
(124).  
Blocking recruitment of monocytes/macrophages: Cancer cells secrete 
a wide variety of cytokines to attract and recruit circulating monocyte and 
polarize them towards TAMs. Hence, many strategies have attempted to 
block the recruitment of monocytes/macrophages to the tumor 
microenvironment. Among these, treatment with anti-CCL2 antibodies in 
combination with chemotherapy, reduced tumor growth and metastasis in 
several tumor models (125-128). CCL2 antibodies have also been tested in 
several Phase I and Phase II clinical trials (129-131), with variable results. 
Another chemokine, CCL5, when targeted with antibodies (Maraviroc), also 
associated with clinical response in a small cohort of patients with advanced 
stage colorectal cancer (132). Other strategies like, bisphosphonates 
(which induce apoptosis in bone macrophages, osteoclasts and tissue 
macrophages) and trabectedin (which deplete MDSCs and also TAM 
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population to some extent) have also yielded positive responses in bone 
metastatic cancers, like breast and prostate cancers (133, 134)  
Different strategies to target TAMs and the different clinical trials that are 
either completed or ongoing, have been discussed in more details elsewhere (65). 
Several studies over the past few years have attempted at investigating the 
biomarker potential of TAMs in several cancers. In most cases, either CD68, a pan 
macrophage marker or CD163 (a M2 type marker), CD204 (macrophage 
scavenger receptor A) or CD206 (induced by IL-4) have been used to identify 
tumor infiltrating macrophages. A high degree of TAM infiltration correlated with 
tumor grade, more advanced stage of the disease and poor clinical outcome in 
most of the cancers studied, including breast, bladder and pancreatic cancers. In 
stark contrast, a negative correlation between TAM infiltration and disease stage 
was observed in gastric cancers (135). Further, in some cancers, like non-small-
cell-lung-cancer and colorectal cancer, a high degree of TAM infiltration correlated 
with a favorable patient prognosis (136, 137). Interestingly, 
chemotherapy/radiotherapy can significantly alter the TAM phenotype, as a result 
affect the overall clinical outcome and the potential of TAMs as a predictive 
biomarker. In many preclinical models using either chemotherapy or radiotherapy, 
M2-like macrophages localized in the perivascular regions of the tumor and 
promoted disease relapse post therapy. This can be attributed to extensive tissue 
damage due to therapy which results in the recruitment of myeloid cells and 
triggering of repair mechanisms by immunosuppressive macrophages (111, 138). 
For instance, in patients with Hodgkin’s Lymphoma and follicular lymphoma who 
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underwent chemotherapy, a high degree of CD68+ TAMs correlated with 
decreased survival compared to patients who did not receive chemotherapy (139, 
140). However, in follicular lymphoma patients undergoing R-CHOP regimen, 
increased CD163+ TAM infiltration was associated with favorable outcome (141). 
This indicated that TAM function largely depends on the type of treatment used 
and they can either hamper or bolster anti-tumor immune response. Similarly, in 
case of radiotherapy, it augments macrophage infiltration into irradiated tissues. 
TAMs then either promote tissue repair mechanisms and thereby contribute to 
disease recurrence by adopting an immunosuppressive phenotype or activate anti-
tumor immune response in the host and decreasing metastatic burden (103, 142, 
143). For example, post radiotherapy, there is an increased expression of CSF-1 
and hence increased macrophage infiltration in a preclinical xenograft mouse 
model of human intracranial glioblastoma. However, combination therapy with 
radiation and Pexidartinib (CSF-1R antagonist) potentiated the therapeutic 
benefits of radiotherapy.  One of the clever ploys deployed by cancer cells is to 
overexpress ‘don’t eat me’ signals like CD47, to avoid phagocytosis by 
macrophages or other antigen presenting cells. As expected, antibody targeting 
CD47 resulted in antibody dependent cellular phagocytosis (ADCP) and yielded 
beneficial results in several preclinical mouse studies and have entered clinical 
trials. Moreover, targeting CD47 which is expressed by cancer stem cells at large, 
enabled the phagocytosis and removal of the latter by macrophages. Further, 
targeting CD47 in combination with chemotherapy showed beneficial results in 
patient derived xenograft models (144). Also, blocking CD47 in combination with 
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PDL1 blockade resulted in enhanced antitumor responses (145). However, tumor 
cell phagocytosis is a contentious topic. Increased phagocytosis of tumor cells by 
macrophages although beneficial at first, however, it skews the TAMs more 
towards protumorigenic type. The latter associates with recurrence and metastasis 
by creating an immunosuppressive microenvironment (104). Further, conventional 
anti-angiogenic therapies mostly fail because of increased infiltration of myeloid 
cells. Hypoxia resulting from vasculature destruction by anti-angiogenic drugs 
induces enhanced infiltration of macrophages that can then trigger angiogenic 
responses. Moreover, macrophages often overexpress immune checkpoint 
inhibitor molecules, like PDL-1, PDL-2, ligands for CTLA-4 among others. These 
are often further upregulated on macrophages in response to hypoxia (146). 
Antibody mediated targeting of CTLA-4 resulted in the removal of Tregs by the 
FcγR+ macrophages (147, 148). Therefore, synergistically targeting TAMs with 
anti-checkpoint inhibitor antibodies may be clinically beneficial and are currently 
undergoing early clinical assessment. Overall, these suggest that even though 
macrophage centered therapeutic strategies are currently being explored, they will 
probably yield best results when used in combination with other standard of care 
therapies or to complement other immunotherapies. 
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Fig. 2.1. Origin of tumor associated macrophages. Blood monocytes and 
monocyte derived suppressor cells (MDSCs) get recruited to the tumor tissue in 
response to a wide array of chemokines and cytokines released from the tumor. 
Once they infiltrate the tumor tissue, the monocytes and MDSCs differentiate to 
TAMs following exposure to tumor microenvironment derived factors. In some 
cancers, tissue resident macrophages can proliferate in situ and give rise to TAMs. 
This figure has been adapted from Mantovani et al. “Tumour-associated 
macrophages as treatment targets in oncology.” Nat Rev Clin Oncol. 2017. doi: 
10.1038/nrclinonc.2016.217. with permission.  
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Fig. 2.2. TAMs promote immune suppression in the tumor 
microenvironment. TAMs engage in cross-talk with other immune cell types in 
the microenvironment to suppress anti-tumor immune response. TAMs secrete 
immunosuppressive cytokines like IL-10, TGF-β which promote Treg cell formation 
and inhibit dendritic cell maturation. Metabolic reprogramming of TAMs result in 
metabolic starvation of T cells and inhibit their activation and effector functions. 
They also upregulate checkpoint inhibitor molecules like PDL-2 to further inhibit T 
cell activation. This figure has been adapted from Mantovani et al. “Tumour-
associated macrophages as treatment targets in oncology.” Nat Rev Clin Oncol. 
2017. doi: 10.1038/nrclinonc.2016.217. with permission.  
 
 
 
 
 
 
55 
 
56 
 
Fig. 2.3. TAMs promote tumor cell intravasation. TAMs engage in a bi-
directional cross-talk with tumor cells and promote tumor cell invasion. TAMs 
produce TGF-β that induce EMT in cancer cells and facilitate their migration and 
matrix remodeling and adhesion to matrix proteins. CSF-1 from tumor cells and 
EGF from cancer cells potentially results in their ‘lock-step’ conformation and the 
two cell types migrate together along the collagen fibers towards blood vessels. 
The cancer cells then pile up on the blood vessels and the macrophages help them 
intravasate through a structure known as ““Tumor Microenvironment of 
Metastasis” (TMEN). This figure has been adapted from Noy et al. “Tumor-
Associated Macrophages: From Mechanisms to Therapy.” Immunity. 2014. 
doi.org/10.1016/j.immuni.2014.09.021. with permission.  
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Fig. 2.4. TAMs promote tumor metastasis. Once the tumor cells are arrested in 
the blood vessels of target seeding organs, macrophages facilitate their 
extravasation into the tissue by increasing the vascular permeability. Also, TAMs 
promote survival of the tumor cells in the new metastatic site and suppress immune 
cell activation. This figure has been adapted from Noy et al. “Tumor-Associated 
Macrophages: From Mechanisms to Therapy.” Immunity. 2014. 
doi.org/10.1016/j.immuni.2014.09.021. with permission.  
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Fig. 2.5. Brief summary of different clinical trials to target TAMs. This figure 
has been adapted from Mantovani et al. “Tumour-associated macrophages as 
treatment targets in oncology.” Nat Rev Clin Oncol. 2017. doi: 
10.1038/nrclinonc.2016.217. with permission.  
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Fig. 2.6. TAMs are double-edged swords in cancer therapies. TAMs can either 
increase or dampen the therapeutic efficacy for anti-cancer treatments. Some 
conventional therapies (like doxorubicin, gemcitabine) can either promote the 
formation of antigen presenting cells or skew TAMs towards inflammatory M1 type. 
On the other hand, cytotoxic therapies or radiation therapies cause cell death and 
tissue damage which recruit fresh myeloid cells. The latter trigger a misdirected 
tissue repair response, re-vascularization, protection of cancer stem cell niche and 
suppression of adaptive immune response.  This figure has been adapted from 
Mantovani et al. “Tumour-associated macrophages as treatment targets in 
oncology.” Nat Rev Clin Oncol. 2017. doi: 10.1038/nrclinonc.2016.217. with 
permission.  
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Fig. 2.7. TAMs after chemotherapy as predictor for patient outcome. TAMs 
can either foster or dampen therapeutic efficacy of anti-cancer treatments and 
hence can act as predictor for clinical outcome following therapy. This figure has 
been adapted from Mantovani et al. “Tumour-associated macrophages as 
treatment targets in oncology.” Nat Rev Clin Oncol. 2017. doi: 
10.1038/nrclinonc.2016.217. with permission.  
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Fig. 2.8. Different approaches to target TAMs. Various approaches are being 
tried to either promote the cytotoxicity of TAMs by re-programing them to M1-type, 
activation of adaptive responses or inhibit their recruitment, survival or 
immunosuppression caused by them. This figure has been adapted from 
Mantovani et al. “Tumour-associated macrophages as treatment targets in 
oncology.” Nat Rev Clin Oncol. 2017. doi: 10.1038/nrclinonc.2016.217. with 
permission.  
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2.2. A brief overview of Pancreatic Cancer 
2.2.1. Epidemiology 
Pancreatic Cancer is one of the most lethal type of cancers and accounts 
for 3% of all cancers and 7% of all cancer related deaths in the United States. The 
American Cancer Society predicts 53,670 people will be diagnosed with pancreatic 
cancer in 2017. The mortality rate due to the disease is estimated at 43,090 in the 
United States alone in 2017 (2017 Cancer Facts and Figures of American Cancer 
Society). It is the 3rd leading cause of cancer related deaths in the US. By 2020, it 
is estimated to become the 2nd leading cause of cancer related deaths in the US, 
surpassing colorectal cancer. Early stages of Pancreatic Cancer are 
asymptomatic, however, for patients diagnosed with symptoms, the disease has 
already metastasized where less than 15% cases are suitable for surgical 
resection (149). Hence, chemotherapy presents the standard and only line of care 
for most of the patients, but gemcitabine provides only modest regression of the 
cancer. Almost all the patients undergoing therapy rapidly develop 
chemoresistance.  Pancreatic cancer is one of the few cancers for which the 5-
year survival rate has not improved significantly in the last 40years with 74% of 
patients dying within the first year of diagnosis and only 9% of the patients surviving 
more than 5 years. Despite extensive research, we are still desperately searching 
for the ‘magic bullet’ that can cure pancreatic cancer. There are several risk factors 
that have been associated with the disease. For example, obesity and inactivity, 
use of tobacco, exposure to certain chemicals, Type 2 diabetes, chronic 
pancreatitis, Cirrhosis of the liver, diets rich in fat have all been causally associated 
69 
 
with pancreatic cancer. In addition, genetic alterations or familial predisposition 
can also cause pancreatic cancer. For example, hereditary breast and ovarian 
cancer syndrome caused by BRCA1/2 gene mutation, familial atypical multiple 
mole melanoma (FAMMM) syndrome caused by mutations in the p16/CDKN2A 
gene, hereditary non-polyposis colorectal cancer (HNPCC) caused by a defect in 
MLH1 or MSH2 gene, familial pancreatitis caused by mutations in PRSS1 gene, 
Peutz-Jeghers syndrome, caused by defects in the STK11 gene, Von Hippel-
Lindau syndrome, caused by mutations in the VHL gene can all increase the risk 
of exocrine pancreatic cancer. (Detailed information regarding the causes, risk 
factors and prevention of pancreatic cancer is available in the official webpage of 
American Cancer Society). Pancreatic cancer stage and grade is measured using 
the standard TNM system, where T stands for the primary tumor size, N means 
whether the cancer has spread to nearby lymph nodes and finally M, indicating if 
the disease has metastasized to distant organs (more detailed information about 
the TNM grading can be found on the webpage 
https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-
staging/staging.html).  
2.2.2. Pathology 
The pancreas is a unique organ comprising of both exocrine and endocrine 
glands. The exocrine gland secretes digestive enzymes like chymotrypsinogen, 
trypsinogen amylase and pancreatic lipase. The endocrine gland, more commonly 
known as the Islets of Langerhans, produce 3 types of hormones into the blood 
stream, namely, glucagon, insulin and somatostatin. Pancreatic cancer can 
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broadly be of two main types, exocrine neoplasia and endocrine neoplasia, as 
described below in details: 
Exocrine cancer is most common type of pancreatic malignancy. About 95% 
of pancreatic tumors are adenocarcinomas (pancreatic ductal adenocarcinoma, 
PDAC). PDAC appears as a white yellow mass with the surrounding normal 
pancreatic tissue showing signs of atrophy, fibrosis and dilated ducts (150). The 
neoplasms can either present as well differentiated glands (carcinoma) or poorly 
differentiated sarcomatoid carcinomas (151). PDAC evolves from either of three 
types of pre-neoplastic lesions, namely, microscopic pancreatic intraepithelial 
neoplasia (PanIN), macroscopic cysts, namely, the intraductal papillary mucinous 
neoplasm (IPMN) and mucinous cystic neoplasm.  
The most well characterized and by far the most common precursor lesions 
for PDAC development are PanINs. Based on their cytological and architectural 
irregularities, PanINs were categorized as: PanIN-1A (flat lesion) and PanIN-1B 
(micropapillary type) that show low-grade dysplasia; PanIN-2 lesions that develop 
features like, additional loss of cell polarity, nuclear crowding, cell enlargement, 
and hyperchromasia with frequent papillary formation; PanIN-3 is the most 
advanced lesions clinically and exhibit severe nuclear atypia, luminal necrosis, and 
epithelial cell budding into the ductal lumen (152-154). However, recently, this 
three-tier classification has been replaced by a revised two-tier low grade (PanIN-
1 and PanIN-2) and high grade (PaniN-3) classification system. As per this system, 
the high-grade lesions have the most potential to generate PDAC (155). Indeed, 
low grade lesions are common in adult normal pancreas or patients suffering from 
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chronic pancreatitis. But PanIN-3 lesions are exclusively detected in invasive 
PDAC (154). 
IPMNs are less ordinary form of precursor lesion for PDAC. They arise in 
the main pancreatic duct or its major branches and are characterized by papillary 
like elongation of ductal epithelium and production of mucin (151, 152). Although 
they present better prognosis, there have been multiple incidences where IPMNs 
advanced to malignancy. Previously they were classified as villous dark cell type, 
papillary clear cell type, and compact cell type, in combination of mucin expression 
profiles. Later, based on morphology and mucin expression profiles, they were re-
classified into gastric type (=papillary clear cell type), intestinal type (=villous dark 
cel type), pancreatobiliary type, and oncocytic type (=compact cell type, 
=intraductal oncocytic papillary neoplasm (IOPN) (156, 157). Benign, borderline, 
and malignant lesions are detected in gastric and intestinal types, however, 
progression of IPMNs into carcinoma usually occurs from the intestinal type (158). 
The pancreatobiliary type and oncocytic type are mostly malignant lesions (156, 
157). Mucinous cystic neoplasms (MCNs) are rare and slow growing pre-
neoplastic lesions. They are found only in women, and are characterized by the 
development of epithelial cysts that are lined by mucin producing cuboidal or 
columnar cells and remain surrounded by ovarian stroma. Given their larger size, 
MCNs are easily distinguished from PanINs. Further, they can be categorized as 
either adenoma, borderline or malignant non-invasive or invasive neoplasia (152). 
Several other pancreatic cancers, relatively less common, of exocrine origin are 
known, for example, adenosquamous carcinomas, squamous cell carcinomas, 
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signet ring cell carcinomas, undifferentiated carcinomas, and undifferentiated 
carcinomas with giant cells (https://www.cancer.org/cancer/pancreatic-
cancer/about/what-is-pancreatic-cancer.html).  
Acinar cell carcinoma is a rare exocrine pancreatic neoplasia and accounts 
for less than 2% of exocrine pancreatic cancers. The malignant cells produce 
elevated levels of pancreatic enzymes like lipases and appear granular under the 
microscope. This is because they contain excess amount of zymogen in their 
cytosol. In ACC, the malignant cells can be arranged in two fashions: acinar, where 
the cells form a thin lumen with basal nuclei and moderate amount of eosinophilic 
cytosol in the apical portion of the cells, or solid, where the cells are arranged as 
sheets or nests with no apparent lumen. Basally palisaded nuclei can be detected 
at the interface of solid nests of malignant cells and stroma (152). Adenosquamous 
carcinoma, another rare variety, forms glands as adenocarcinoma but cells 
undergo squamous differentiation with disease progression. Colloid carcinoma is 
another form of exocrine pancreatic cancer where nests of cancer cells appear to 
be floating in extracellular mucin. This form of the disease is comparatively less 
aggressive. Hepatoid carcinoma is a very rare disease where the cancer cells 
appear like liver cells. Mucinous cystic neoplasm is more commonly found in 
women, where malignant cysts containing mucin forms at the tail of the pancreas 
and can become invasive over time. Pancreatoblastomas, more commonly known 
as pancreatic cancer of infancy, is found in children. The cancer cells look like 
nests of squamoid cells floating in a pool of more uniform looking cells, but can 
undergo acinar and neuroendocrine differentiation. Serous Cystadenomas is a 
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benign cystic tumor that can be surgically removed. Signet Ring cell carcinoma, 
another rare variety of pancreatic cancer, is characterized by the presence of large 
mucin globule in the cells that pushes the nucleus to the side of the cell, giving it a 
signet ring like appearance. Solid-Pseudopapillary Neoplasms are found in women 
in their 30’s. Some parts of the tumors can be solid or produce finger like 
projections. Although less harmless, it can metastasize if not removed. 
Undifferentiated carcinomas are extremely aggressive in nature and the malignant 
cells do not resemble any cell type in the body. Undifferentiated Carcinoma with 
Osteoclast-like Giant Cells is another extremely rare type of exocrine pancreatic 
cancer where the individual malignant cells become gigantic and resemble 
osteoclasts in the bone (http://pathology.jhu.edu/pc/BasicTypes2.php?area=ba).  
Pancreatic endocrine tumor (PNET) is more commonly known as Islet cell 
tumor. 1 in every 100,000 people is diagnosed with this rare type of disease and 
accounts for less than 2% of all pancreatic tumors (159). It is less aggressive than 
pancreatic exocrine tumors and grows more slowly. Although the exact molecular 
mechanism of PNET is not clearly determined, people with four types of inherited 
disorders, namely, Multiple Endocrine Neoplasia Type I (caused by a mutation in 
MEN1 gene on chromosome 11q13), von Hippel-Lindau disease (arises due to 
mutation in VHL gene on chromosome 3), von Recklinhausen’s disease (caused 
by NF1 gene on chromosome 17) and tuberous sclerosis complex (caused by 
mutation in TSC1 and TSC2 genes on chromosome 8) have been reported to have 
higher incidence of PNET. Intriguingly, PNET encompasses a broad range of 
neoplasms of the pancreatic endocrine cells and can either be insulinomas (insulin 
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secreting tumors), gastrinomas (gastrin secreting tumor), glucagonomas 
(glucagon secreting tumors), VIPomas (vasoactive intestinal polypeptide secreting 
tumor), somatostatinomas (somatostatinoma secreting tumor) and GRFomas 
(growth hormone releasing factor, GRF secreting tumor). PNET can also be non-
functional, meaning these tumors do not produce any hormone and therefore hard 
to detect at early stages of development and are only diagnosed when the disease 
has advanced into late stages (https://www.pancan.org/facing-pancreatic-
cancer/learn/types-of-pancreatic-cancer/endocrine-pancreatic-neuroendocrine-
tumors/).  
2.2.3. Role of the Tumor Micro-environment in PDAC: current therapies and 
challenges 
A key distinguishing feature of PDAC is the strong desmoplastic stroma that 
constitutes the bulk of the tumor. The robust desmoplastic reaction comprises of 
cancer associated fibroblasts, pericytes, endothelial cells, various immune cell 
infiltrates, pancreatic stellate cells and several cytokines and growth factors that 
remain in a complex extra cellular matrix (ECM) and contribute to disease 
pathogenesis and clinical outcome. The complex stroma in PDAC can be 
separated into the following compartments: the tumor cells, the hematopoietic 
compartment, the mesenchymal compartment and the ECM. The pancreatic tumor 
cells secrete cytokines and chemokines to recruit the immune cells and arrest them 
in a dysfunctional stage. For example, the tumor cells secrete G-MCSF to induce 
the generation of MDSCs. They also express inhibitory ligands like PDL-1, TGF-β, 
IL-10 and IDO that can directly suppress the activity of CD8 T cells. The stroma 
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acts as a physical barrier and restricts successful delivery of therapeutic drugs. For 
example, in the PDAC TME, there is extensive secretion from tumor cells and 
deposition of the glycosaminoglycan hyaluronan or hyaluronic acid (HA) (160). HA 
is negatively charged and therefore can imbibe large amount of water, expand and 
exert stress on the collagen fibers. The latter contract under the tensile stress, 
increase the interstitial fluid pressure (IFP) which ultimately results in vascular 
collapse and hence the hypoperfusion (161) and limited access of drugs to the 
tumor interior. Indeed, treatment with pegylated hyalurinidase (PEGPH20) 
degraded HA, decreased IFP and improved drug delivery by increasing 
intratumoral vessel patency (161, 162). Administration of PEGPH20 in combination 
with gemcitabine decreased the metastatic burden and increased the objective 
response rate (161). A recent phase III clinical trial in combination with gemcitabine 
improved survival in metastatic PDAC patients (163). Other potential targets 
include cancer associated collagen, decorin, fibronectin, versican, and connective 
tissue growth factor (CTGF), all of which have been reported to correlate with 
PDAC progression (164). A monoclonal antibody against CTGF in combination 
with gemcitabine is currently used in clinical investigation in PDAC patients 
(NCT01181245). The pancreatic stellate cells (PSC) also play a significant role in 
stromal resistance in PDAC. Pancreatic tumor cells stimulate the PSCs become 
activated to myofibroblasts and secrete ECM components and promote 
fibrogenesis (165). Olive et al. showed that inhibition of Sonic Hedgehog pathway 
(Shh) can deplete the stroma and improve drug delivery by increasing vascularity 
(166). However, it was accompanied with rapid development of therapy resistance 
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and more aggressive disease features. Additionally, a phase I and phase II clinical 
trial launched by Infinity Pharmaceuticals was stopped owing to poor clinical 
performance of the drug.  
Intriguingly, the significance of the hematopoietic compartment in PDAC 
can be understood from the fact that they constitute 50% of the total cells in the 
PDAC tissue. As in the case of most tumors, in PDAC, the infiltrating macrophages 
(TAMs), MDSCs, and T cells engage in complex paracrine signaling that eventually 
results in suppression of T cell response and generation of Tregs and MDSCs. In 
human PDAC, the frequency of MDSCs in circulation correlates with the stage of 
the disease (167). Frequency of Granulocyte MDSC (Gr-MDSC) correlates with 
more advanced stage of the disease (168). Depletion of MDSC in autochthonous 
PDAC model resulted in activation and infiltration of T cells (169). However, 
depletion of Gr-MDSC increased the population of monocytic MDSC (Mo-MDSC). 
Additionally, a recent phase I study aimed at depleting Gr-MDSCs did not work in 
patients (170).  This creates an immune privileged TME that aids and abets the 
tumor progression. Tregs comprise another significant factor for therapy failure. 
They accumulate as early as in pre-invasive lesions, thereby dampening T cell 
response from the earliest stages of disease progression (169) and abundantly 
present in the blood, lymph nodes and primary lesion in PDAC patients (171, 172) 
and correlated with poor survival (173). Currently, several strategies are being 
tested to target Tregs (174).  For example, two approved antibodies against the 
immune checkpoint inhibitor CTLA-4, namely Ipilimumab and Tremelimumab are 
currently being tested in several clinical trials in PDAC. Although Ipilimumab failed 
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to show significant benefit in a phase II clinical trial of locally advanced or 
metastatic disease, it has shown promise when used in combination with GVAX, 
a G-MCSF gene transfected vaccine aimed at activating immune cell response 
(175). Currently several other clinical trials are ongoing where patients are being 
treated with a combination of Ipilimumab and GVAX or Ipilimumab and 
gemcitabinehydrochloride 
(https://clinicaltrials.gov/ct2/show/study/NCT01896869,https://clinicaltrials.gov/ct2
/show/NCT01473940). Another potential immunotherapeutic method is genetically 
modifying autologous T cells and adoptively transfer them back to the patients to 
equip them to mount immune response against the tumor associated antigens 
(TAA). This is achieved by using modified T cell receptor (TCR) or chimeric antigen 
receptors (CAR). Several CAR based preclinical studies performed in mice yielded 
promising results with tumor regression and increased disease free survival (176-
178).  
Among the myeloid cells, dendritic cells (DC) are the most potent antigen 
presenting cells (APC) that can potentially present antigen to activate adaptive T 
cell response (koski 2008 immunol rev). However, like most cancers, in pancreatic 
cancer DC function is compromised by secretion of factors that interfere with DC 
recruitment, activation and survival (179). In pancreatic cancer, DCs are mainly 
located at the tumor edge and their recruitment to the microenvironment 
compromised. Fewer DC in circulation correlated with poor outcome in PDAC and 
increased number of circulator DCs correlated with better survival in both 
resectable and non-resectable tumor (180-182). Therefore, strategies to activate 
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DC can in turn result in alerting the adaptive immune response against the tumor 
cells. In PDAC patients treated with gemcitabine or cisplatin, DC functions were 
restored and showed synergistic effect with chemotherapeutic drugs (183, 184).  
TAMs are the major constituent of pancreatic tumor stroma. Macrophages 
can secrete inflammatory cytokines and molecules to promote acinar-ductal 
metaplasia, a dedifferentiated state that can potentially become malignant (185). 
Not only are macrophages abundantly present in the preinvasive lesions (169), but 
they also are a rich source of cytokines, chemokines, proteases, angiogenic 
molecules and growth factors that can remodel the ECM, induce EMT in cancer 
cells and facilitate metastasis as well as suppress anti-tumor T cell responses. Like 
most solid tumors, CD163+ or CD204+ macrophages are associated with shorter 
survival in PDAC, whereas increased infiltration of M1-type macrophages is a 
predictor of longer survival in patients (173). Distinct aspects of TAM in PDAC are 
discussed in detail in the following sections. 
2.2.4. Role of macrophages in the progression of Pancreatic Cancer 
As mentioned earlier, the hallmark of Pancreatic Cancer is its rich 
desmoplastic microenvironment, which is some cases can account for up to 80% 
of the tumor mass. The stroma comprises tumor infiltrating immune cells including 
macrophages, Tregs, endothelial cells, myofibroblasts and extracellular matrix 
components (186). Infiltrating immune cells are one of the major concerns for 
development of therapy resistance in Pancreatic Cancer. Macrophages are the 
most abundantly found immune cell type in the pancreatic cancer TME and 
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contribute to various aspects of pancreatic cancer progression, therapy resistance 
and disease relapse, as described below in details: 
Macrophages and prognosis in pancreatic cancer: It is now well established 
that TAMs promote tumor progression by inducing tumor associated angiogenesis, 
facilitating EMT and invasion, increasing the stemness of cancer stem cells and 
suppressing the anti-tumor immune response. CD163+ TAMs were detected in 
primary lesions of pancreatic cancer, compared to adjacent normal tissues and 
chronic pancreatitis and positively correlated with tumors in the tail and body of the 
pancreas (187). Further, elevated TAM infiltration could be causally associated 
with lymph node metastasis, neural invasion of the tumor, therapy resistance and 
poor survival in pancreatic cancer (188, 189). However, it is important to note that 
macrophage phenotype can be stage dependent and evolves with advancement 
of the disease. For example, in the initial stages of PDAC, macrophages are more 
M1-type but get skewed more towards M2-like TAMs with progression of cancer 
(96).  
Factors important for the recruitment and polarization of macrophages in 
pancreatic cancer: Tumor cell derived chemokines, cytokines and other growth 
factors recruit circulating monocytes and polarize them towards pro-tumoral TAMs 
as the monocytes infiltrate the TME. One of the most potent chemokines in this 
regard is C-C chemokine ligand 2 (CCL2) that acts via its receptor CCR2 (68, 107). 
Several cytokines, like macrophage colony stimulating factor (M-CSF) and 
endothelial monocyte-activating polypeptide II (EMAPII) have been shown to 
recruit monocytes to tumor site. However, M-CSF is not frequently expressed by 
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pancreatic cancer cells (190). The latter on the other hand, express significantly 
higher level of granulocyte macrophage (GM-CSF) that can potentially generate 
MDSCs (191). Additionally, pancreatic cancer cell derived GM-CSF is sufficient for 
the development of CD11b+ TAMs and suppression of immune response against 
the tumor (191). Once inside the TME, tumor cell and other stromal cell derived 
factors hijack the monocytes and re-educate them towards TAM phenotype. In 
Pancreatic cancer, several factors have been identified in this context. For 
example, Heparanase, which cleaves heparan sulfate glycosaminoglycans, can 
potentially augment STAT3 signaling in TAMs and contribute to their pro-
tumorigenic activity (192).  
Role of macrophages in various aspects of pancreatic cancer pathogenesis: 
As in other types of cancers, TAMs in pancreatic cancer have been causally 
associated with various aspects of the disease, such as angiogenic and hypoxic 
responses, silencing of the adaptive immune response against cancer cells, EMT 
and cancer invasion, stem cell survival and metastasis. TAMs are known to induce 
angiogenesis by releasing well characterized panel of pro-angiogenic molecules, 
such as, VEGFA, TNF-α, basic fibroblast growth factor (bFGF) and thymidine 
phosphorylase (TP). Inside the TME, TAMs are known as the most potent source 
of VEGFA. They also secrete other molecules and enzymes, like, MMP-2, MMP-
7, MMP-9, MMP-12, COX-2, CCL2, CXCL12, CXCL8, CXCL13 and CCL5, all of 
which can act as angiogenesis modulators. However, pancreatic cancer is 
strikingly less dependent on angiogenesis, showing substantially lesser number of 
microvessels compared to normal pancreas  and hence is hypovascular (193). In 
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contrast, there are reports which have correlated the expression of VEGFA with 
high vessel density in pancreatic cancer, increased risk for metastasis and poor 
disease outcome. Further, TAMs can express TIE-2 and localize in the hypoxic 
region of the tumor in response to Angiopoietin-2 (Ang-2) secreted from the 
hypoxic vascular cells and contribute to angiogenic switch (194). M-CSF secreted 
into the TME can also upregulate the expression of TIE-2 on TAMs (195). TAMs 
have been shown to promote the self-renewal and tumorigenic and metastatic 
propensity of CSCs in various cancers (196). In PDAC, pharmacologically 
targeting CSF-1R or CCR2 and thereby inhibiting TAM recruitment significantly 
reduced the number of pancreatic cells expressing the CSC marker ALDH (197).  
EMT is a hallmark feature of cancer cells prior to metastasis. Pancreatic 
cancer cell lines like, Panc-1 and BXPC3 when cultured in the presence of TAMs, 
upregulate mesenchymal markers and suppress the expression of E-Cadherin. 
Cytokines like IL-10, macrophage migration inhibitory factor (MIF) and CCL-18 
have been reported to contribute to EMT (198). It is thus likely that these molecules 
secreted from TAMs act in concert to promote EMT in pancreatic cancer. It is well-
known that TAMs secrete molecules and enzymes to remodel the matrix for cancer 
cell invasion and migration. In PDAC, TAMs produce macrophage inhibitory 
protein-3 alpha (MIP-3α) that can regulate cancer cell invasion through the 
production of MMP-9. Another important function of TAMs is facilitating 
lymphangiogenesis, a crucial factor for metastasis. Studies have shown strong 
correlation between infiltration of CD163+ and CD206+ TAMs and 
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lymphangiogenesis (199) and poor prognosis resulting from lymph node 
metastasis.  
One of the main challenges for treating PDAC is the desmoplastic reaction 
associated with it. PDAC stroma is essentially immunosuppressive in nature. 
TAMs, which are abundantly present in the PDAC TME, constitute one of the key 
factors responsible for suppression of adaptive immune response against the 
cancer cells. As mentioned earlier, TAMs successfully suppress immune activation 
in the TME by inducing the formation of Tregs and secreting immunosuppressive 
cytokines like, IL-10, TGF-β which potentially blunt the activation and function of 
helper and cytotoxic T cells and arresting them in an immature stage. TAMs can 
also secrete factors like IL-4, IL-13, IL-1β and G-MSCF which can potentially 
generate MDSCs and further cause immunosuppression (200). Of note, TAMs, 
Tregs, MDSCs all express several immune checkpoint inhibitor molecules like 
PDL-1, CTLA-4 etc. It is thus likely that all these immunosuppressive immune cells 
work synergistically in PDAC TME and contribute to disease progression and 
therapy resistance.  
2.2.5. Probable Strategies for Targeting TAMs in Pancreatic Cancer 
TAMs are indispensable for cancer progression. Hence, extensive research 
is currently ongoing to develop potential therapies and target intratumoral TAMs. 
In the TME, the life span of a macrophage can be divided into three stages: 
mobilization from bone marrow and recruitment to target tissue, transformation 
depending on local cues derived from the microenvironment and pro-tumoral 
activities. Therefore, anti-macrophage therapies attempt at targeting either the 
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recruitment step, survival of TAMs or re-educating and re-polarizing them towards 
anti-tumor type. For example, CCL-2/CCR2 axis is important for the recruitment of 
circulating monocytes to tumor site in PDAC and blocking this axis inhibits the 
mobilization of bone marrow monocytes and their subsequent recruitment to tumor 
site and has shown promising results in several clinical trials in various neoplasms. 
PF-04136309, a small molecule inhibitor for CCR2 (developed by Pfizer) depleted 
CCR2+ CD14+ monocytes and macrophages from primary pancreatic cancer and 
pre-metastastic liver. This also activated anti-tumor immune response and 
reduced tumor growth and metastasis in mice (201).  
M-CSF and CSF-1R signaling axis is very important for macrophage 
functioning. Targeting this axis has yielded promising results in various cancers 
(202). Despite the fact that PDAC TME produces more G-MCSF compared to M-
CSF, several reports have documented the benefit of targeting CSF-1R axis in 
reducing CSCs and improving therapeutic response in vivo (197). Also targeting 
this axis depletes the CD206+ TAMs and re-polarize the remaining macrophages 
towards an activated phenotype (203). Another attractive approach of targeting 
TAMs is to re-educate them towards an inflammatory and activated M1-like 
phenotype, which will then support the activation of anti-tumor adaptive immune 
response. One of the prominent studies in this regard was done by administering 
CD40 agonist antibody. CD40 is a cell surface receptor expressed in various APCs 
like monocytes, macrophages, DCs. Its ligand CD40L is expressed on activated T 
cells. Binding of the ligand with CD40 results in the proliferation and activation of 
CD4+ and CD8+ T cells (204). Preclinical studies using CD40 agonist induced 
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infiltration of CD40+ macrophages into the tumor and induced elevated levels of 
M1-type markers in intratumoral macrophages (MHC class II, CD86) and mounted 
robust anti-tumor response (122). Further, CD40 agonists (CP-870, 893) in 
combination with gemcitabine significantly increased treatment efficacy in a small 
cohort of 22 patients with surgically incurable pancreatic cancer (123). Using 
RECIST criteria, 4 patients showed partial response, 11 patients with stable 
disease with PET demonstrating 25% reduction in FDG uptake in the primary 
tumor. 1 patient with partial response also showed complete regression of 7.6cm 
liver mass and 47% regression in second liver metastasis. Also, the level of 
inflammatory cytokines increased in the patients.  
There are several other reports that have attempted at targeting TAM 
survival in the TME using mouse models and have observed moderate to 
promising results. However, anti-TAM therapy in pancreatic cancer is still in its 
infancy. One important caveat is that most of the therapeutic strategies proposed 
in the current section have been validated in mouse tumor models. Also, many 
therapies that have shown promising results in other cancers have not yet been 
validated in PDAC. Hence, more extensive research is required to successfully 
target TAMs in PDAC in the future.  
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Fig. 2.9. Anatomy of the pancreas. a: Gross anatomy of the pancreas. b: The 
exocrine pancreas. c:  A single acinus. d: A pancreatic islet embedded in exocrine 
tissue. The pancreas consists of separate functional units for performing two major 
functions: secretion of digestive juices and glucose metabolism. The acinar cells 
that produce the digestive enzymes form the bulk of the pancreatic tissue and are 
organized into grape-like clusters. The ducts produce mucus and bicarbonate to 
the enzyme mixture and terminate in main and accessory pancreatic ducts and 
empty into the duodenum. The endocrine pancreas secretes hormones into the 
bloodstream. The α- and β-cells produce glucagon and insulin, respectively. 
Pancreatic polypeptide and somatostatin are produced in the PP and δ-cells and 
regulate the secretory properties of other pancreatic cells.   This figure has been 
adapted from Bardeesy et al. “Pancreatic cancer biology and genetics.”  Nat Rev 
Cancer 2002. doi:10.1038/nrc949 with permission.      
86 
 
87 
 
Fig. 2.10. Progression of PanIN lesions to Pancreatic Ductal 
Adenocarcinoma. Pancreatic Cancer progresses sequentially through the 
formation of PanIN lesions (low grade to high grade) to invasive carcinoma, 
acquiring mutations in stages. The hallmark mutations occur in the genes K-RAS 
and the tumor suppressors CDKN2, TP53, SMAD4/DPC4 and BRCA2. The figure 
has been adapted from http://2010.igem.org/Team:ESBS-
Strasbourg/proteolux/application/cancer.  
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Fig. 2.11. Different components of the desmoplasia associated with PDAC. 
PDAC TME is comprised of cancer associated fibroblasts, TAMs, Tregs, other 
immune cells, endothelial cells, and matrix proteins and contribute to the dense 
desmoplasia that is the hallmark feature of PDAC. Cancer associated fibroblasts 
deposit matrix which creates solid stress and compresses the vasculature for 
limited diffusion into the tumor. TAMs, Tregs are mainly responsible for suppression 
of the immune responses against the tumor cells. The figure has been adapted 
from Carr et al. “Pancreatic cancer microenvironment, to target or not to target?”. 
Embo Mol Med 2016. doi:  10.15252/emmm.201505948 with permission.  
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 Fig. 2.13. Therapeutic agents and strategies to target TAMs at different 
stages of pancreatic cancer pathogenesis. The figure has been adapted from 
Cui et al. “Targeting tumor-associated macrophages to combat pancreatic 
cancer.” Oncotarget 2016. doi:  10.18632/oncotarget.9383 with permission.  
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3.1. Efferocytosis: A Brief Overview 
Efferocytosis is a strictly orchestrated process where phagocytes, such as 
macrophages recognize and engulf apoptotic cells and remove them from the 
system in an immunologically silent manner. Programmed cell death, such as 
apoptosis is an indispensable process, starting from early developmental stages 
and lasting over an organism’s lifetime, for the maintenance of physiological 
homeostasis. In adult humans, one million cells undergo apoptosis per second as 
part of the regular turnover process (205, 206). However, under normal 
homeostatic conditions, we rarely observe any apoptotic cell. This is because the 
apoptotic cellular debris is as efficiently removed through the process of 
efferocytosis as it is generated, to avoid inappropriately evoking the adaptive 
immune responses. If apoptotic cells are not engulfed, they leak out their cellular 
contents as secondary necrosis and this result in aberrant immune responses by 
exposure to self-antigens and a break in tolerance. Indeed, in absence of 
clearance of apoptotic cells, lethal developmental defects, autoimmune disorders 
or even cancers can occur. Also, components leaked out as secondary necrosis 
can be recognized by IgG autoantibodies which in turn can activate the 
inflammatory immune response. All these events thereby underscore the 
importance of efferocytosis in maintaining normal human physiology. 
In the tissues, the task of recognizing, engulfing and clearing the apoptotic 
cells have been endowed upon professional phagocytes, like macrophages as well 
as nonprofessional phagocytes, such as epithelial cells or fibroblasts. Tissue 
Resident Macrophages are the most well characterized cell population that 
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efficiently clear dying cells in different tissues. However, in the absence of 
professional phagocytes, nonprofessional phagocytes can fill up the niche. For 
example, in the mammary gland or the intestinal epithelium, where macrophages 
are scarce, the tissue epithelial cells and fibroblasts play a leading role in clearing 
the apoptotic cellular debris. In addition to the alveolar macrophages, bronchial 
epithelial cells can also clear the cellular debris resulting from airway epithelial cells 
undergoing apoptosis (207).  
3.1.1. Stages of efferocytosis 
The process of efferocytosis occurs in 4 stages:  
1. Release of ‘find me’ signals from dying cells to recruit phagocytes to 
the site of cellular corpses: In most of the cases, phagocytes are not 
proximal to the site of cell death. Therefore, to recruit phagocytes to the 
location of cell death, the dying cells express a variety of ‘find me’ molecules 
that act as chemotactic signals for the phagocytes e.g. ATP, Sphingosine-
1-Phosphate (S1P), Lysophosphatidylcholine (LPC), CX3CL1 and a wide 
variety of other molecules. ATP released from dying cells in a caspase 
dependent manner via the activation of pannexin-1 channels is recognized 
by purinergic receptors, like P2Y2 on phagocytes (208). Fractalkine or 
CX3CL1 released from dying cells bind to CX3CR1 expressed on 
phagocytes and mediates their migration to site of cell death (209). 
2. Phagocyte recognition of apoptotic cells and activation of ‘eat me’ 
molecules on the dying cells: Once the phagocytes reach the site of cell 
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death, the apoptotic cells upregulate various molecules that serve as ‘eat 
me’ signals to the former. Also, these molecules help the phagocytes to 
distinguish between apoptotic cells from neighboring healthy cells. Among 
others, Phosphatidyl Serine (PtdSer) is arguably the most well-known ‘eat 
me’ molecule expressed on the surface of apoptotic cells. This is then 
recognized by several molecules like, T-cell immunoglobulin mucin receptor 
4 (TIM4), brain-specific angiogenesis inhibitor 1 (BAI1), and stabilin-2 as 
well as several bridging molecules, like milk fat globule-EGF factor 8 (MFG-
E8) and Gas6. These then engage integrin αvβ3, αvβ5, or Tryo3-Axl-Mer 
(TAM) receptors on the surface of the phagocytes to begin the uptake 
process. There are several other molecules like ICAM3, Calreticulin, 
Oxidized LDL-like moieties and glycosylated surface proteins  that have 
been reported to further enhance this process by acting as ‘eat me’ 
molecules. Of note, healthy cells express several ‘don’t eat me’ molecules 
on their surface, like CD47 which is recognized by cognate receptor SIRPα 
on phagocyte, that impairs phagocytosis of living cells even in the presence 
of externalized PtdSer (210). Indeed, constitutive expression of CD47 is a 
clever ploy used by cancer cells to avoid being phagocytosed (17). 
Administration of neutralizing antibodies against CD47 has shown 
promising results in mouse tumor models (211) and extensive research is 
ongoing to develop effective neutralizing antibodies against CD47 to treat 
lethal malignancies. CD31 and CD300a are two additional ‘don’t eat me’ 
molecules, albeit less well characterized in comparison with CD47. 
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3. Uptake of the apoptotic corpse: Once the phagocyte captures the dying 
cell, the next step in the process of efferocytosis is internalization of the 
apoptotic cell by the phagocyte. This process is similar to macropinocytosis 
and requires active membrane ruffling. Once the ‘eat me’ molecules engage 
the cognate receptors on the phagocyte, there occurs extensive 
cytoskeleton rearrangement in the latter to facilitate the uptake process. 
This is mediated by the Rho family of small GTPases like RhoA, ROCK, 
Rac and Cdc42. RhoA negatively regulates efferocytosis and its depletion 
enhances the uptake process (210). Its effect is mainly mediated by 
increasing the kinase activity of ROCK, which in turn phosphorylates Myosin 
Light Chain and increases the contractility of the cell (212), thereby 
inhibiting the formation of pseudopods and phagocytic cup formation. 
However, RhoA activation at later stages may aid the digestion process by 
enhancing phagosome acidification (213). Different pathways have been 
proposed so far, that can regulate the uptake process. All pathways 
ultimately lead to the evolutionarily conserved Rac1. GTP-bound active 
Rac1 promotes Arp2/3 activation and cytoskeleton rearrangement through 
Scar/WAVE pathway for phagocytic cup formation (214, 215). 
4. Processing, degradation and clearance of engulfed cell: Once the 
apoptotic cell is inside the phagocyte, the latter begins the process termed 
as phagosome maturation that eventually leads to degradation of the cargo. 
In fact, recent studies indicate the events downstream of uptake, that is 
proper digestion and clearance affects the phagocyte’s ability to engulf 
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additional targets (216-218). For efficient clearance, phagosomes 
containing the cellular corpse undergoes acidification and ultimately fuse 
with the lysosomes (219, 220). The process of efferosome (phagosome 
containing apoptotic cell debris) maturation and degradation of apoptotic 
cells in professional phagocytes proceeds very rapidly, thus making it 
technically challenging for researchers to investigate the process. The 
maturation of early phagosomes to mature late phagosomes and eventual 
fusion with the lysosomes is similar as in classical endocytosis. First, 
Dynamin, a GTPase is recruited to the phagocyte-apoptotic cell interface. 
This then interacts with Vps34 on the nascent phagosome, and recruits 
GDP-bound GTPase Rab5. Rab5 is then activated by GEFs like Gapex-5 
(221) which then promotes Vps34 activation and generation of PtdIns(3)P 
on the surface of the phagosome. Next, Mon1 and its partner Ccz-1 form a 
complex and act as Rab5 effector and recruit Rab7 and its activation 
(222)an event that is crucial for phagosome maturation. Indeed, in Mon1 
depletion conditions, phagosomes were arrested at Rab5+ stage and failed 
to transit to Rab7+ late phagosomes. Next, the HOPS complex gets 
activated and the phagosome fuses with the lysosome. Inside the mature 
phagolysosomes, the apoptotic cells are then degraded by the acidic 
proteases and nucleases.  
Recently, another pathway has been proposed that can contribute 
significantly to the overall degradation and clearance process. This 
pathway, named LC3-associated autophagy (LAP) is at the interface of 
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autophagy and phagocytosis. LAP gets activated once a phagocyte 
internalizes a cargo using surface receptors, like Toll like receptors 1/2 (TLR 
1/2), TLR4, TLR 2/6, FcR, and TIM4 (recognizes PtdSer on apoptotic cells) 
and play a vital role in regulating the immune response. Interestingly, it has 
been reported that bacterial viability is needed to initiate LAP, however this 
is not the case for zymosan bioparticles or efferocytosis of apoptotic cells. 
Despite sharing several common molecular players, there are certain 
fundamental differences between canonical autophagy and LAP. For 
example, the latter recruits LC3 to the phagosomes as early as within 5-
10minutes of phagocytosis whereas in canonical autophagy, LC3 
recruitment can take up to several hours.  In brief, following engulfment, the 
Class III PI3K complex, comprising of Beclin 1, VPS34, UVRAG and 
Rubicon are recruited to the phagosome (here LAPosome) containing the 
apoptotic debris. The PI(3)P generated by VPS34 is important for the 
recruitment of the downstream LAP components (such as, ATG5, ATG12, 
ATG16L, and ATG7). PI(3)P and Rubicon stabilize NOX2, the predominant 
NADPH oxidase in phagocytes, for the production of ROS at the 
phagosome. Both PI(3)P and ROS help recruit LC3 to the LAPosome 
surface which then fuses with the lysosome for degradation of the cargo 
(223, 224).   
3.1.2. What happens to the efferocyte: Efferocytosis a fate-determining event 
for macrophages? 
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As mentioned earlier, inappropriate inflammation or aberrant activation of 
the immune response needs to be kept in check for the maintenance of 
physiological homeostasis. Hence, the hallmark feature of efferocytosis is the lack 
of immunogenic response. Several clinical conditions have been identified where 
defective clearance of dying cells contribute to the pathogenesis. Indeed, defects 
in the efferocytosis receptors like, MerTK, CD36 or MFG-E8, give rise to 
autoimmunity in mice and humans, especially systemic lupus erythematosus 
(SLE) (225). 
The effects of efferocytosis can vary depending on the type of the 
efferocyte. For example, the rate of digestion of engulfed apoptotic cells is much 
slower in DCs than in macrophages (226), thereby allowing the dying cell derived 
antigens to associate with the MHC molecules for presentation to the adaptive 
immune system. Further, DCs have been reported to exhibit selectivity in their 
ability to engulf and digest cellular corpses. CD8a+ and CD103+ DCs that express 
the transcription factor Batf3 are much more efferocytic than CD11b+ DCs that are 
dependant on the transcription factor IRF4 (227). Also, the more efferocytic DCs 
(CD8+ and CD103+) can then migrate to the lymph nodes where they can cross-
present the antigens to the cytotoxic T cells for their cross-priming. Apoptotic cell 
derived immunogens can also escape the efferosomes and associate with MHC1 
molecules for cross-presentation. Presence of elevated levels of TLR3/7 in the 
endosomes can facilitate this process and subsequent activation of CD8+ T cells. 
The effect of efferocytosis on non-professional phagocytes like, epithelial cells or 
stromal cells is not clearly understood and needs further investigation. In case of 
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macrophages, efferocytosis reprograms phagocytes to an anti-inflammatory 
phenotype. Following engulfment of apoptotic cells, phagocytes suppress the 
production of inflammatory cytokines like, IL-12, TNF-α and IL-1 and upregulate 
the production of immunosuppressive cytokines like, TGF-β and IL-10 (225). Both 
TGF-β and IL-10 are potent in dampening effector helper T cell response by 
stimulating regulatory T cells and T helper 2 cells. Also, in case of any inflammatory 
condition, like microbial infection, the infiltrating inflammatory cells (such as 
neutrophils) are cleared through efferocytosis by macrophages during the 
resolution phase. In macrophages with impaired LAP, phagosome acidification 
does not occur resulting in defective degradation of apoptotic debris. These LAP 
deficient macrophages produce considerable amounts of inflammatory cytokines 
like IL-6 and IL-1β, but not anti-inflammatory cytokines like IL-10. The exact 
molecular mechanism that couples the two processes of efferocytosis and immune 
suppression is not clearly understood and is under extensive investigation. 
However, recent studies have identified several nuclear receptor (NR) family 
members for their role in the regulation of inflammatory response during 
efferocytosis. For example, depletion of LXR-α/β in macrophages fail to produce 
TGF-β and IL-10 but secrete copious amount of IL-1β and IL-12 (228). However, 
the molecules that trigger these nuclear receptors or bridge the various stages of 
efferocytosis with gene regulation is still not clearly known. 
Finally, the efferocytic macrophages must also be removed from to 
establish tissue homeostasis. Three possibilities have been proposed: either the 
efferocytic macrophages exit the body through mucosa or emigrate to the blood or 
101 
 
lymph or they undergo programmed cell death and are removed locally by tissue 
resident macrophages (225). Contrary to the idea that macrophages lack the 
imigratory property to lymphatics in comparison with DCs, it was documented that 
following efferocytosis, CD11Bhigh macrophages convert to CD11Blow satiated 
phagocytes with enhanced pro-resolving properties and display propensity to 
migrate from the site of inflammation to the lymphoid organs (229). This is crucial 
for the return of homeostasis in the tissue. However, the satiated macrophages 
can also release chemoattractants to recruit new monocytes for continued 
clearance of cellular debris.  
3.1.3. Efferocytosis in different conditons 
The impact of effecrocytosis has been studied under different conditions. A few 
are discussed in detail below. 
Efferocytosis in microbial clearance: Efferocytosis plays a vital role in microbial 
clearance (230). Many of the pathogens that infect cells deploy mechanisms to 
hijack the cellular machinery in order to persist inside the host cell. The infected 
cell activates the apoptosis pathway to get rid of the pathogen. Cytotoxic T cells 
can also extrinsically induce apoptosis in the infected cell by secreting perforins or 
granzymes or via the Fas/FasL pathway. The apoptotic cell with its load of 
infectious particles is next engulfed by macrophages through efferocytosis. This 
can potentially have two possible outcomes: either the pathogen will be destroyed 
along with the engulfed dying cell or the pathogen can use the process of 
efferocytosis as a “Trojan Horse” mechanism to disperse into and infect new host 
cells. For example, during the infection of Leishmaniasis major, infected 
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neutrophils undergo apoptosis. These dying neutrophils with their intracellular load 
of pathogen are then efferocytosed by macrophages and this is a crucial step for 
establishment of the disease. Strikingly, infection of macrophages with 
Mycobacterium tuberculosis usually induces necrosis to allow dispersion to new 
cells (231). However, it does induce apoptosis in some of the infected 
macrophages. These apoptotic macrophages are next efferocytosed by uninfected 
macrophages that then destroy the pathogen along with the dying cell corpse using 
phagolysosomal fusion machinery (232). What is intriguing, in many cases the 
infection with bacterial pathogen circumvents the phagolysosomal fusion and 
degradation. This can be attributed to the ability of many pathogens to arrest 
phagosome maturation and prevent phagolysosomal fusion. For example, 
Mycobacterium tuberculosis have several bioactive lipids on their surface that 
interfere with the recruitment of endosome and lysosome and hence phagosome 
maturation (233, 234). However, when the apoptotic cell containing the pathogen 
is efferocytosed by uninfected macrophages, it results in clearance of the 
pathogen. This may be possible because the pathogen, when infected along with 
the dying cell, remains in the efferosome and hence may not have access to the 
host cell efferocytosis machinery. Also, despite the fact that many of the molecular 
components are similar in the processes of classical phagocytosis and 
efferocytosis, a different subset of effector molecules are involved in efferosome 
maturation than a phagosome (219, 220). For example, canonical Rab5 GEF, 
Rabex5 is involved in phagosome maturation but not in efferosome maturation. 
Instead, Gapex5 may potentially act as Rab5 GEF during maturation of 
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efferosomes. Hence, it is possible that the pathogen is not equipped with 
remodeling or interfering with these family of proteins and hence efferosome 
maturation proceeds resulting in the eventual pathogen clearance. Of note, 
molecular players associated with autophagy are also known to be involved in 
efferocytosis mediated pathogen clearance (223). As mentioned earlier, 
efferocytosis of apoptotic cells induce the secretion of anti-inflammatory molecules 
and cytokines in macrophages. However, when a macrophage ingests an 
apoptotic cell infected with pathogen, two possible conflicting signals are expected: 
pathogen associated molecular patterns (PAMPs) that drive inflammatory 
signaling pathways, and apoptotic cell that triggers the anti-inflammatory 
responses. Currently, the unique signal elicited by a macrophage following 
efferocytosis of pathogen-infected cell is still not clearly understood. 
Efferocytosis in atherosclerosis: Atherosclerosis is a clinical condition where 
plaques form inside arteries due to deposition of fatty materials, like, cholesterol, 
fatty substances, cellular waste products, calcium and fibrin. As plaques continue 
to accumulate, it narrows the artery wall, gradually slowing down blood flow and 
decreasing oxygen availability to cells. Atherosclerosis can result in clinical 
conditions like a heart attack, angina, stroke and gangrene. Macrophages play 
crucial role in all stages of atherosclerosis (235). They are recruited to clean up 
the plaque and their ability of efferocytosis correlates with disease stage and 
plaque stability. The conventional M1/M2 phenotype of macrophages depends on 
the stage of the lesion in atherosclerosis and is dynamic and complex, and 
probably undergoes conversion depending on a variety of factors (236). As the 
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fatty materials get deposited on the artery wall, it recruits circulating monocytes 
and differentiate them to macrophages. The latter engulf the lipoproteins and store 
the lipids in droplets, becoming foam cells in the process. The foam cells secrete 
inflammatory cytokines and finally undergo apoptosis. They are then cleared by 
efferocytosis by freshly recruited macrophages, which results in resolution of 
inflammation in the early lesions and thus reduction in lesion cellularity and size. 
However, in the more advanced lesions, the process of apoptosis exceeds 
efferocytosis and hence clearance of apoptotic macrophages is impaired. This 
results in the accumulation of apoptotic macrophages and subsequent secondary 
necrosis. Gradually a necrotic core builds up which leads to further inflammation 
and formation of vulnerable plaque and acute thrombosis.  
3.1.4. Efferocytosis in cancer: TAMs paving a pro-metastatic niche? 
The exact role of phagocytosis of cancer cells by phagocytes is a 
contentious topic. As mentioned earlier, cancer cells upregulate the expression of 
‘don’t eat me’ signals e.g. CD47 to escape being phagocytosed. Treatment with 
neutralizing antibodies against CD47 have shown promising results in various 
mouse tumor models and extensive research is currently ongoing to develop anti 
CD47 therapies for clinical trials. Recently, Gordon et al. has shown that TAMs 
express PD-1, a well-known checkpoint inhibitor for T cell activation and its 
expression negatively regulates the ability of the macrophages to phagocytose 
cancer cells. Blockade of PD-1-PDL-1 increased the phagocytic ability of TAMs 
and resulted in reduced tumor burden and increased survival in mice (237). 
However, efferocytosis of dying cancer cells can act as a double-edged sword. 
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The non-immunogenic properties of efferocytosis that prevails under normal 
homeostasis conditions can be mimicked by malignant cells to create an 
environment of immunosuppression in the TME. For example, in their recent 
elegant study, Stanford et al. reported an immunosuppressive role of cancer cell 
phagocytosis (104). Within the TME, apoptosis of cancer cells is a common 
feature, arising because of nutrient limitation and rapid proliferation of malignant 
cells. These dying tumor cells are then efficiently phagocytosed and cleared by the 
TAMs. Interestingly, using mouse model for postpartum breast cancer (ppBC), 
Stanford et al. showed efferocytosis of dying tumor cells increased the production 
of Th-2 like cytokines (IL-4, IL-10, IL-13, TGF-β) in TAMs and increased the risk of 
metastasis by 10-fold. Additionally, tumor associated tissue repair processes, 
expansion of regulatory T cell population (Treg) and production of 
immunosuppressive cytokines by phagocytes were all dependent on efferocytosis 
induced TGF-β signaling. Further, pharmacologically blocking efferocytosis of 
dying cancer cells significantly reduced the risk for metastasis in ppBC. Of note, 
evasion of phagocytosis by upregulation of ‘don’t eat me’ signals is a hallmark of 
cancer cells and several studies have indicated towards a therapeutically 
beneficial effect of enhancing cancer cell clearance by phagocytes. Additionally, 
although treatment with cytotoxic therapies in cases provide partial response, 
eventually result in relapse of the disease with more aggressive features. These 
cases are characterized by an initial activation of the immune cells followed by 
their subsequent impairment to mount a robust antitumor immune response. 
Stanford et al. showed in their elegant study that this could be attributed to 
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efferocytosis mediated enhanced pro-tumorigenic polarization of TAMs. 
Administration of cytotoxic therapy resulted in significant death of tumor cells in the 
TME. Intriguingly, the TAMs that phagocytosed these dying tumor cells became 
more pro-tumoral and showed increased tissue healing, production of Th-2 like 
immunosuppressive cytokines and more Treg induction in the TME, as well 
significantly increased risk for distant metastasis. Indeed, treatment with a 
combination of chemotherapy and efferocytosis blocker not only reduced the risk 
for therapy-enhanced metastasis but also limited the number of TAMs and 
immunosuppression in the TME. This study raised the attractive possibility that 
inducing cell death using chemotherapeutic agents as well as inhibiting their 
clearance by phagocytes can activate the adaptive immune response against the 
tumor and can emerge as potential therapy in the future.  
In addition to this, depletion of the efferocytosis receptor, MERTK, 
dampened tumor growth and metastasis in syngeneic breast, melanoma and colon 
cancer models (238). Bone marrow transplantation of MERTK-/- cells into lethally 
irradiated MMTV-PyVMT mice slowed tumor progression. Additionally, MERTK-/-
CD11b+ macrophages isolated from MERTK-/- tumors produced significantly 
higher amount of IL-6 and IL-12p40, hallmarks of immune activation. In line with 
this, there was increased infiltration of cytotoxic CD8 cells into the tumor.  
The expression of PtdSer, the well-known ‘eat me’ signal is deregulated in 
cancer. In the TME, PtdSer is expressed by tumor cells, immature vasculature as 
well as tumor cell derived exosomes. Tumor associated dendritic cells that engulf 
PtdSer expressing tumor cells remain arrested in an impaired functional state, 
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incapable of expressing the costimulatory molecules required for optimum antigen 
presentation to the T cells. Following chemotherapy or radiotherapy, the apoptotic 
index in the TME is increased which correlates with increased PtdSer expression. 
This eventually results in further immunosuppression. Moreover, the cognate 
receptors and other bridging molecules expressed on TAMs interact with PtdSer 
on tumor cells and hinder tumor recovery by creating an immunosuppressive local 
environment. All these studies indicated that molecules associated with 
efferocytosis of dying tumor cells probably act as critical immune checkpoint 
inhibitors and targeting these molecules can work akin PDL-1 and CTLA-4. Indeed, 
pre-clinical studies showed that administration of PtdSer blocker resulted in 
immune activation in the TME, marked by increase in M1 macrophages, reduction 
in the number of MDSCs and infiltration of cytotoxic T cells (239). Currently 
Bavituximab, a PtdSer targeting antibody is being tested in multiple clinical trials, 
either as monotherapy or in combination with other therapies and has so far shown 
signs of activity (240). 
These studies taken together, raise an important question, if cancer cells 
are targeted using chemotherapy or radiotherapy, and the phagocytosis of the 
apoptotic cells are blocked pharmacologically by immunomodulating TAMs, will 
the defective efferocytosis activate anti-tumor immune response in the host? 
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Fig. 3.1. Find me and Eat me signals during efferocytosis. Interaction between 
different molecules that mediate recognition and uptake of apoptotic cells. The 
figure has been adapted from Hochreiter-Hufford et al. “Clearing the Dead: 
Apoptotic Cell Sensing, Recognition, Engulfment, and Digestion.” Cold Spring 
Harbor Perspectives in Biology. 2013. doi: 10.1101/cshperspect.a008748  
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Fig.3.2. Phagosomal maturation during efferocytosis. During efferocytosis, 
Dynamin is first recruited to the apoptotic cell/phagocyte interface. Dynamin then 
interacts with Vps34, resulting in Rab5 recruitment and activation. Activated Rab5 
further activates Vps34, resulting in the formation of PI(3)P on the phagosome 
surface. In the next step, Mon1-CCz complex recruits Rab7 recruitment to the 
phagosome. Finally, the HOPS complex is recruited, Rab7 is activated and 
eventually the phagosome containing the apoptotic cell fuses with with the 
lysosome for degradation of the cargo. The figure has been adapted from 
Hochreiter-Hufford et al. “Clearing the Dead: Apoptotic Cell Sensing, Recognition, 
Engulfment, and Digestion.” Cold Spring Harbor Perspectives in Biology. 2013. 
doi: 10.1101/cshperspect.a008748  
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Fig.3.3. LC3 associated autophagy (LAP) during efferocytosis. Following 
engulfment of apoptotic cell corpse, the Class III PI3K complex, comprising of 
Beclin 1, VPS34, UVRAG and Rubicon are recruited to the LAPosome containing 
the apoptotic debris. The PI(3)P generated by VPS34 recruits the downstream LAP 
components (such as, ATG5, ATG12, ATG16L, and ATG7). PI(3)P and Rubicon 
stabilize NOX2 for the production of ROS at the phagosome. Finally, PI(3)P and 
ROS help recruit LC3 to the LAPosome surface which then fuses with the 
lysosome for degradation of the cargo.  LAP mediated efferocytosis results in 
decreased production of IL-12, TNF-α, IL-1β and IL-6 and enhanced secretion of 
IL-10 and TGF-β, thereby dampening the inflammatory immune activation. The 
figure has been adapted from Green et al. “The clearance of dying cells: table for 
two.” Cell Death Differ 2016 doi: 10.1038/cdd.2015.172 with permission.  
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Fig.3.4. Efferocytosis in cancer. Efferocytosis of apoptotic cells by TAMs in TME 
resulting in increased pro-tumorigenic polarization of TAMs. Enhanced production 
of immunosuppressive cytokines stimulates regulatory T cells and dampens 
effector T helper and cytotoxic T cell response against tumor, resulting in increased 
risk for relapse post therapy and distant metastasis. This figure is adapted from 
Stanford et al. “Efferocytosis produces a prometastatic landscape during 
postpartum mammary gland involution.” JCI 2014 doi:10.1172/JCI76375 with 
permission.  
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Concluding remarks and dissertation hypothesis 
Macrophages comprise a heterogenous population of innate immune cells 
and are highly plastic in nature. They are endowed with diverse functions, ranging 
from maintenance of homeostasis by phagocytosing and clearing apoptotic debris 
in tissues, metabolic homeostasis, development of organs, angiogenesis to 
combating inflammations or pathogenic infections. They can also bridge the innate 
and adaptive arms of the immune system by their ability to prime naïve T cells. 
Depending on the milieu of cytokines and chemokines they are exposed to in the 
tissue microenvironment, macrophages can exist as classically activated or M1 
type or alternatively activated or M2 type. M1 type macrophages are cytotoxic and 
release pro-inflammatory cytokines to eliminate infected or injured cells. However, 
post infection or injury, M1 type cells polarize towards a reparative M2 type, that 
secrete angiogenic growth factors, tissue remodeling matrix metalloproteases and 
other immunosuppressive cytokines for suppressing T cell responses, that 
augment the wound healing and tissue repair processes. Intriguingly, 
macrophages comprise a substantial population of many solid tumors, including 
breast, prostate, and pancreatic cancers. In most of the cancers studied so far, the 
intratumoral infiltration of macrophages correlate with disease stage and severity 
and is causally associated with poor clinical outcome. Tumor associated 
macrophages (TAMs) comprise a complex population of cells. Although their gene 
expression profiles are characteristic of the M2 type, they also express several M1 
type genes. Extensive studies over the past few years have shown that TAMs are 
indispensable for tumor progression. They have been associated with several 
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stages of neoplastic development, like, attainment of epithelial to mesenchymal 
transformation (EMT), survival and proliferation of cancer cells, maintenance of 
cancer stem cell niche, tumor associated angiogenesis and lymphangiogenesis, 
suppression of anti-tumor immune responses and distant metastases. Research 
is currently ongoing to discover strategies to re-educate TAMs towards a 
classically activated M1 type. Several clinical trials targeting various aspects of 
TAMs either alone or in combination with other therapies have been reported (54, 
56, 65). 
Neuropilins (NRPs) are non-tyrosine kinase, cell surface glycoproteins that 
are widely characterized for their roles in development, migration and 
angiogenesis. Two isoforms are known till date, NRP1 and NRP2. They are 
endowed with unique as well as redundant functions. NRPs have been implicated 
in several neoplasms where they are often overexpressed and correlate with 
cancer cell survival under stress, proliferation, metastasis and poor patient 
survival. Research over the past few years have focused on the role and function 
of NRPs in different immune cell compartments. For example, NRP1 is a marker 
for mouse regulatory T cells and is associated with immunosuppression. It is also 
expressed in macrophages and is important for their protumoral activities (241). In 
contrast, NRP2 is less characterized in the immune subsets. Although previous 
studies detected NRP2 expression in macrophages, its function and the molecular 
pathways that govern these functions are still not clearly known. Our lab has 
previously reported a novel role for NRP2 in regulating endocytic maturation in 
cancer cells. NRP2 positively regulates the maturation of early to late endosomes. 
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This is important for cancer cells that heavily rely on endocytic machinery for their 
oncogenic activities (242). The primary role of macrophages is phagocytosis. This 
function is indispensable for clearance of pathogens, pathogen infected cells as 
well as for maintenance of physiological homeostasis. Following internalization of 
cargo, nascent phagosomes in macrophages mature to late phagosome and 
phagolysosome, recruiting and fusing with the classical endocytic compartments 
and gradually becoming more and more acidic in the process (219-222). Since the 
processes of endosomal and phagosomal maturation are similar, and involve 
several common downstream effectors, we hypothesize that NRP2 regulates 
phagosome maturation in macrophages; hence NRP2 depletion will affect 
pathogen clearance in macrophages. Our study aims to fully understand the role 
of NRP2 in macrophage biology and how this may affect macrophage function in 
normal physiology as well as clinical settings.  
One of the essential functions of TAMs in the TME is efferocytosis of 
apoptotic cancer cells. In the TME, the apoptotic index is high owing to either 
nutrient limited growth condition or rapid proliferation of cancer cells or any 
therapeutic stress. The dying cell corpses need to be removed as efficiently as 
they are generated and impairment of their clearance results in the leakage of 
cellular contents into the surrounding milieu as secondary necrosis. This can 
potentially activate anti-tumor immune responses. Intriguingly, efferocytosis of 
dying tumor cells makes TAMs more tumorigenic and immunosuppressive, and 
significantly increases the risk for metastasis. Blockade of efferocytosis can 
potentially reduce the risk for metastatic cancer and disease recurrence (104). We 
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hypothesize that NRP2 in TAMs regulates clearance of apoptotic tumor cells and 
maintains an immunosuppressive environment in the TME; hence NRP2 ablation 
in macrophages will slow down tumor progression and activate anti-tumor immune 
response.  The goal of this study is to understand the role of NRP2 in macrophages 
and how this NRP2 driven function may affect TAMs and tumor progression. 
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal types of 
cancers with high incidence and low survival rates. One of the hallmarks of PDAC 
is the dense desmoplastic reaction that acts as a physical barrier to therapeutics. 
TAMs are abundantly present in PDAC and have been causally associated with 
distinct stages of disease progression, metastasis, therapy resistance and 
correlate with poor outcome (243-245). Despite the exciting potential of a targeted 
immunotherapy for treating PDAC, it is a clinical reality that tumors relapse, often 
with more aggressive features. Our goal is to identify the function of NRP2 in TAMs 
and how targeting this axis may affect PDAC progression. Collectively, the 
outcome of the study will address the requirement for developing strategies to 
target NRP2 in TAMs either alone or as combination therapy in the effective 
treatment of PDAC. 
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Chapter II 
Materials and Methods: 
2.1 Antibodies used 
NRP2 (CST 3366 for mouse, R&D AF2215 for human), CD8 (CST 98941), CD4 
(ab183685), CD68 (ebioscience 14-0681-82), F4/80 (ebioscience 14-4801-82), 
CD31 (ab28364), α-SMA (ab5694, kind gift from Dr. Maneesh Jain, University of 
Nebraska Medical Center), Granzyme B (ab4059), Rab5 (ab13253), Rab7 
(ab50533), Rho GDI (Santa Cruz Biotechnology sc373724), β-actin (Cell Signaling 
Technology, 4970), Hsc 70 (Santa Cruz Biotechlogy, sc 7298), α,β tubulin (Cell 
signaling technology 2148). 
2.2 Cell culture and generation of human PBMC and murine bone marrow 
derived macrophages: 
Monocytes isolated from the peripheral blood of healthy human donors were 
obtained from the elutriation core facility at the University of Nebraska Medical 
Center. Cells obtained were >97% pure. PBMCs were then cultured at 37ºC with 
5% CO2 in RPMI 1640 containing 10% fetal bovine serum, 2mM glutamine, 100 
µg/mL streptomycin and 100U/mL penicillin for the indicated time points. M1 
macrophages were obtained by maintaining PBMCs in culture for 6 days with 100 
ng/mL G-MCSF; fresh media containing G-MCSF was added to the cells every 
alternate day. On day 7, cells were stimulated with 1 µg/mL LPS and 10 ng/mL 
human recombinant IFN-Y for 24 hours. M2 macrophages were obtained by 
similarly maintaining PBMCs in culture for 6days with 100 µg/mL human 
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recombinant M-CSF and activated with IL-4, IL-10, IL-13 (10 ng/mL each) for 24 
hours on day 7.  
For generation of murine macrophages, mice were first euthanized by CO2 
asphyxiation, and the animal surface sprayed with 70% ethanol. tibia and femur 
were harvested from mice, cleaned of all muscle and connective tissue. Intact 
bones were then transferred to tissue culture dish containing Dulbecco’s 
Phosphate Buffered Saline (PBS) on ice. Bone marrow was flushed from both the 
ends of the bone shafts with ice cold PBS using a 25-gauge needle and 30cc 
needle, and collected into 50mL falcon tubes on ice. Cells were centrifuged at 
2000rpm for 10minutes. The cell pellet was resuspended in RPMI and filtered 
through a 70µm Nylon mesh filter to remove muscle and connective tissue. Cells 
were centrifuged again and 1mL Erythrocyte Lysis Buffer added to the pellet for 
lysing the red blood cells and allowed to stand for 1minute at room temperature. 
To neutralize, 1omL of RPMI media was added, homogenized by pipetting 
thoroughly with a 10mL pipette and centrifuged again at 2000 rpm for 10minutes. 
The cell pellet was resuspended α-MEM media containing 10% fetal bovine serum, 
2mM glutamine, 100 µg/mL streptomycin and 100U/mL penicillin and the number 
of cells counted using a hemocytometer. Trypan Blue staining was performed to 
analyze the cell viability. Based on the experiment, the required number of cells 
were plated in either tissue culture dishes, two well chambers, or 6-well plates and 
cultured at 37ºC with 5% CO2 in the above-mentioned media for the indicated 
periods of time. For the generation of M1 macrophages, 50 ng/mL murine 
recombinant G-MCSF was added into the culture for 7days; on day 2, the non-
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macrophage lineage cells were removed by replacing the supernatant with fresh 
media containing G-MCSF. Repeated boosts of G-MCSF was added to the cells 
every alternate day. Finally, on day7, the old media was replaced with new media 
containing 1µg/mL LPS and 10ng/mL murine recombinant IFN-Y and kept for 24 
hours. M2 macrophages were obtained by similarly adding murine M-CSF into the 
culture for 7days. Cells were activated by the addition of 10ng/mL IL-4 for 24 hours. 
For some experiments, to knock out NRP2, 4-HydroxyTamoxifen (1mM stock in 
methanol) was added into the culture media at a concentration of 0.3 µM every 
alternate day for 3-5days. 
For isolation of peritoneal macrophages, mice were euthanized as mentioned 
earlier and sprayed with 70% ethanol and mounted on a Styrofoam block. The 
outer skin of the peritoneum was cut using scissors and forceps and gently pulled 
back to reveal the inner lining of the peritoneum. Using a 27gauge needle, 5mL ice 
cold PBS was injected into the peritoneal cavity carefully so that no organs were 
punctured. The peritoneum was gently massaged for 5mins to dislodge any 
attached cells into the cavity. Using a 25gauge needle, as much fluid was collected 
from the cavity as possible. Care was taken so that no fat or connective tissue or 
blood contamination occurred. The fluid containing peritoneal macrophages were 
collected into 15mL falcon tubes on ice. They were centrifuged at 2000rpm for 
10mins, resuspended in complete α-MEM media mentioned earlier. The cell 
number was counted using a hemocytometer and plated for experiments. 
Peritoneal macrophages were maintained in M-CSF containing media for 3 days, 
following which they were subjected to different assays. (Z)-4-HydroxyTamoxifen 
123 
 
was added into the cell culture medium (dose as mentioned earlier in this section) 
for 3 consecutive days to knock out NRP2. 
Panc-1 cells were purchased from ATCC. UN-KC-6141 and KPC cells were 
generated by Dr. Surinder K. Batra, University of Nebraska Medical Center and 
were a kind gift to us from his laboratory. All these cell lines were maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) media containing 10% fetal bovine 
serum, 2mM glutamine, 100 µg/mL streptomycin and 100U/mL penicillin at 37ºC 
with 5% CO2.  For generation of conditioned media, cells were plated in 75mm2 
tissue culture flasks and allowed to grow till 75% confluency. The complete media 
was then removed and cells washed twice with PBS without Calcium or 
Magnesium and replaced with only DMEM for 48hours. The conditioned media 
was then collected, centrifuged at 100rpm for 5minutes, strained through 0.22µm 
filter and kept at -80ºC until use.  
Jurkat cells were purchased from ATCC and cultured in RPMI-1640 medium 
containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L 
glucose, and 1500 mg/L sodium bicarbonate, 10% FBS, 100 µg/mL streptomycin 
and 100U/mL penicillin at 37ºC and 5% CO2.  
2.3 Generation of human and murine Tumors Associated Macrophages 
(TAMs) ex vivo: 
To generate tumor associated macrophages ex vivo, PBMCs and BMDMs were 
treated with conditioned media (50% v/v) collected from pancreatic cancer cell line 
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Panc-1 (ATCC) and UN-KC-6141 or KPC cell lines respectively for the indicated 
periods of time.  
2.4 Generation of mouse model: 
The NRP2flox/flox mouse was developed by Peter Mombaerts, Max Planck 
Research Unit for Neurogenetics. The Nrp2 targeted mutation was generated in 
129P2/OlaHsd derived E14 ES cells and has a loxP-tauGFP-pA+-FNF cassette 
inserted into the first intron and a corresponding loxP site inserted upstream of the 
start codon. The FRT-flanked neomycin resistance sequence (FNF) was excised 
by crossing to mice with the Tg(ACTB-flp)4917Dym transgene insertion, which was 
generated in a mixed B6;SJL background, yielding the Nrp2tm1.1Mom targeted 
mutation on a mixed background that is predominantly 129P2 and C57BL/6. These 
mice were bred to pure C57BL/6 background and were a kind gift to us from our 
collaborator, Dr. Michael Muders, Germany. The FVB- Tg(Csf1r-Mer-iCre-
Mer)1Jwp/J mice (developed by Dr. Jeffrey W Pollard, Albert Einstein College of 
Medicine) were purchased from Jackson Laboratories. These Tg(Csf1r-Mer-iCre-
Mer)1Jwp transgenic mice express a Cre recombinase/mutant murine estrogen 
receptor double-fusion protein under the direction of the mouse Csf1r, colony 
stimulating factor 1 receptor, promoter. Tamoxifen-inducible cre activity is detected 
in bone-marrow-derived macrophages and yolk sac macrophages. When these 
Tg(Csf1r-Mer-iCre-Mer)1Jwp mice are bred with mice containing a loxP-flanked 
sequence of interest, tamoxifen-inducible, Cre-mediated recombination will result 
in deletion of the flanked sequences in Csf1r-expressing cells; making them useful 
for studying inflammation, metastasis and tracking myeloid lineage cells. 
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The MerCreMer double fusion protein consists of Cre recombinase flanked on 
each end with a mutated murine estrogen receptor (mer) ligand binding domain 
(amino acids 281-599, G525R); which does not bind its natural ligand (17'-
estradiol) at physiological concentrations but will bind the synthetic estrogen 
receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, with lesser 
sensitivity, ICI 182780. Restricted to the cytoplasm, MerCreMer can only gain 
access to the nuclear compartment after exposure to tamoxifen. A transgenic 
construct containing tandem copies of icre/Esr1*, or Mer-icre-Mer, under the 
control of the mouse Csf1r, colony stimulating factor 1 receptor, promoter, was 
injected into fertilized FVB/N mouse eggs. Founder line 1 was subsequently 
established. Upon arrival at The Jackson Laboratory, the mice were crossed to 
FVB/NJ at least once to establish the colony. For our experimental purpose, the 
FVB-Tg(Csf1r-Mer-iCre-Mer)1Jwp/J (henceforth called CSF1R-Cre) mouse was 
first bred with C57BL/6 mice for one generation (n1). Cre+ mice from this n1 
generation was then crossed with NRP2flox/flox mice to generate 
NRP2flox/floxCSF1R-Cre compound mice. Following administration of 
intraperitoneal injection of Tamoxifen (75mg/kg body weight from 20mg/mL stock 
in corn oil, every day for 5-7days) or (Z)-4-hydroxytamoxifen into cell culture 
medium specifically and selectively knocks out NRP2 from myeloid cells 
expressing CSF1R, like monocytes, macrophages and dendritic cells in an 
inducible manner. 
2.5 Mouse genotype analysis: 
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Approximately, 0.5cm piece tails of 3-4 weeks old mice were snipped and digested 
using the tail extraction buffer and thermostable protease from Kapa Hotstart 
Genotyping kit (Kapa Biosystems). Each reaction mixture contained 88µL of PCR 
grade water, 10µL of 10X KAPA Express extract buffer (final concentration 1X) 
and 2µL (1U/µL) of KAPA Express enzyme. Lysis was performed for 15min at 75ºC 
and then stopped at 95ºC for 5mins. The digested samples were centrifuged at 
13000rpm for 5mins and supernatants were transferred to clean tubes without 
disturbing the cell pellet. Following manufacturer’s protocol, the genomic DNA was 
diluted 10-fold in 10 mM Tris-HCl (pH 8.0–8.5) and then used for PCR. Each PCR 
reaction mix consisted of 0.5µM final concentration of each of forward and reverse 
genotyping primers, 2X KAPA2G Fast (HotStart) Genotyping Mix with dye, 1µL of 
crude DNA extract (diluted) and 10.25 µL of PCR grade water. KAPA2G Fast 
Genotyping Mix (2X) is a ready-to-use master mix containing all components for 
fast PCR, except primers and template. The 2X ReadyMix contains KAPA2G Fast 
DNA Polymerase (with or without antibody-mediated HotStart), KAPA2G Buffer A, 
dNTPs (0.2 mM each at 1X), MgCl2 (1.5 mM at 1X) and stabilizers. The ReadyMix 
also contains two inert dyes, allowing for the analysis of PCR reaction products by 
agarose gel electrophoresis without the need to add a DNA loading solution. After 
PCR amplifications, the amplicons were run on a 2% agarose gel containing 3% 
v/v Ethydium Bromide prepared in 1X TAE buffer, and visualized using BioDoc-It 
Imaging system. 
2.6 Nucleofection: 
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siRNA transfection in PBMCs was performed using Human Monocyte 
Nucleofection kit (Lonza, VPA-1007) following manufacturer’s protocol. 25nM 
siNRP2 or Scrambled antisense RNA was used. Cells were analyzed or subjected 
to any assay 48-72 hours after siRNA transfection. 
2.7 Immunoblot Analyses: 
Briefly, cells were washed with ice cold PBS followed by lysis with CHAPS lysis 
buffer (150mM KCl, 50mM HEPES (pH 7.4), 0.1% CHAPS, 2mM EDTA, 20µg/mL 
Leupeptin, 10µg/mL Aprotinin, 5mM DTT, 1mM PMSF and Halt protease and 
phosphatase inhibitor cocktail) on ice. Cells were gently scraped using cell scraper 
and sonicated on ice. Supernatant was separated by cold centrifugation (13000 
rpm for 5 mins) and total protein was estimated using Bradford method (Biorad, 
Hercules, CA). SDS sample buffer was added and the sampled were heated at 
95ºC for 8mins. The whole cell extracts were next run on 4–20% Mini-PROTEAN® 
TGX™ Gel (BioRad) and transferred to polyvinylidene difluoride (PVDF) 
membrane (Life Technologies, Carlsbad, CA). Protein transfer was to PVDF 
membrane was checked regularly by Ponceau stain. The membrane was then 
blocked in either 5% non-fat dry milk or 5% Bovine Albumin Serum (BSA) in 1X 
TBST (1X Tris Buffered Saline, 0.1% Tween-20) for atleast 1hour. The blocked 
membrane was then incubated overnight in 1X PBS containing appropriate dilution 
of primary antibodies overnight at 4ºC with continuous shaking at low speed. The 
next day, membrane was washed with 1X TBST for 5min (x5) and then incubated 
for 1hr in 1X TBST containing appropriate dilution of horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) with 
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continuous shaking at low speed. The membranes were washed in 1X TBST for 
5min (x5). The protein bands were detected using SuperSignal™ West Femto 
Maximum Sensitivity Substrate. For successive immunoblots, membranes were 
stripped in Stripping Buffer (Thermo Fisher Scientific) for 20mins, re-blocked in 1X 
TBST containing either 5% BSA or 5% non-fat dry milk and probed as mentioned 
before.  
2.8 RNA isolation using Trizol: 
Cells were harvested and washed twice with PBS. 1mL of TRI ReagentTM 
(Invitrogen, CA) was added per 10million cells (if the cells were more and appeared 
cloudy, more trizol was added accordingly). They were gently scraped using cell 
scraper and collected in 2mL eppendorfs and kept for 5mins at room temperature. 
300µL of Chloroform was added into each tube and mixed well by inverting the 
tubes for 15-20seconds. The tubes were allowed to stand for 5mins at room 
temperature following which they were centrifuged at 12000 rpm for 15mins at 4ºC. 
The clear upper supernatant was extracted without disturbing the cellular layer and 
collected into fresh eppendorfs. To this, we added 500µL isopropanol and 1µL of 
Glycogen (RNA graded from Invitrogen) and samples were allowed to stand for 
5mins at room temperature. The samples were then centrifuged at 12000rpm for 
15min at 4ºC. The supernatant was decanted and 1mL of 75% ethanol was added, 
mixed and spun at 7500rpm for 5mins at 4ºC. The supernatant was decanted and 
tubes air-dried for 10mins. The pellet was resuspended in 25µL DEPC water. The 
concentration and quality of the RNA was analyzed using Nanodrop 
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Spectrophotometer. The RNA was either stored at -80ºC until use or processed 
immediately for cDNA synthesis. 
2.9 Quantitative Real-Time PCR (qRT-PCR): 
Total RNA was extracted using TRIzol reagent as mentioned above. 1µg of RNA 
was used to synthesize cDNA by Transcriptor First Strand Synthesis kit (Roche, 
Indiapolis, IN, 04379012001). Quantitative real time PCR (qRT-PCR) was then 
carried out using Power SYBRGreen master mix (Life Technologies, Grand Island, 
NY, 4368706) as described using Applied Biosystems (ABI) 7500 Real Time PCR 
machine. The acidic ribosomal phosphoprotein, 36B4 gene was used to normalize 
and calculate the relative levels of mRNA expression of genes of interest, using 
the 2-ΔΔCt methods and expressed as arbitrary units. The sample analysis was 
performed in duplicates. Data is represented as ±SEM. 
2.10 Continuous E.coli phagocytosis and clearance assay: 
(i) continuous phagocytosis to demonstrate phagosome maturation defect: The 
pHrodo™ Red E. coli BioParticles™ Conjugate suspension was prepared following 
manufacturer’s protocol. The particles are non-fluorescent outside the cell, but 
fluoresce red in the phagosomes. The intensity of red fluorescence increases with 
increasing acidity of cellular compartment where the particles are localized. An 
optimized dose of 65µg/mL bioparticles were used for phagocytosis.  
For continuous phagocytosis assay, either human PBMC derived macrophages or 
murine BMDM were grown in two welled chambers as described in 2.2. Human 
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PBMC derived macrophages were subjected to nucleofection on day5 to knock 
down NRP2 and the assay was performed on day7. Before the assay, cells were 
washed twice with 1X DPBS. The fluorescent E.coli particles were then added at 
a concentration of 65µg/mL and incubated at 37ºC for the indicated periods of time 
to allow adequate particle internalization. Different time points were used 
depending upon the objective of the experiment. Phagocytosis was arrested by 
placing the cells on ice and washing vigorously 3-5 times with 1X DPBS to remove 
the excess particles. Cells were then fixed with 4% paraformaldehyde at 4ºC for 
20 minutes and washed with DPBS to remove the excess fixative. Nuclei were 
stained using the nuclear dye Hoechst in PBS for 5 minutes, washed twice with 1X 
PBS and analyzed by either Zeiss LSM 800 with Airyscan or Zeiss 710 Confocal 
Laser Scanning Microscope at UNMC confocal core facility, and data were 
analyzed and processed with the Zeiss Zen 2010 software. All confocal data were 
quantified using ImageJ software and graphical illustrations made using GraphPad 
Prism software as mentioned later. 
(ii) E.coli uptake assay: Human macrophages or mouse BMDMs were grown in 
two well chambers as mentioned in 2.10 (i). Before the assay, cells were washed 
twice with 1X DPBS and added 65µg/mL red fluorescent E.coli particles for 1hr at 
37ºC to allow the cells to phagocytose the particles. Uptake was arrested by adding 
ice cold DPBS. Cells were thoroughly rinsed with DPBS to remove excess 
bioparticles from the supernatant. Cells were next fixed with 4% PFA for 20mins 
at 4ºC, washed thrice with DPBS to remove excess fixative and nuclei stained with 
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Hoechst. Cells were then analyzed by confocal microscopy as described in 2.10 
(i).  
(iii) in vitro E.coli clearance assay: BMDMs or mouse peritoneal macrophages 
were grown in two well chambers as described earlier. On day of the experiment, 
cells were washed twice with 1X DPBS and added 500 µL of Opti-MEM media per 
well. pHrodo red E.coli bioparticles were added at a concentration of 65 µg/mL for 
15mins (pulse) to allow the cells to uptake the bioparticles. Immediately after 
15mins, uptake was stopped by adding ice cold DPBS. Cells were washed 
vigorously with DPBS (x3) to remove any E.coli particle that was not taken up or 
loosely adhered to cell surface. Fresh complete α-MEM media was added and the 
gradual maturation and clearance (breakdown) of the E.coli particles was 
monitored at different time points (chase). At each time point, chambers were 
taken out, cells vigorously washed with DPBS (x5) and fixed with 4% PFA for 
20mins at 4ºC, nuclei stained with Hoechst and analysed using confocal 
microscopy as described earlier. 
Where mentioned, human macrophages grown for phagocytosis as described in 
2.10 (i) were washed with 1X DPBS twice and added pHrodo red fluorescent 
tagged E.coli bioparticles (30 µg/mL) and allowed the cells to phagocytose the 
bioparticles for 45mins. Cells were then gently washed with DPBS to remove the 
excess pHrodo red bioparticles from the media, added fresh DPBS into which 
green fluorescent E.coli bioparticles were added (30 µg/mL) for another 45mins. 
This allowed us to monitor phagosome maturation by chasing the maturation of 
pHrodo E.coli bioparticles containing phagosomes as well as uptake of E.coli 
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particles using the green bioparticles. At the end of the experiment, cells were 
vigorously washed with ice cold DPBS to stop uptake and fixed with 4% PFA for 
20mins at 4ºC. Cells were washed with DPBS (x3) to remove excess fixative, 
nuclei stained with Hoechst and analyzed by Confocal microscopy as described in 
2.10 (i). 
2.11 In vitro Apoptotic Cell Clearance Assay: 
For this assay, Jurkat cells were grown as mentioned in 2.2. Prior to the assay, the 
cells were centrifuged at 1000rpm for 5mins, washed with 1X PBS (x2). They were 
resuspended in only RPMI and incubated in 50µM Etoposide (Abcam) overnight 
at 37ºC and 5% CO2 for 12hrs. This treatment routinely yielded 80-90% apoptotic 
cells. The next day, cells were centrifuged at 2000 rpm for 10mins and the pellet 
was washed twice with PBS. The cells were incubated with pHrodo™ Red, 
succinimidyl ester (Thermo Scientific) following manufacturer’s instructions. This 
dye enabled us to view the apoptotic cells in the phagosomes only after they are 
internalized. Cells were centrifuged at 2000rpm for 10mins. The cell pellet was 
washed twice with 1X DPBS and resuspended in Opti-MEM medium (Gibco). 
Mouse BMDMs or peritoneal macrophages were plated in two well chambers and 
grown in the presence of M-CSF as described earlier in 2.2. (Z)-4-
HydroxyTamoxifen was added to knock out NRP2 as described earlier. On the day 
of the assay, the old medium was removed, cells were washed twice with 1X PBS 
and added 500µL Opti-MEM medium per well. Apoptotic Jurkat cells were added 
(1:5 macrophage : jurkat ratio) for either 15min or 30min (pulse) and allowed the 
cells to uptake at 37ºC. Following this, uptake was stopped by adding ice cold 
133 
 
DPBS; cells were vigorously washed with DPBS (x3) to remove any cell that was 
not phagocytosed or remained loosely bound to the cell surface. Fresh complete 
α-MEM media was added and the clearance of apoptotic cells were monitored over 
time (chase). At each time point, cells were vigorously washed with DPBS (x5), 
fixed with 4% PFA at 4ºC for 20mins and washed again with DPBS (x3) to remove 
excess fixative. Nuclei were counterstained using Hoechst for 5mins and analysed 
using confocal microscopy as mentioned earlier. 
2.12 In vitro Zymosan Clearance Assay: 
For this assay, BMDMs were grown in two well chambers as described earlier. On 
the day of the experiment, cells were washed twice with 1X DPBS and added 500 
µL of Opti-MEM media per well. pHrodo red zymosan particles were added at a 
concentration of 65 µg/mL for 15mins (pulse) to allow the cells to uptake the 
particles. Immediately after 15mins, uptake was stopped by adding ice cold DPBS. 
Cells were washed vigorously with DPBS (x3) to remove any zymosan particle that 
was not taken up or remained loosely adhered to cell surface. Fresh complete α-
MEM media was added and the gradual maturation and clearance (breakdown) of 
the zymosan particles was monitored at different time points (chase). At each time 
point, chambers were taken out, cells vigorously washed with DPBS (x5) and fixed 
with 4% PFA for 20mins at 4ºC, nuclei stained with Hoechst and analysed using 
confocal microscopy as described earlier. 
2.13 Subcutaneous Tumor implantation: 
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UN-KC-6141 cells were maintained in culture as described earlier. For 
subcutaneous implantation, cells were allowed to grow until 50% confluency. The 
night before implantation, the old medium was replaced with fresh complete 
medium. The next day, the cells were washed with 1X DPBS, and then trypsin was 
added to the cells for 2mins, neutralized by adding equal volume of media 
containing FBS and centrifuged at 1000rpm for 5mins. Cells were washed twice 
with DPBS and resuspended in DPBS and cell number and viability counted using 
Trypan Blue. Cells with less than 90% viability were discarded. Cells were 
centrifuged again and resuspended in HBSS. For implantation, 500,000 cells in 
HBSS were mixed with equal volume of Matrigel (without growth factors) so that 
the total volume was 100µL and kept on ice. 
The right dorsal flanks of mice were gently shaved using Veet hair removal crème 
and a spatula. Care was taken so as not to irritate or inflame the skin of the mice. 
The cell mixture was slowly pulled up using a 1mL syringe and 22gauge needle 
and kept on ice. The skin of the mouse around the dorsal right flank was gently 
pinched using the index and middle finger and pulled away from the body of the 
mouse, and the cells were slowly and carefully injected into the pocket created. 
For our studies, mice were divided into two groups (n=3 or 5 in each group). To 
deplete NRP2 from the macrophages, the test group was injected with Tamoxifen 
intraperitoneally (75mg/kg body weight from a 20mg/mL stock in corn oil) everyday 
till the end point of the experiment. The control group was injected with corn oil as 
vehicle control. The tumor growth was manually monitored regularly using digital 
slide calipers and weight of the mice recorded. Once the end point of the 
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experiment was reached, mice were euthanized by CO2 asphyxiation following 
IACUC protocol and tumors harvested. Harvested tumors were washed gently in 
ice cold DPBS, transferred to new tubes containing DPBS and kept on ice. Tumors 
were fixed in 10% formaldehyde overnight and transferred to 70% ethanol and 
given to Tissue Science Facility at UNMC for paraffin embedding, sectioning (4 
µm) and Hematoxylin and Eosin (H&E) staining. Sections were subjected to 
staining for different proteins as described later. 
2.14 Histology and Immunostaining: 
Immunohistochemistry and immunofluorescence staining on histological sections 
were performed using the following procedure: slides containing tissue sections 
(4µm thick) were kept on heat block at 58ºC for 2hours. They were then rehydrated 
in a sequential passage of solutions starting with Xylene for 20mins, 100% ethanol 
for 15mins, 95%, 90%, 80%, 75%, 50% and 20% ethanol for 5mins each followed 
by immersion in double distilled water for 10mins. For IHC only, slides were next 
immersed in 3% Hydrogen Peroxide (H2O2) in methanol for 1hr at room 
temperature followed by incubation in double distilled water for 5mins. Antigen 
retrieval was performed using Dako antigen retrieval solution (either pH9 or pH6, 
depending on the antigen of interest). The antigen unmasking solution was first 
preheated at a high temperature in the microwave until boiling and then the slides 
were immersed into it and boiled on a 98ºC water bath for 45mins. Following this, 
the slides were gradually allowed to cool to room temperature for atleast 1hr and 
then washed with 1X PBS thrice, 5mins each. Slides were then blocked with 5% 
goat serum in 1XPBS containing 0.2% saponin at 4ºC for 1hr in a moist chamber. 
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Then the tissue sections were covered with 1X PBS containing 0.2% saponin and 
3% BSA and the required concentration of primary antibodies, and incubated 
overnight in a moist chamber at 4ºC. The next morning, slides were washed in 1X 
Tris Buffered Saline (TBS) solution for 5mins (x5). Secondary antibodies were then 
diluted in in 1X PBS containing 0.2% saponin and 3% BSA at 1:200 concentration 
for biotinylated antibodies (IHC) or 1:500 for fluorophore conjugated antibodies (IF) 
and incubated for 1hr in dark in a moist chamber. For IHC staining, slides were 
next washed with 1X TBS for 5min (x6) and then incubated with Avidin-Biotin 
complex for 40mins at room temperature, following manufacturer’s instructions. 
Slides were then rinsed with 1X TBS for 5mins (x3) and added diaminobenzidine 
solution containing 0.3% H2O2 as a substrate for peroxidase (Dako) until the 
desired staining intensity was developed. Slides were washed in double distilled 
water and hematoxylin added for counter staining. The slides were then rinsed 
under running tap water to remove excess counter staining, and the dehydrated 
by gradual passage of slides from double distilled water to xylene in a reverse 
order mentioned earlier for rehydration of slides. Slides were finally mounted with 
Permount and covered with glass cover slips. Clear nail polish was used to seal 
the sides of the cover slips. The whole slides were next digitally scanned at Tissue 
Science Facility, UNMC. For IF, following incubation with secondary antibody, 
slides were thoroughly washed with 1X TBS for 5mins (x5) and finally once with 
distilled water and then mounted with Vectashield mounting media containing 
DAPI (Vector Laboratories, Burlingame, CA). For monolayer culture, 
immunofluorescence staining was performed as described: briefly, cells were 
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grown on poly-DL-lysine–coated coverslips (BD Biosciences) for indicated periods 
of time before fixation and analysis by confocal microscopy. Cells were rinsed with 
Dulbecco's Phosphate-Buffered Saline (DPBS; Invitrogen)(x3), followed by fixation 
with ice cold 4% paraformaldehyde at 4ºC for 20 minutes. Cells were then washed 
with DPBS (x3). Finally, cells were blocked using 1% BSA and 0.2% saponin in 
PBS for 1hr at 4ºC in a moist chamber. The slides were then incubated overnight 
in the same blocking buffer containing appropriate concentration of primary 
antibodies at 4ºC in a moist chamber. The next day, the coverslips were carefully 
washed in 1X PBS (x5) and added fluorescent conjugated antibodies (1:200) in 1X 
PBS containing 1% BSA and 0.2% saponin for 2hrs at 4ºC in a moist chamber. 
The coverslips were finally washed in 1X PBS (x5) and mounted on glass slides 
with mounting media containing DAPI as mentioned above and sealed with clear 
nail polish. Slides were viewed using either Zeiss LSM 800 with Airyscan or Zeiss 
710 Confocal Laser Scanning Microscope at UNMC confocal core facility, and data 
were analyzed and processed with the Zeiss Zen 2010 software. All confocal data 
were quantified using ImageJ software and graphical illustrations made using 
GraphPad Prism software as mentioned later. 
The list of all the primary antibodies used have been listed earlier. For the purpose 
of Immunofluorescence staining, the secondary antibodies conjugated with 
fluorophores were purchased from Invitrogen Corporation, and DAPI from Vector 
laboratories was used for counter staining the nuclei. For IHC, biotinylated 
antibodies were purchased from Invitrogen. The ABC Peroxidase Standard 
Staining Kit  was purchased from Thermo Fisher Scientific.  
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2.15: TUNEL staining 
To assess the number of apoptotic or necrotic cells in the tumor tissues, TUNEL 
staining was performed following manufacturers’ instructions (Roche In Situ Cell 
Death Detection Kit, TMR red, catalogue number 12156792910). 
2.16 Isolation of TAMs from subcutaneous mouse tumors: 
TAMs were isolated as described elsewhere (246). Subcutaneous mouse tumors 
were generated as mentioned above. The tumors from both control and test 
animals were harvested and kept in ice cold RPMI media on ice. Each tumor was 
cut into small pieces using scissors or scalpel and the digestion media was added 
(RPMI media containing the following: 10U/mL Collagenase I, 400U/mL 
Collagenase IV, 30U/mL DNAse I- all diluted in HBSS) and kept at 37ºC for 
30mins. Following this, the tumor pieces were crushed with the plunger of a 10mL 
syringe, 5mL RPMI media was added and homogenized well using a 10mL pipette. 
The tumor suspension was filtered by passing through a 70µm nylon gauze and 
the collected into fresh tubes. The suspension was centrifuged at 450g for 6min at 
4ºC; the supernatant was discarded and the pellet was resuspended in 2mL 
erythrocyte lysis buffer to remove the RBCs. The tubes were allowed to stand for 
2mins at room temperature, neutralized by the addition of 12mL of RPMI media, 
passed through a sterile 70µm nylon gauze and centrifuged again at 450g for 
6mins at 4ºC and the supernatant discarded. The pellet was resuspended in 
Lymphoprep solution at a concentration of 1-2X107 cells/mL and transferred to 
fresh tubes. To this was added 6mL RPMI media very cautiously to obtain a two-
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phase gradient. The gradients were centrifuged at 800 x g for 30 min at room 
temperature without acceleration or break. The interphase (enriched in myeloid 
cells and lymphocytes as well as the upper layer containing the RPMI media were 
collected into fresh tubes without disturbing the lymphoprep layer. The cells were 
washed once with MACS buffer, centrifuged at 800g for 5mins at 4ºC and the 
supernatant discarded. The cell pellet was finally resuspended in MACS buffer at 
a concentration of 108 cell/mL. TAMs were isolated using CD11B magnetic beads 
and LS columns (both from Miltenyi Biotech) following manufacturer’s instructions. 
The CD11B+ myeloid cells were arrested in the columns and the non-labelled cells, 
which were mainly the enriched T cells, were collected as flow-through in separate 
tubes. The TAMs thus collected were centrifuged and Trizol was added and kept 
in -80ºC for processing for RNA-Seq analysis.  
2.17 Transcriptome analysis using RNA-Seq: 
CD11b+ cells were isolated from subcutaneous PC tumors using magnetic beads 
as mentioned in 2.15. RNA was isolated from the control and test group with n=3 
animals contributing to each pool. This was done in order to obtain sufficient 
amount of RNA. RNA-Seq service was obtained from Kelvin Chan and his team at 
Seqmatic. Extracted RNA was QC with Agilent TapeStation RNA screentape. The 
RIN value of the control sample was 9.1 and that of the test was 9.4. A paired end 
read 2x75bp sequencing run of RNA libraries were performed using the Illumina 
NextSeq 500 instrument. For analysis, raw reads were demultiplexed by barcode 
and output into FASTQ format. Cutadapt was used to filter out adapter sequences 
and low-quality bases. Filtered sequence reads were aligned to mouse reference 
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genome mm10 using HISAT2 aligner. Reads mapping to exon regions as defined 
by Ensembl gene annotations were counted using FeatureCounts. Data analysis 
was performed with the help of Seqmatic, California and the Bioinformatics and 
Systems Biology Core at UNMC. To address the limitation of number of samples, 
we chose to identify differentially expressed genes using log2 fold metric instead 
of p-value. Genes with a cutoff value log2 fold change1 were selected and those 
with zero counts in both control and test samples or in either of them were 
eliminated for stringency. The Ingenuity Pathway Knowledge Base (IPA) was used 
to identify the enriched canonical pathways and cellular and molecular functions 
among the differentially expressed genes in the two samples. In addition to the 
IPA, the Database for Annotation, Visualization and Integrated Discovery (DAVID), 
the Gene Ontology Project, Kegg Pathway and extensive literature curation was 
performed to identify functional terms associated with the differentially expressed 
genes. Among the enriched functional annotation clusters, we selected 
representative clusters (as mentioned in the Results section) to analyze the effect 
of NRP2 depletion on phagocytosis, macrophage phenotype and secretion of 
chemokines and cytokines as well as interaction between macrophages and 
leucocytes/lymphocytes. 
2.18 Statistical Analyses: 
All the graphical illustrations statistical tests were performed using Prism-6 
software (GraphPad software, Inc., La Jolla, CA). All data reported in graphs are 
expressed as mean ± standard error of mean (SEM) unless otherwise mentioned 
and were compared using unpaired student T-test, p values were considered 
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statistically significant when less than 0.05. All experiments were repeated at least 
3times unless specified. 
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    Chapter III 
NRP2 is expressed in M1 and M2 type macrophages and regulate 
phagocytosis by modulating early to late phagosomal maturation. 
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3. NRP2 is expressed in M1 and M2 type macrophages and regulate 
phagocytosis by modulating early to late phagosome maturation. 
3.A. Introduction 
Macrophages are highly plastic and functionally diverse cells of the immune 
system and undertake an array of functions, like maintenance of homeostasis by 
phagocytosing and clearing apoptotic debris in tissues, metabolic homeostasis, 
development of organs, angiogenesis to combating inflammations or microbial 
infections. They can also bridge the innate and adaptive arms of the immune 
system by their ability to prime naïve T cells. Briefly, macrophages can exist as 
classically activated or M1 type or alternatively activated or M2 type. M1 type 
macrophages are cytotoxic and release pro-inflammatory cytokines to eliminate 
infected or injured cells. However, post infection or injury, M1 type cells polarize 
towards a reparative M2 type, that secrete angiogenic growth factors, tissue 
remodeling matrix metalloproteases and other immunosuppressive cytokines for 
suppressing T cell responses, that augment the wound healing and tissue repair 
processes (15, 54, 56, 247).  
Neuropilins (NRPs) are non-tyrosine kinase, cell surface glycoproteins that 
are widely characterized for their roles in development, migration and 
angiogenesis. Two isoforms are known till date, NRP1 and NRP2. NRPs are often 
overexpressed in several neoplasms and correlate with cancer cell survival under 
stress, proliferation, metastasis and poor patient survival. Research over the past 
few years have focused on the role and function of NRPs in different immune cell 
compartments. In comparison to NRP1, NRP2 is less characterized in the immune 
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subsets (241). Although previous studies detected NRP2 expression in 
macrophages, its function and the molecular pathways that govern these functions 
are still not clearly known. The primary role of macrophages is phagocytosis. This 
function is indispensable for microbial clearance. Following internalization of 
cargo, nascent phagosomes in macrophages mature to late phagosome and 
phagolysosome, recruiting and fusing with the classical endocytic compartments 
and gradually becoming more and more acidic in the process (219, 220). The 
processes of endosomal and phagosomal maturation are similar in many aspects, 
often recruiting identical effector molecules. Our previous report documented a 
requirement for NRP2 in endosomal maturation in cancer cells (242). However, its 
role in phagocytosis in macrophages is not well understood. Based on our previous 
observation that NRP2 positively regulates endosomal maturation in cancer cells 
and the similarity between endosomal and phagosomal maturation processes, we 
hypothesized that NRP2 regulates phagocytosis in macrophages. 
In this chapter, we report the expression pattern of NRP2 in human and 
murine macrophages under M1 and M2 polarizing conditions. Using human 
macrophages and bone marrow derived macrophages isolated from transgenic 
mice generated in our lab, where NRP2 can be selectively depleted from the 
myeloid cells, we observed NRP2 regulates phagosomal maturation in 
macrophages and hence pathogen clearance in vitro. Further, NRP2 depletion 
does not significantly affect the uptake of phagocytic cargo. In agreement with the 
phagosomal maturation defect, we observed an increased accumulation of Rab5+ 
early phagosomes and a concomitant decrease in the number of Rab7+ late 
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phagosomes in absence of NRP2. Overall, our study documents a novel role of 
NRP2 in regulation of phagocytosis in macrophages.  
3.B. Results 
NRP2 is expressed in human and murine bone marrow derived M2 type 
macrophages: NRP2 is not expressed by monocytes or bone marrow precursor 
cells. To get M2 type macrophages, monocytes isolated using elutriation from the 
peripheral blood of healthy human donors were differentiated using M-CSF for 
7days, following which they were exposed to M2 polarizing cytokines, like IL-4, IL-
10 and IL-13 for 24hrs. A similar differentiation protocol was followed for 
differentiating mouse bone marrow derived precursor cells. NRP2 is not detected 
at protein level in either human monocytes or murine bone marrow derived 
precursor cells, but an enhanced mRNA (not shown) and protein expression was 
observed during the differentiation of the human monocytes to mature M2 type 
macrophages (Fig. 3.1 A). Interestingly, there was no further increase in the 
expression level of NRP2 following treatment with M2-polarizing cytokines, IL-4, 
IL-10 or IL-13. Further, the data suggested a post translational modification of 
NRP2 as the cells gradually differentiated to mature macrophages. Various post 
translational modifications have been reported for NRP2. For example, it 
undergoes polysialylation in microglia. The post translational modification of NRP2 
in macrophages is beyond the scope of the current study.  
A similar enhancement in the mRNA (not shown) and protein level of NRP2 was 
observed during the differentiation of murine bone marrow derived precursor cells 
to mature macrophages following treatment with mouse recombinant M-CSF for 
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7days, and then exposure to M2-polarizing cytokines, like IL-4, IL-10 or IL-13 for 
24hrs (Fig. 3.1 B). 
NRP2 is expressed in human and murine bone marrow derived M1 type 
macrophages: To generate inflammatory M1 type macrophages, monocytes 
isolated from the peripheral blood of healthy human donors using elutriation was 
differentiated using G-MCSF for 7days, following which the cells were treated with 
a combination of LPS and IFN-Y for 24hrs. As mentioned in 3.B.1, NRP2 is not 
detected at protein level in the human monocytes. However, an upregulation in the 
expression of NRP2 mRNA (not shown) and protein was observed as the cells 
differentiated towards M1 type macrophages. There was further enhancement in 
the expression of NRP2 following stimulation of the cells with a combination of LPS 
and IFN-Y (Fig. 3.2 A). Similarly, in murine bone marrow derived precursor cells, 
NRP2 expression was not observed at a detectable level. However, an 
enhancement in NRP2 protein level was observed as the precursor cells 
differentiated to M1 type macrophages. Here also, following stimulation with a 
combination of LPS and IFN-Y for 24hrs, further upregulation in the protein level of 
NRP2 was observed (Fig. 3.2 B).  
NRP2 regulates phagocytosis in human macrophages: Phagocytosis is one of 
the key functions of macrophages and important for maintenance of physiological 
homeostasis as well as microbial clearance during infections. Phagocytosis, a 
special form of endocytosis, recruits similar downstream effector molecules and 
the two pathways eventually converge onto each other. Because we previously 
observed that NRP2 regulates endocytosis in cancer cells, therefore, we wanted 
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to investigate whether NRP2 regulates phagocytosis in macrophages. To confirm 
if NRP2 plays a role in phagocytosis in human macrophages, we differentiated 
human PBMCs on M-CSF for 7days. NRP2 was depleted using siRNA approach. 
We incubated the macrophages with pHrodo red and pH insensitive green E.coli 
bioparticles at an optimized concentration of 65µg/mL for 1.5hrs. The pHrodo E.coli 
bioparticles are non-fluorescent at neutral pH, however their fluorescence intensity 
increases with an increase in acidity of the vesicle they are localized in. Following 
engulfment, phagocytic cargo remains in nascent early phagosomes of higher pH, 
which sequentially mature to late phagosomes, becoming more and more acidic 
and finally fuse with the lysosomes. Therefore, a bright red fluorescence dot in the 
cell indicates a mature phagocytic vesicle containing the E.coli, which has or is 
going to be fused with lysosomes and thus can indicate an active phagocytic 
process. On the other hand, the pH insensitive E.coli particle (green) uniformly 
fluoresces irrespective of the pH of the phagosome or phagolysosome it is 
delivered to. This experimental approach enabled us to test the ability of the 
macrophages to mature the phagosomes (red) as well as their uptake efficiency 
(green) in the presence and absence of NRP2. A schematic for the experimental 
design is shown in Fig. 3.3 A. Quantification of the average total cell fluorescence 
revealed a significant decrease in the intensity of red puncta in siNRP2 treated 
macrophages. This indicated that as compared to control where phagosomes 
containing E.coli bioparticles matured to acidic late phagosomes or fused with 
lysosomes, in NRP2 depleted macrophages, the maturation of  early phagosome 
to more acidic less phagosome or the formation of phagolysosome was delayed. 
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However, the uptake efficiency in mock and siNRP2 treated macrophages were 
similar, as evident from the intensity of the green puncta (Fig. 3.3 B). Fig. 3.3 C 
and D represent the quantification of the result and knockdown efficiency of NRP2 
following electroporation with siNRP2. This data suggested that NRP2 regulates 
phagosomal maturation in macrophages, without significantly affecting the uptake 
process. NRP1 and NRP2 share structural homology and can have redundant 
functions. To test if NRP1 regulates phagosomal maturation in macrophages, 
phagocytosis assay was repeated using pHrodo E.coli bioparticles following NRP1 
depletion. However, we did not observe any difference in the maturation of 
phagosomes when NRP1 was knocked down in macrophages (Fig. 3.4 A). Fig. 
3.4 B and C respectively show the graphical representation of the result and the 
knockdown efficiency for NRP1. This indicates NRP2 uniquely regulates 
phagocytosis in macrophages. 
Because during any type of infection or injury, GM-CSF induced M1-type 
macrophages are predominantly found in tissues and phagocytose pathogens, we 
tested the role of NRP2 in phagocytosis in GM-CSF treated human macrophages. 
For this, we repeated the phagocytosis assay using pHrodo E.coli bioparticles 
following NRP2 depletion by siRNA approach. Our results indicated a similar 
maturation delay in absence of NRP2 (Fig. 3.5 A). Fig. 3.5 B and C respectively 
show the graphical representation and the knockdown efficiency of NRP2. Next, 
to assess if NRP2 regulates the uptake of phagocytic cargo in GM-CSF treated 
macrophages, phagocytosis assay was repeated using pH insensitive E.coli 
bioparticles (red) following NRP2 depletion. We did not observe any significant 
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change in the uptake efficiency of macrophages depleted of NRP2 (Fig. 3.6 A). 
Fig. 3.6 B and C show the quantification of the phagocytic uptake and the 
knockdown of NRP2 respectively. Overall, these data suggest that NRP2 regulates 
phagocytosis in macrophages through modulation of phagosomal maturation.  
NRP2 regulates phagocytosis in murine macrophages: We validated our 
observations made in human macrophages using a transgenic mouse model that 
we have developed in our lab. We have developed a compound mouse by crossing 
NFP2fl/fl mice with Tg (Csf1r-Mer-iCre-Mer)1Jwp mice for selective and inducible 
knockout of NRP2 in myeloid lineages following intraperitoneal administration of 
Tamoxifen (75mg/kg body weight from 20mg/mL stock in corn oil) for 3-5days or 
addition of (Z)-4-Hydroxytamoxifen to the cell culture medium at a concentration 
of 0.3µM for 3-5days (Fig. 3.7 A). We optimized NRP2 knockout using different 
concentrations of (Z)-4-HydroxyTamoxifen (Fig. 3.7 B). For future experiments, 
0.3 µM concentration was used.  
For phagocytosis assay, bone marrow derived precursors were 
differentiated to M2 type macrophages with M-CSF for 7days. (Z)-4-
HydroxyTamoxifen was added to the cell culture medium at a concentration of 
0.3µM every alternate day to knock out NRP2. Phagocytosis assay was performed 
using pHrodo red E.coli bioparticles at an optimized concentration of 65µg/mL for 
1.5hrs. As in case of human macrophages, NRP2 depleted murine BMDMs had 
significantly less number of red visible puncta as compared to the control cells 
where bright red phagocytic vesicles were observed (Fig. 3.8 A). Reduction in the 
intensity of visible red fluorescence or number of bright red puncta indicated a 
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delay in the formation of acidic late phagosomes or phagolysosomes. Fig. 3.8 B 
and C show the graphical representation of the result and knock out efficiency for 
NRP2 respectively. NRP1 protein level remained unaffected following addition of 
HydroxyTamoxifen (Fig. 3.8 C), indicating that NRP2 uniquely regulates 
phagocytosis in macrophages. 
Next, we wanted to test if NRP2 regulates uptake of phagocytic cargo in 
mouse macrophages. For this, mouse bone marrow derived macrophages were 
exposed to 65µg/mL pH insensitive E.coli bioparticles (red) for 1hr and uptake 
efficiency monitored using confocal microscopy. We did not observe any significant 
change in the uptake efficiency of macrophages following depletion of NRP2 (Fig. 
3.9 A). Fig. 3.9 B and C show the graphical quantification of the result and the 
depletion of NRP2 respectively.  
Since maturation of nascent phagosomes is a prerequisite for efficient degradation 
of engulfed cargo, next, we wanted to assess the effect of NRP2 depletion on 
macrophages to clear bacterial load in vitro. For this, we conducted a phagocytic 
pulse and chase experiment using pHrodo E.coli particles. A schematic diagram 
explaining the experimental design is shown in Fig. 3.10 A. First, bone marrow 
derived precursors were differentiated to M2 type macrophages as mentioned 
earlier and NRP2 knocked out using (Z)-4-HydroxyTamoxifen. pHrodo red E.coli 
bioparticles were added to the cells at a concentration of 65µg/mL for 15mins 
(pulse). Excess bacteria that either not engulfed or remained loosely adherent 
were removed by vigorous washing. Next, phagosomal maturation and 
degradation and clearance of the bacteria from the cells was monitored at chase 
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time points= 15mins, 45mins, 1.5hrs, 2hrs and 4hrs using confocal microscopy. In 
the control macrophages, starting from 0min up to 2hrs chase and 4hrs, there was 
a gradual increase in the intensity and number of red phagocytic vesicles indicating 
their maturation and probably fusion with lysosomes. Interestingly, at 4hrs chase, 
there was once again a decrease in the intensity of the visible red puncta, 
suggesting degradation of the E.coli bioparticles (Fig. 3.10 B). Compared to the 
control, NRP2 depleted macrophages had significantly less red intensity and less 
number of visible red puncta upto 2hrs chase (Fig. 3.10 B). However, at 4hrs 
chase, higher value of total cellular fluorescence in the NRP2 depleted cells in 
comparison to the control macrophages indicated that phagosomes have probably 
started maturing in the former, whereas the bioparticles are almost degraded at 
that time in the control cells. This indicated that in control cells, phagosomes 
containing E.coli bioparticles matured and fused with lysosomes and degraded the 
phagocytic cargo, whereas in absence of NRP2, there was a delayed maturation 
of phagosomes. Fig. 3.10 C and D respectively show the quantification of the 
result and the knockout of NRP2. show the quantification of the result and the 
knock out efficiency for NRP2 respectively. Overall, these results further highlight 
the fact that NRP2 regulates phagocytic activity in macrophages. Cells infected 
with bacteria try to degrade the pathogen by phagosomal maturation and their 
subsequent lysosomal degradation. Based on our observations, it is thus 
conceivable that NRP2 depletion will impair the ability of professional phagocytes 
like macrophages to clear bacterial load following infection. 
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Following uptake of E.coli bioparticles, TLR4 pathway is activated. One major 
concern would be whether NRP2 selectively regulates TLR4 mediated phagosome 
maturation and degradation or whether NRP2 can regulate phagosome maturation 
or clearance of particles that recruit other pathways for their maturation and 
clearance. To test this, we performed phagocytic pulse and chase experiment 
using pHrodo red zymosan particles (that signal through TLR2 pathway) that are 
are non-fluorescent at neutral pH, but start fluorescing in the phagosomes. For this 
assay, murine BMDMs were cultured in the presence of M-CSF for 7days and 
NRP2 depleted by the addition of 0.3µM (Z)-4-HydroxyTamoxifen into the culture. 
Zymosan particles were added to the cells at a concentration of 65µg/mL for 
15mins (pulse) following which the degradation was monitored at 6hrs, 10hrs, 
14hrs and 18hrs (chase). A schematic diagram showing the experimental design 
is provided in Fig. 3.11 A. After 15mins pulse, both the control and NRP2 depleted 
macrophages showed similar number of zymosan containing phagosomes. At 
6hrs, we observed a burst in the visible red fluorescence in both the control and 
NRP2 depleted cells. This indicated the beginning of the maturation process. 
However, at 10hrs, 14hrs and 18hrs, the control macrophages gradually matured 
the phagosomes and efficiently degraded and cleared the zymosan particles, as 
evident from the gradually decreasing intensity of visible red puncti structures of 
the zymosan particles. Interestingly, NRP2 depleted macrophages significantly 
delayed the degradation and clearance process. This was evident from the bright 
red fluorescence and bigger size of the zymosan particles that persisted within the 
cells, even at 18hrs, when the control cells had efficiently broken down individual 
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particles (3.11 B). This data confirms our hypothesis that NRP2 regulates 
phagocytic activity in macrophages and that its depletion significantly delays the 
clearance bacteria and zymosan particles in vitro. Fig. 3.11 C and D respectively 
show the graphical representation of the data and the knock out efficiency of 
NRP2.  
NRP2 inhibits early to late phagosome maturation in macrophages: Our 
previous findings demonstrated that NRP2 regulates phagosomal maturation; 
depletion of NRP2 either genetically or by siRNA approach resulted in delayed 
maturation of E.coli containing phagosomes as well slowed down the clearance of 
E.coli and zymosan bioparticles in macrophages. Nascent phagosome maturation 
occurs in a step-wise manner through sequential recruitment of Rab5 to the early 
phagosomes followed by Rab7 to the late phagosomes. To test the effect of NRP2 
depletion on phagosome maturation, we next assessed the Rab5+ early 
phagosomes and Rab7+ late phagosomes in NRP2 proficient and deficient cells. 
In NRP2 depleted human macrophages, there was an increased accumulation of 
Rab5+ early phagosomes and a concomitant decrease in the Rab7+ late 
phagosomes (Fig. 3.12 A). Similar observations were made in mouse bone 
marrow derived macrophages following NRP2 knock out (Fig. 3.13 A). Fig. 3.12 
B and 3.13 B show the graphical representations for changes in early and late 
phagosome maturation in human and mouse macrophages respectively. Fig. 3.12 
C and 3.13 C respectively show that total cellular level of Rab5 and Rab7 remain 
unaffected following NRP2 depletion in human and mouse macrophages 
respectively. Knockdown or knockout for NRP2 is also shown in Fig. 3.12 C and 
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3.13 C respectively. Overall, these data suggest that NRP2 regulates phagosome 
maturation in macrophages. Depletion of NRP2 arrests maturing phagosomes in 
the early stages and impairs their maturation to late phagososomes or 
phagolysosomes.  
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3.C. Summary and Discussion 
Limited information is currently available about the function of NRP2 in 
macrophages. Previous literature as well as our current data show NRP2 is not 
expressed at a detectable level in freshly isolated human monocytes or bone 
marrow derived precursor cells in mouse. Its expression is induced as the cells 
differentiate towards mature macrophages, under M1 as well as M2 polarizing 
conditions. This raises the important question what might be the potential function 
of NRP2 in macrophages under normal physiological conditions (for example, 
when macrophages predominantly exist as M-CSF induced M0/M2 type) or during 
infections or inflammations (where GM-CSF is abundant, and macrophages mainly 
polarize towards inflammatory M1 type) and whether it can be potentially targeted 
for therapeutic purposes in the future. Our current study has answered some of 
these questions. Earlier literature suggested that Neuropilins are required for 
cellular locomotion. The directional migration of neuronal and endothelial cells is 
regulated by Neuropilins and their co-receptors such as Plexins and VEGF 
receptors. Interestingly, recent report also indicated the presence of a specific 
polysialylated form of NRP2 in dendritic cells, which is required for their movement 
to lymph nodes (36). Although NRP2 may potentially promote the migration, 
studying other molecular pathways it can govern will be crucial for the 
comprehensive understanding of its role in macrophages under normal as well as 
pathological conditions.  
We have previously reported a requirement for NRP2 in regulating 
endocytic activities in cancer cells, where it favors the maturation of early to late 
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endosome (242). Recognition of microbial pathogens and their phagocytosis is one 
of the most important functions of macrophages for maintenance of homeostasis. 
Following phagocytic engulfment, the internalized cargo initially remains in a 
nascent phagosome which needs to acquire the microbicidal enzymes and acidify 
its lumen for degradation of the cargo. For this maturation process, the 
phagosomes need to undergo a tightly co-ordinated sequence of fusion and fission 
with distinct compartments of the endocytic pathway (219, 220). Notably, the 
phagocytosis and classical endocytosis pathways are similar in many aspects, 
recruiting similar families of effector molecules for the maturation process. In their 
report, Stamatos et al. reported a progressive loss of polysialylation in monocytes 
and monocyte derived cells as they migrate to the pulmonary and peritoneal sites 
of inflammation. Removal of polysia enhanced macrophage phagocytosis of 
Klebsiella pneumoniae. However, it is not clear if this effect could be attributed to 
NRP2 alone (61). In the current study, we reveal a novel role of NRP2 in regulating 
phagocytosis in macrophages. NRP2 and NRP1 share structural homology and 
may have redundant functions. Importantly, the regulation of phagocytic activity is 
specific for NRP2 as NRP1 depletion did not influence the phagocytic activity of 
macrophages. To further assess how NRP2 regulates the phagocytic activity of 
macrophages, we tested whether NRP2 depletion leads to a defect in the uptake 
of phagocytic cargo or delays the maturation of phagocytic vesicles after the cargo 
has been engulfed. Our experiments with E.coli and zymosan particle conjugated 
with pH sensitive as well as pH insensitive fluorescent dye showed that NRP2 
depletion did not result in a significant decrease in the uptake of phagocytic cargo. 
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However, it regulates the overall degradation and clearance of internalized cargo 
by affecting the maturation of early phagosomes to late phagosomes or 
phagolysosomes. We corroborated our observations in human peripheral blood 
derived as well as mouse bone marrow derived macrophages. Therefore, NRP2 
mediated phagosomal maturation is a global phenomenon in human as well as 
mouse derived macrophages. A conclusive proof for the involvement of NRP2 in 
regulating the maturation process of phagosomes came when we observed an 
increase in Rab5+ early phagocytic vesicles with a concomitant decrease in Rab7+ 
late phagocytic vesicles, suggesting a defect during the exchange of Rab5 to Rab7 
in phagosomes. Generation of Rab7+ phagosomes is crucial for phagosome 
maturation, and is a prerequisite step for their fusion with lysosomes. Yet current 
knowledge on the detailed steps of phagosome maturation is limited. It is believed 
that the process begins with the recruitment of Dynamin (a large GTPase) which 
then interacts with Vps34 (a PI3 Kinase) and helps recruit Rab5 to the phagosome 
surface. Rab5, following its activation by Gapex-5 (Rab5 GEF), promotes Vps34 
activation. Vps34 generates PtdIns(3)P on the phagosome surface where the 
vacuolar fusion protein complex, Mon1A-Ccz1, is recruited. Mon1A-Ccz1 helps the 
recruitment and activation of Rab7 in the membrane and also promotes the 
recruitment of the homotypic fusion and vacuole protein sorting (HOPS) complex. 
Rab7 then interacts with HOPS to facilitate the fusion of phagosome to lysosomes 
(219-222)In. Since NRP2 depletion in macrophages resulted in more Rab5+ with 
a simultaneous decrease in Rab7+ phagosomes, we concluded that the molecular 
effectors downstream of Rab5 are regulated by the NRP2 axis. Further studies are 
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warranted to identify and understand how NRP2 regulates the maturation defect 
in macrophages.  
It is important to understand the clinical implications of NRP2 regulated 
phagocytosis in macrophages under different conditions. Since phagosome 
maturation is prerequisite for successful pathogen killing, many microbes have 
developed mechanisms to interfere with the phagosome maturation process. For 
example, Mycobacterium tuberculosis arrests phagosome maturation by 
preventing phagolysosomal fusion and the acquisition of lysosomal hydrolases 
(248). Interestingly, besides its role in pathogen killing, a phagosome also serves 
as a signaling platform for other related processes. The dynamics and molecular 
changes that a phagosome undergoes during the maturation phase enable other 
immune cells to respond to pathogen threat and maintain physiological 
homeostasis. Acceleration in phagosome maturation enhances pathogen killing. 
Whereas a delay in the maturation process preserves the antigenic peptides from 
degradative enzymes in the acidic mature phagosomes or phagolysosomes and 
favor presentation to T cells. This has been observed in case of macrophages and 
dendritic cells; macrophages acidify their phagosomes faster than dendritic cells. 
This enables the macrophages to rapidly degrade the internalized cargo whereas 
slow maturation in dendritic cells preserves antigen epitopes for longer period of 
time. Contrary to popular belief, it is now known that macrophages can also 
potentially present antigens to T cells  and activate the immune responses (249). 
Additionally, MHC I complexes can be recruited to phagosomes through fusion of 
phagosomes and endosomal recycling vesicles and become accessible to the 
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antigenic peptides generated in the phagosomes (250). Next, they can be cross-
presented to CD8+ T cells and activate robust immune reaction. Also, 
macrophages may undergo apoptosis due to uncleared pathogen burden. Cellular 
contents leaked out can then be taken up by dendritic cells, resulting in enhanced 
T cell responses. This strategy is used for designing effective vaccines for various 
pathogens. Based on our observations, NRP2 favors phagosome maturation and 
hence aid in microbial clearance in macrophages. Although NRP2 depletion delays 
phagosome maturation, it is too early to assume if it will favor antigen presentation 
in macrophages and warrants further investigation. However, NRP2 may be useful 
for development of better vaccines in the future.  
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Fig. 3.1 Expression of NRP2 in M2 type macrophages. Immunoblot analyses 
showing expression pattern of NRP2 in M2 type human and mouse bone marrow 
derived macrophages. (A) Freshly isolated human monocytes were differentiated 
to mature macrophages with M-CSF for 7days to generate resting or M2 type 
macrophages. IL-4/10/13 was added on day7 for 24hrs to complete the M2 type 
polarization. NRP2 was not detected in the monocytes but expression increased 
as cells differentiated to mature macrophages. (B) Bone marrow cells isolated from 
WT C57/BL6 mice were differentiated to resting or M2 type type macrophages 
using M-CSF for 7days. Cells were exposed to IL-4/10/13 on day7 for 24hrs to 
complete the M2 type polarization. NRP2 was not detected in freshly isolated the 
bone marrow, but expression increased significantly during the differentiation to 
macrophages. 
  
161 
 
 
  
 
 
 
 
 
 
 
 
 
A 
B 
162 
 
Fig. 3.2 Expression of NRP2 in M1 type macrophages. Immunoblot analyses 
showing expression pattern of NRP2 in M1 type human and mouse bone marrow 
derived macrophages. (A) Freshly isolated human monocytes were differentiated 
to mature macrophages with GM-CSF for 7days to generate M1 type 
macrophages. A combination of LPS+IFNγ was added on day7 for 24hrs to 
complete the M1 type polarization. NRP2 was not detected in the monocytes but 
expression increased as cells differentiated to mature macrophages. (B) Bone 
marrow cells isolated from WT C57/BL6 mice were differentiated to M1 type 
macrophages using GM-CSF for 7days. Cells were exposed to a combination of 
LPS+ IFNγ on day7 for 24hrs to complete the M1 type polarization. NRP2 was not 
detected in freshly isolated the bone marrow, but expression increased 
significantly during the differentiation to macrophages. 
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Fig. 3.3 NRP2 regulates phagosome maturation in macrophages without 
affecting uptake in human macrophages. (A) Schematic diagram for 
phagocytosis assay. (B) Phagocytosis assay for assessing the ability of M-CSF 
treated human macrophages to uptake E.coli bioparticles and phagosome 
maturation following NRP2 depletion by siRNA transfection. Cells were exposed 
to pH insensitive (green) and pHrodo E.coli (red) bioparticles for 1.5hr and 
analyzed microscopically. The first column shows the phagosome maturation (red 
puncta) in the scr (upper) and siNRP2 treated (bottom) cells. The second column 
shows the uptake efficiency (green puncta) in the scr (upper) and siNRP2 treated 
(bottom) cells. The third column represents merged images to show that NRP2 
primarily affects phagosome maturation, but not phagocytic uotake in 
macrophages. Scale bars, 20µm. Single cell magnified within the boxed region to 
show green or red E.coli particle. (C) Uptake efficiency was measured as green 
cellular fluorescence whereas the intensity of red fluorescence was an indication 
for phagosome maturation. Results were represented as bar graph, values as 
mean ± SEM. Dapi was used for staining the nucleus in all the experiments. 
Student t test was used for comparison between 2 groups of cells. *P < .05; **P < 
.005; ***P < .0005. ns=not significant. (D) Immunoblot analysis shows knockdown 
efficiency for NRP2 following electroporation.  
  
165 
 
Fig. 3.3 
 
 
 
 
 
A 
 A 
C 
A 
B 
 
D 
166 
 
Fig. 3.4 NRP1 does not regulate phagosome maturation in macrophages. (A) 
Phagocytosis assay to show NRP1 depletion does not have any effect on 
phagosome maturation in macrophages. Human macrophages were cultured for 
7days with M-CSF. Phagocytosis assay was conducted with pHrodo E.coli 
bioparticles following NRP1 depletion by siRNA transfection. Phagosome 
maturation was microscopically assessed from the intensity of red fluorescent 
puncta. Insets show magnified image of cell containing bacteria. Scale bars 10µm. 
Dapi was used for nuclear staining. (B) Phagosome maturation in the presence 
and absence of NRP1 was quantified using Image J software and represented in 
bar graph as mean ± SEM. Student t test was used for comparison between 2 
groups of cells. *P < .05; **P < .005; ***P < .0005. ns= non-significant. (C) Western 
blot shows knockdown of NRP1.  
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Fig. 3.5 NRP2 regulates phagosome maturation in GM-CSF treated 
macrophages. (A) Phagocytosis assay to assess the effect of NRP2 on 
phagosome maturation in GM-CSF treated human macrophages. Human 
monocytes were differentiated with GM-CSF for 7days and then exposed to 
pHrodo E.coli bioparticles for 1.5hr. Cells were fixed and analyzed by confocal 
microscopy. Phagosome maturation was scored from the intensity of red 
fluorescent puncta. Individual cell is magnified in the inset. Scale bars 10µm. Dapi 
was used for nuclear staining. (B) Bar graph showing quantification of phagosome 
maturation in GM-CSF treated macrophages following NRP2 depletion. Values are 
mean ± SEM. Student t test was used for comparison between 2 groups of cells. 
*P < .05; **P < .005; ***P < .0005. ns= non-significant. (C) Western blot shows 
knockdown for NRP2.  
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Fig. 3.6 NRP2 does not affect uptake of phagocytic cargo in GM-CSF treated 
macrophages. (A) Phagocytosis assay to test the effect of NRP2 on phagocytic 
uptake in GM-CSF treated human macrophages. Cells were exposed to pH 
insensitive E.coli (red) for 1hr to allow the macrophages uptake the bacteria. Cells 
were then fixed and analyzed by confocal microscopy. The intensity of red 
fluorescent puncta was used as a measure for uptake efficiency of the cells. 
Individual cells are magnified in the insets. Scale bars 10µm. (B) Uptake efficiency 
of the macrophages was quantified using Image J software and represented as 
bar graph.  Values are mean ± SEM. Dapi was used for nuclear staining. Student 
t test was used for comparison between 2 groups of cells. *P < .05; **P < .005; 
***P < .0005. ns= non-significant. (C) Western Blot analysis showing knockdown 
efficiency of NRP2 following siRNA transfection. 
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Fig. 3.7 Scheme for transgenic mouse generation and knock out of NRP2 
from macrophages. (A) CSF1R-iCre mouse is bred with NRP2f/f mouse to get 
CSF1R-iCre;NRP2f/f mouse. NRP2 can be genetically knocked out from myeloid 
cells following intraperitoneal administration of Tamoxifen or adding (Z)-4-Hydroxy 
Tamoxifen into cell culture medium. (B) Western blot showing knock out of NRP2 
from macrophages with different doses of Z)-4-Hydroxy Tamoxifen. 
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Fig. 3.8 NRP2 regulates phagosome maturation in mouse macrophages. (A) 
Bone marrow cells isolated from CSF1R-iCre;NRP2f/f were cultured for 7days with 
M-CSF and NRP2 knocked out by adding (Z)-4-Hydroxy Tamoxifen to the culture 
medium. Cells were challenged with 65 µg/mL of pHrodo E.coli bioparticles for 
1.5hrs. Cells were fixed and phagosome maturation was analysed by confocal 
microscopy. Dapi was used for nuclear staining. Inset shows magnified image of 
individual cell. Scale bar, 10µm. (B) Phagosome maturation was quantified as total 
cellular red fluorescence using Image J software and represented as bar graph. 
Values are mean ± SEM. Student t test was used for comparison between 2 groups 
of cells. *P < .05; **P < .005; ***P < .0005. ns= non-significant. (C) Western Blot 
analysis showing depletion of NRP2. 
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Fig. 3.9 NRP2 does not significantly affect the uptake of phagocytic cargo in 
mouse macrophages. (A) Representative image for phagocytosis assay with 
bone marrow derived macrophages isolated from NRP2fl/flCSF1R-iCre mice to 
show the effect of NRP2 depletion on uptake phagocytic cargo. Cells were 
challenged with pH insensitive E.coli bioparticles for 1hr and analyzed by Confocal 
microscopy. Scale bars, 10µm. Magnified images within the inset show the 
phagosomes containing E.coli bioparticle. Dapi was used for staining the nuclei. 
(B) Quantification for uptake efficiency of macrophages (red puncta, measured as 
total cellular fuorescence using Image J software) in the presence and absence of 
NRP2, represented in bar graph as mean ± SEM. Student t test was used for 
comparison between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. ns= non-
significant. (C) Western Blot analysis showing depletion of NRP2. 
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 Fig. 3.10 Effect of NRP2 depletion on bacterial clearance in vitro by 
macrophages. (A) Schematic diagram depicting bacterial clearance assay. (B) 
Bone marrow cells isolated from NRP2fl/flCSF1R-iCre mice were differentiated to 
macrophages for 7days using M-CSF. NRP2 was knocked out by the addition of 
(Z)-4-Hydroxy Tamoxifen to the cell culture medium. Macrophages were 
challenged with 65µg/mL pHrodo E.coli bioparticles for 15min (pulse time) and 
then assessed for their ability to mature the phagosomes and degrade the bacteria. 
Images were acquired at chase time = 0min, 15min, 45min, 90min, 120min and 
240min using Confocal microscopy. Scale bars, 10 µm. Magnified images within 
the inset show the phagosomes containing E.coli particles. Dapi was used for 
nuclear staining. (C) Phagosome maturation and degradation of fluorescent 
bioparticles was assessed as corrected total cell fluorescence using Image J 
software.  Cells were analyzed at times indicated at the graph abscissa and 
represented in bar graphs as mean ± SEM. Student t test was used for comparison 
between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. ns= non-significant. 
(D) Western blot for NRP2 depletion is shown.  
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Fig. 3.11 NRP2 affects zymosan clearance in vitro by macrophages. (A) 
Schematic diagram for zymosan clearance assay. (B) Bone marrow derived 
macrophages isolated from NRP2fl/flCSF1R-iCre mice were cultured for 7days with 
M-CSF. Cells were challenged with pHrodo zymosan particles for 15mins (pulse 
time) and then analyzed for phagosome maturation and degradation of zymosan 
particles following knocking out NRP2. Images were acquired at chase time= 0hr, 
6hr, 10hr, 14hr and 18hr. Scale bars, 10µm. Magnified images within the inset 
show the phagosomes containing zymosan particles at each time point. Dapi was 
used to detect the nucleus. (C) Phagosome maturation and degradation of 
fluorescent zymosan particles was scored as corrected total cell fluorescence 
using Image J software.  Cells were analyzed at times indicated at the graph 
abscissa and represented as bar graph. The values are mean ± SEM. Student t 
test was used for comparison between 2 groups of cells. *P < .05; **P < .005; ***P 
< .0005. ns= non-significant. (D) Western blot for NRP2 depletion is shown. 
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Fig. 3.12 NRP2 inhibits phagosome maturation in human macrophages. 
Depletion of NRP2 inhibits maturation of early to late phagosomes in 
macrophages. (A) Immunostaining of early and late phagosomal maturation 
markers in human macrophages following NRP2 depletion by siRNA transfection. 
The upper panel represents early phagosome marker Rab5 (green). Scale bars 
10µm. The lower panel shows representative images for the late phagosomal 
marker Rab7 (green). Scale bars 20µm. Magnified images of individual cell is 
shown in the inset for each condition. Dapi was used for staining the nucleus. (B) 
Immunostaining data for Rab5 and Rab7 were quantified as cellular fluorescence 
using Image J software and represented as bar graph. The upper panel shows 
graphical representation of Rab5 in the presence and absence of NRP2. The lower 
panel shows bar graph representing the change in Rab7 following NRP2 depletion. 
All values are shown as mean ± SEM. Student t test was used for comparison 
between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. (C) Western Blot 
analyses showing total cellular Rab5 and Rab7 and NRP2 depletion in whole cell 
lysates from human macrophages following knockdown of NRP2.  
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Fig. 3.13 NRP2 inhibits phagosome maturation in mouse macrophages. (A) 
Immunostaining of early and late phagosomal maturation markers in mouse bone 
marrow derived macrophages following NRP2 depletion by addition of (Z)-4-
Hydroxy Tamoxifen to cell culture media. The upper panel represents early 
phagosome marker Rab5 (red). The lower panel shows representative images for 
the late phagosomal marker Rab7 (red). Scale bars 10µm. The insets are 
magnified image of individual cell for each condition. (E) Representative bar 
graphs showing quantification of Rab5 and Rab7 using Image J software. The 
upper panel is the bar graph for change in Rab5 following NRP2 depletion. The 
lower panel is the graphical representation of change in Rab7 following NRP2 
depletion. All values are shown as mean ± SEM. Dapi was used for staining the 
nucleus in all the experiments. Student t test was used for comparison between 2 
groups of cells. *P < .05; **P < .005; ***P < .0005. (C) Western Blot analyses¬¬ 
showing total cellular Rab5 and Rab7 in whole cell lysates from mouse 
macrophages following knockdown of NRP2. 
185 
 
Fig. 3.13  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
C 
186 
 
       Chapter IV 
 
NRP2 is essential for clearance of dying cells and affects tumor 
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4. NRP2 is essential for clearance of dying cells and affects tumor 
progression and anti-tumor immune responses 
4.A Background, Hypothesis and Objectives 
            Macrophages are important component of the immune system and 
undertake a diverse array of functions like, clearance of cellular debris, 
development, metabolic homeostasis, microbial clearance and angiogenesis. 
Briefly, depending on the converging signals they are exposed to in the tissue 
microenvironment, macrophages can exist in two states: exposure to danger 
signals like bacteria or other infections skew them towards a classically activated 
or M1 type; these cells are cytotoxic and produce pro-inflammatory cytokines, 
ROS/NOS and robustly activate T cell responses. Post injury or infection, during 
the resolution phase, macrophages are polarized to alternatively activated or M2 
state where they produce angiogenic and tissue remodeling factors that augment 
the wound healing process. Macrophages have been implicated in several clinical 
conditions, like RA, diabetes, atherosclerosis and cancer. Macrophages comprise 
a substantial population in the TME and have been causally associated with 
distinct stages of disease progression, including EMT, angiogenesis, stem cell 
niche maintenance, metastasis and therapy resistance. TAMs are complex cell 
population; although gene expression profiles suggest TAMs closely represent the 
conventional M2 type macrophages, they also express several genes 
characteristic of the M1 type. NRPs have been implicated in TAMs. NRP1 is 
expressed in TAMs and is important for their migration to the hypoxic core of the 
tumor and their protumoral activities. Although NRP2 expression has been briefly 
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reported in TAMs, knowledge about its function and the molecular pathways it 
governs is lacking. 
Despite several targeted immunotherapies currently being explored pre-
clinically or in clinical trials, most cancers relapse, with more aggressive features. 
One of the essential functions of TAMs in the TME is efferocytosis of apoptotic 
cancer cells. The role of efferocytosis in cancer has remained elusive. However, 
there are some evidences to indicate that the non-immunogenic properties of 
efferocytosis that prevails under normal homeostasis conditions can be mimicked 
by malignant cells to create an environment of immunosuppression in the TME. In 
a tumor, the apoptotic index is high because of the rapid growth of cancer cells in 
a nutrient limited hostile environment or because of treatment with 
chemotherapeutic drugs, and therefore mimic the environment of a non-resolving 
wound. TAMs show increased efferocytosis, which also facilitates immune 
tolerance by rendering the former more protumorigenic and increase the risk for 
metastasis. A protumoral role of efferocytosis was also observed where tumor 
progression was dampened following genetic depletion of the efferocytosis 
receptor MerTK (Cook 2013). MerTK-/- CD11b+ cells isolated from the tumors 
showed signs of immune activation. Intriguingly, intratumoral dendritic cells 
engulfing tumor cells expressing the well-known ‘eat me’ signal, PtdSer remain 
arrested in an immature state of differentiation, incapable of expressing the co-
stimulatory molecules required for optimum T cell activation (Bondanza A JEM 
2004), resulting in further immunosuppression in the TME. However, the molecules 
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that couple the two pathways, viz. efferocytosis and immune modulation are still 
not well known.  
The goal of this study is to understand the role of NRP2 in TAMs and how 
this may affect tumor progression. Pancreatic Ductal Adenocarcinoma (PDAC) is 
one of the most lethal types of cancers with high incidence and low survival rates. 
One of the hallmarks of PDAC is the dense desmoplastic reaction that acts as a 
physical barrier to therapeutics. TAMs are abundantly present in PDAC and have 
been causally associated with distinct stages of disease progression, metastasis, 
therapy resistance and correlate with poor outcome. Despite extensive research, 
therapeutic modalities are still not available to effectively treat PDAC. Our goal is 
to identify the function of NRP2 in TAMs and how targeting this axis may affect 
PDAC progression. Based on our previous reports and findings in Chapter 3, we 
hypothesized that NRP2 regulates efferocytosis of apoptotic cells in TME and 
maintains immune tolerance. In this chapter, we report that NRP2 is expressed in 
macrophages in human and mouse PDAC.  We also observed that NRP2 in 
macrophages regulates efferocytosis and that its depletion significantly delays the 
clearance of apoptotic cells in vitro. Further, we investigated the effect of NRP2 
mediated apoptotic cell clearance on pancreatic cancer progression, using a 
subcutaneous tumor model. NRP2 depletion resulted in a moderate decrease in 
tumor progression. Interestingly, NRP2 does not have any role in TAM recruitment 
into the tumors, however, NRP2 depletion significantly increased the intratumoral 
infiltration of cytotoxic CD8+ T cells. This could be attributed to the delayed 
clearance of apoptotic cancer cells in the TME and cross presentation to cytotoxic 
190 
 
T lymphocytes. CD11b+ TAMs from the tumors were isolated and Next Generation 
RNA-Sequencing analysis performed. Gene enrichment analysis showed 
deregulation of several genes associated with phagosomal maturation, exocytosis 
and recycling, immunosuppressive phenotype of TAMs as well as leucocyte 
migration and activation processes. In brief, our data strongly support our 
hypothesis that NRP2 regulates efferocytosis in macrophages and maintains 
immune tolerance in TME. Further, NRP2 depletion results in delayed apoptotic 
cell clearance and activates immune response against tumors and slows down 
tumor progression. Overall, the study strongly suggests the importance for the 
development of an adjuvant therapeutic strategy targeting the NRP2 axis in 
macrophages and to reduce pancreatic cancer recurrence and metastasis.  
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4.B Results 
NRP2 is expressed in tumor associated macrophages (TAMs) in Pancreatic 
Cancer. 
We obtained pancreatic cancer tissue sections (from the Rapid Autopsy Program 
at UNMC) from 10 PDAC patients who died with no history of treatment. We tested 
the presence of NRP2 expressing TAMs by co-staining with anti NRP2 and CD68 
(a pan macrophage marker) antibodies. We observed that most of the 
macrophages in the tumor microenvironment were NRP2 positive (Fig. 4.1 A). 
However, we also detected the presence of few NRP2lo or NRP2- CD68+ 
macrophages in certain areas of 2 tissues. NRP2 expressing F4/80+ macrophages 
were also detected in mouse pancreatic tumor tissue derived from KC mouse (Fig. 
4.1 B). To generate TAMs in vitro, freshly isolated human monocytes or bone 
marrow cells from WT mice were differentiated for 7days with CM from either 
human PC Panc-1 or mouse PC UNKC-6141 and KPC cell lines respectively. In 
both the conditions, NRP2 expression increased as the cells differentiated to TAMs 
(Fig. 4.2 A-C). Overall, these results suggest that NRP2 is expressed by TAMs in 
vivo as well in vitro.  
NRP2 regulates phagosomal maturation in TAMs in vitro. 
Our previous findings indicated that NRP2 regulates phagosomal maturation in 
macrophages under M2 and M1 polarizing conditions, in human as well as in mice. 
Next, we wanted to test if NRP2 regulates phagosomal maturation in TAMs. To 
test this, we treated human monocytes with CM derived from Panc-1 cells for 
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7days to differentiate them to TAMs in vitro. Phagocytosis assay was performed 
with pH sensitive pHrodo E.coli particles and monitored under confocal 
microscope. Compared to the control, NRP2 deficient macrophages showed 
significantly lesser number of visible red puncta (Fig. 4.3 A). This suggests that 
phagsosomes containing E.coli particles matured into either late phagosomes or 
phagolysosomes and hence fluoresced bright red in the acidic vesicles. In contrast, 
in NRP2 depleted macrophages, the phagosomes did not mature to acidic late 
phagosomes or phagolysosomes and hence there was a significant decrease in 
the visible fluorescence intensity of the bioparticles. Fig. 4.3 B and C show the 
graphical representation of the result and the knockdown efficiency of NRP2 by 
siRNA approach.  
The assay was repeated using bone marrow derived macrophages isolated from 
CSF-1R-iCRE;NRP2f/f mice. Cells were treated with CM derived from mouse 
pancreatic cancer cell lines UNKC-6141 and KPC. (Z)-4-HydroxyTamoxifen was 
added to cell culture medium to genetically delete NRP2 from the macrophages. 
Phagosomal maturation was assessed using the pH dependant pHrodo E.coli 
bioparticles. In the wild type cells, bright red puncta indicated phagosomal 
maturation to acidic late phagosomes or phagolysosomes. There was a significant 
reduction in the intensity as well number of bright red puncta in the NRP2 depleted 
cells, indicating a delay in the maturation process (Fig. 4.3 D,G). Fig. 4.3 E,H and 
F,I show the graphical representation of the results and the knock out efficiency of 
NRP2. 
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Overall, these results indicated that NRP2 regulates phagosomal maturation in 
TAMs (human and mice) and that its depletion results in a significant delay in the 
maturation process.  
NRP2 in macrophages regulates efferocytosis of apoptotic cells. 
Efferocytosis is a strictly orchestrated process where professional phagocytes, 
such as macrophages recognize and engulf apoptotic cells and remove them from 
the system in an immunologically silent manner. Maturation of nascent efferosome 
containing apoptotic debris and subsequent degradation and clearance share 
similarity with endosomal maturation and lysosomal fusion processes. Both the 
pathways often hire similar family of effector molecules. Based on our previous 
data that NRP2 regulates phagocytosis in macrophages, we wanted to investigate 
its role in the clearance of dying cells by macrophages. To test this, a pulse and 
chase experiment was performed where apoptosis was induced in Jurkat cells 
using 50µM Etoposide and added to M-CSF treated mouse bone marrow derived 
macrophages for 1hr (pulse). Non-engulfed or loosely bound cells were removed 
by vigorous washing and the macrophages were then monitored for their ability to 
degrade and clear the apoptotic cargo (chase). A schematic diagram showing the 
experimental design is depicted in Fig. 4.4 A.  Phagosomes containing engulfed 
dead cells need to fuse with lysosomes to form phagolysosomes. During the 
course of degradation, the latter gradually decrease in size and finally disappear. 
Therefore, in the current experiment, ability of the macrophages to clear apoptotic 
cells was assessed from the breakdown of the apoptotic cells and loss of 
fluorescence (red). At 2hrs chase, there was significant increase in the red 
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fluorescence in both the control (-H-Tam) as well as NRP2 KO cells (+H-Tam). 
However, at 6hrs, there was a significant decrease in the red fluorescent intensity 
and disappearance of apoptotic cells in the control macrophages, indicating the 
apoptotic cells were broken down and degraded. In contrast, even after 12hrs, 
NRP2 KO cells exhibited significant delay in the clearance of apoptotic cell cargo 
(Fig. 4.4 B). This was apparent from larger size of the cargo and higher amount of 
fluorescence that persisted in the cells even after 12hours. Fig. 4.4 C and D 
respectively show the graphical representation of the result and the knock out 
efficiency in macrophages.  
The assay was repeated using peritoneal macrophages isolated from CSF-1R-
iCRE;NRP2f/f mice, and NRP2 knocked out by intraperitoneal administration of 
Tamoxifen. Here also, in NRP2 deficient cells, there was a significant delay in the 
degradation and clearance of apoptotic cells, compared to the NRP2 proficient 
control macrophages (Fig. 4.5 A). Fig. 4.5 B and C respectively show the 
graphical representation of the result and the knock out efficiency of NRP2 in 
macrophages following Tamoxifen treatment.  
Overall, these data suggest that NRP2 in macrophages regulates the clearance of 
apoptotic cells and its depletion significantly increases the life time of the 
efferosome (phagosome containing the apoptotic cargo) and delays their 
clearance. 
Efferocytosis of dying cancer cells in the TME is critical for the pro-tumoral 
behavior of TAMs and contributes to cancer progression and metastasis, and 
recurrence. Based on our previous data that NRP2 depletion affects the clearance 
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of apoptotic cells, we further wanted to test if NRP2 regulates the clearance of 
apopototic debris in TAMs. For this we repeated the efferocytosis pulse and chase 
assay using bone marrow precursor cells isolated from the transgenic mouse 
model (CSF-1R-iCre;NRP2f/f). Cells were differentiated to TAMs using CM from 
the murine pancreatic cancer cell line UNKC-6141 for 7days. (Z)-4-
HydroxyTamoxifen was added into the cell culture, every alternate day, for 7days, 
to genetically knock out NRP2 from the macrophages. Prior to the assay, as 
apoptosis was induced in Jurkat cells using Etoposide (as mentioned earlier). 
Apoptotic Jurkat cells were added to the macrophages for 1hr in 1:10 ratio 
(macrophage:Jurkat) and allowed the engulfment by macrophages. Following this, 
non-engulfed or loosely bound cells were washed away and macrophages 
monitored upto 12hrs for their ability to degrade and clear the apoptotic cells that 
were engulfed. At the beginning of chase, there was no significant difference in the 
intensity of red fluorescence in the control and NRP2 KO cells. At 2hr chase, the 
intensity increased in the control and NRP2 KO macrophages, indicating the 
efferosomes are maturing further and becoming acidic. However, at 6 and 12 hrs 
of chase, there was a significant decrease in the intensity of red fluorescence as 
well as size of the internalized apoptotic debris in the control macrophages. This 
suggests efficient degradation and clearance of apoptotic cells in the control 
macrophages. In contrast, the higher red fluorescent intensity and persistence of 
bigger cellular debris in the NRP2 KO macrophages at the above-mentioned time 
points indicated a delayed clearance of apoptotic cargo in the absence of NRP2 
196 
 
(Fig. 4.6 A). Fig. 4.6 B and C show the graphical representation of the result and 
genetic depletion of NRP2 in the macrophages respectively.  
Overall, these results suggested that NRP2 regulates efferocytosis of apoptotic 
cells in macrophages, during physiological homeostasis (M-CSF) as well as TAM 
polarizing conditions (CM treatment). Further, NRP2 depletion in macrophages 
significantly delayed the degradation and clearance of the apoptotic cells.  
NRP2 in macrophages regulates tumor growth  
(1) NRP2 regulates apoptotic cell clearance in TME and affects tumor growth: 
Studies have shown that efferocytosis of apoptotic tumor cells by TAMs is an 
important factor for maintenance of pro-tumorigenic activities of TAMs. Further, 
blockade of efferocytosis relieves the tumor burden by activating anti-tumor 
immune responses. However, the molecular effectors that couple the processes 
of efferocytosis and immune silencing in phagocytes is still not clearly understood. 
Based on our previous findings that NRP2 regulates efferocytosis of dying cells by 
macrophages (Fig. 4.4-4.6), we sought to next test if NRP2 depletion in TAMs 
affects tumor growth. For this, we used a subcutaneous pancreatic cancer 
progression model. 2X106 UNKC-6141 murine pancreatic cancer cells were mixed 
with Matrigel and subcutaneously implanted into the right flanks of animals. Once 
tumors became palpable, animals were randomly divided into two groups (n=5 
each): Control and test. In the test animals, tamoxifen was administered 
intraperitoneally (75mg/kg body weight of the animals) to genetically deplete NRP2 
from macrophages. Tumor growth was monitored for a period of 21days since day 
of implantation. The overall design of the study is shown in Fig. 4.7. NRP2 
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depletion in macrophages resulted in a decrease in tumor growth (Fig. 4.8 A,B). 
The tumors were excised and weighed and tumor volume measured. The average 
volume of the control tumors was 449.80 mm3 and that of test tumor was 215.15 
mm3, indicating a 52.16% decrease in average tumor volume in the test group (Fig. 
4.8 C). The average weight of the control and test tumors was 0.33 and 0.22 gm 
respectively, suggesting a 33.33% decrease in the average weight of the test 
tumors in comparison the control (Fig. 4.8 D). Importantly, weight of the mice did 
not alter significantly following Tamoxifen administration (Fig. 4.8 F). Fig. 4.8 E 
shows immunoblot for knock out efficiency of NRP2 from bone marrow 
macrophages following Tamoxifen administration intraperitoneally in the control 
and test animals. One concern was whether intraperitoneal administration of NRP2 
could knock out NRP2 from macrophages inside the tumor. RNA-Seq analysis 
(Fig. 4.11 H) revealed a knock-out of NRP2 from the TAMs isolated from the 
tumors. Thus, it is conceivable that the effect on tumor progression and TME arises 
as a consequence of myeloid specific NRP2 depletion.  
Interestingly, histological analysis of the tumor sections revealed a significant 
increase in the percentage of average necrotic area in the test tumors (32%) 
compared to the control (19.2%) (Fig. 4.9 A and B). This could be attributable to 
the impaired clearance of dying tumor cells by NRP2 deficient TAMs. Given that 
NRP2 has a known role in migration, we next tested if NRP2 depletion affected the 
migration of macrophages into the TME, using F4/80 as a macrophage marker. 
We did not observe any significant difference in the number of macrophages in the 
control and test tumors (Fig. 4.10 A and B). We did not observe any significant 
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difference in the CD8+ T cell infiltration or CD31+ vessel density in control versus 
test tumors (Fig. 4.10 C-F).  
(2) NRP2 in macrophages affects tumor growth and suppresses anti-tumor 
immune responses: We repeated our subcutaneous tumor progression experiment 
(n=5). This time, we subcutaneously implanted 500,000 UNKC-6141 cells mixed 
with Matrigel into the right flank of CSF-1R-iCRE;NRP2f/f mice. Once the tumors 
became palpable, tamoxifen was administered as described earlier and tumor 
progression monitored for a period of 25days. We observed a decrease in tumor 
size in the test tumors where NRP2 was genetically knocked out from TAMs (Fig. 
4.11 A). Tumor growth was regularly monitored, and tumor volume calculated 
using the formula v=0.5(LXBXB) where L=longest diameter and B=widest diameter 
of the tumor. Fig. 4.11 B shows the line plot for tumor growth in control and test 
animals over the indicated time point. Importantly, NRP2 depletion in macrophages 
showed a cytostatic effect on tumor growth after day 17 and the growth curve for 
test tumors reached a plateau after this time. In contrast, there was a steady 
increase in the average volume of the control tumors. The excised tumors were 
weighed and measured. The average volume of the control tumors was 325 mm3 
and that of test tumors was 132 mm3, indicating there was a 59.38% reduction in 
average tumor volume following NRP2 depletion in TAMs (Fig. 4.11 C). The 
average weight of the control tumors was 0.42 gm compared to 0.21 gm in the test 
group, suggesting a 50% decrease in tumor weight following NRP2 depletion (Fig. 
4.11 D). Importantly, TUNEL staining of the tumor sections revealed an increase 
in the necrotic area in the test tumors (Fig. 4.11E). We believe NRP2 depletion in 
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macrophages resulted in inefficient clearance of apoptotic tumor cells, which 
eventually underwent secondary necrosis and spilled their nuclear and cellular 
components. Fig. 4.11 G shows immunoblot for knock out efficiency of NRP2 in 
bone marrow derived macrophages in the test mice, following Tamoxifen 
administration. NRP2 is well known for its role in migration. We questioned if the 
increase in necrotic foci in test tumors were a consequence of impaired recruitment 
of macrophages to the site of the tumor or their delayed clearance stemming from 
downstream phagosomal maturation defect in absence of NRP2. Staining with anti 
F4/80 antibody revealed no notable change in macrophage migration and 
recruitment in control and test tumors (Fig. 4.12 A and B). This indicates that 
NRP2 probably is dispensable for the migration of macrophages to the site of 
tumor. Also, it suggests that recruited TAMs display dampened efferocytic ability 
in absence of NRP2 which resulted in increased accumulation of apoptotic or 
necrotic cells in the TME. Staining with anti CD31 antibody revealed no significant 
difference in average vessel density between the control and test tumors, 
suggesting there intratumoral angiogenesis was unaffected following NRP2 
depletion in TAMs (Fig. 4.12 C and D). However, further tests are required to affirm 
if there is any difference in the level of vessel normalization in control versus test 
tumors. Expression of alpha smooth muscle actin (α SMA) has been shown to 
correlate with poor prognosis in many tumors. However, staining with anti- α SMA 
showed no significant difference between control and test tumors (Fig. 4.14 E and 
F). One drawback of the current work is that being a subcutaneous tumor 
progression model, it does not entirely mimic the natural tissue architecture or 
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tumor growth conditions as in an orthotopic model. Also, the presence of skin 
fibroblasts is unavoidable in the current model.  
One of the major contributing factors to tumor growth is suppression of effector 
and cytotoxic T cell activation. Tumor cells as well as other immune and stromal 
cells in the TME secrete a wide array of chemokines, cytokines and other factors 
which interfere with recruitment and activation of effector and cytotoxic T cells. 
Interestingly, we observed a ~3-fold increase in intratumoral infiltration of cytotoxic 
CD8+ T cells in the test tumors following NRP2 depletion. This data suggests 
NRP2 in macrophages suppresses anti-tumor immune response and that its 
depletion in macrophages results in enhanced recruitment of CD8+ T cells into the 
tumor (Fig. 4.13 A and B). Staining with anti-Granzyme B (GrB) antibody revealed 
a mild increase in the average number of GrB+ cells in 3 out of 5 test tumors, 
however, this did not reach statistical significance (Fig. 4.13 C and D). 
Interestingly, staining with anti CD4 revealed an infiltration along the periphery in 
3 of the 5 test tumors in comparison to control tumors (Fig. 4.13 E and F); however, 
this did not attain statistical significance.  
Taken together, the results indicated a role for NRP2 in regulating tumor growth 
and immune response against the tumor, without affecting macrophage 
recruitment and intratumoral angiogenesis.  
Transcriptome analysis of TAMs using next generation RNA-Sequencing.  
To better understand how NRP2 in TAMs mechanistically regulates tumor growth 
and T cell responses, we monitored the growth of subcutaneous PC tumor (n=3) 
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for 15days, following which the animals were sacrificed, and tumors excised. Fig. 
4.14A summarizes the experimental design. The average volume of the control 
tumors was 324.8mm3 whereas that of the test tumors was 129.8mm3, indicating 
a 60% decrease in the average volume of the test tumors (Fig. 4.14 B). The 
average weight of the control and test tumors were 0.27gm and 0.166gm 
respectively, indicating a decrease in the average weight of the test tumors by 
38.51% (Fig. 4.14 C). CD11b+ TAMs isolated using magnetic beads. RNA was 
isolated and pooled from n=3 animals in either control or test group. This was done 
in order to obtain sufficient amount of RNA. RNA-Sequencing was performed as 
mentioned in the methods section. A paired end read 2x75bp sequencing run of 
RNA libraries were performed using the Illumina NextSeq 500 instrument. For 
analysis, raw reads were de-multiplexed by barcode and output into FASTQ 
format. Cutadapt was used to filter out adapter sequences and low-quality bases. 
Filtered sequence reads were aligned to mouse reference genome mm10 using 
HISAT2 aligner. Reads mapping to exon regions as defined by Ensembl gene 
annotations were counted using FeatureCounts. We analyzed our data on the 
basis of log fold change value. We considered transcripts which were differentially 
expressed more than 2 fold (log2 fold change 1) in either control or test sample and 
eliminated all transcripts with zero counts in either sample to maintain stringency. 
After applying the cutoff, we had 3616 genes whose expression was altered by 
atleast 2 fold following NRP2 depletion in macrophages. Out of these, 1567 genes 
were differentially up-regulated whereas 2049 genes were downregulated 
following NRP2 depletion (Fig. 4.14 D). These differentially expressed transcripts 
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were uploaded to the IPA database to identify the major enriched cellular and 
molecular functions in the absence of NRP2 in macrophages. We observed that 
pathways related to immune responses as well as phagosome formation were 
most significantly affected. The top 20 significantly pathways from IPA analysis 
included communication between innate and adaptive immune cells, altered T cell 
and B cell signaling, Th1 and Th2 activation pathway, Primary immunodeficiency 
signaling, Th1 pathway, autoimmune thyroid disease signaling and phagosome 
formation. Among other significantly altered pathways, we detected leucocyte 
extravasation signaling, inhibition of matrix metalloproteases, role of cytokines in 
mediating communication between immune cells, micropinocytosis signaling and 
caveolar mediated endocytosis. Representative IPA pathways related to immune 
responses and phagocytosis pathways with gene enrichment and statistical 
significance is shown in Fig. 4.15 A.  
To gain a better understanding for the functional processes affected by NRP2 
depletion, we determined the biological process gene ontological classification for 
each altered transcript using the DAVID and KEGG databases in combination with 
extensive review of published literature. As observed with IPA analysis, with 
DAVID, we observed that genes related to immune response and 
leucocyte/lymphocyte regulation were abundantly regulated. Also, clusters 
comprising of genes functionally annotated to cytokine and chemokine signaling, 
wounding response, endocytosis or vesicle mediated transport, microtubule 
organization were enriched. Since our in vitro and in vivo data indicated a role of 
NRP2 in the regulation of phagocytosis and efferocytosis as well as activation of 
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CTL response in tumors, we selected representative annotation clusters enriched 
for these functions. Genes from IPA, KEGG and DAVID clusters for T cell related 
immune response, cytokine/chemokine signaling pathways and phagocytosis and 
phagosome maturation were compiled and a unique gene list was created for each 
function and compared with our dataset of 3616 differentially regulated genes. Fig. 
4.15 B and C show representative functional annotation clusters for differentially 
expressed genes in TAMs following NRP2 depletion.  
NRP2 depletion deregulates phagocytosis and endocytosis related 
pathways in TAMs 
For assessing the effect of NRP2 depletion in the phagocytic activity of TAMs, we 
carefully analyzed the expression pattern of genes detected by IPA (canonical 
pathway: phagosome formation) and DAVID (annotation clusters 91 and 92) as 
well as additional genes from our dataset. We detected altered expression of 
several genes belonging to the Rab family of proteins. Genes like Rab15, Rab3a, 
Rab6B, Rab34, Rab39, RabL3, Rab36, Rab13, Rab27B were affected following 
NRP2 depletion in macrophages. Several other genes associated with 
phagocytosis or phagosome/endosome maturation like, Tubb4a, TubA8, Rufy4a, 
Zap70 were deregulated. Interestingly, we detected elevated expression of genes 
encoding Rab7 GTPase activating proteins, TBC domain 1 member 15 and TBC 
domain 1 member 2. Several Guanine Nucleotide Exchange Factors, like Rho GEF 
15, Cdc42 GEF 9, FYVE Rho GEF, RhoD among others were also differentially 
expressed. These indicate that NRP2 is important for endocytosis and 
phagocytosis pathways in macrophages. Interestingly, we found one mircroRNA, 
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mir-24 to be significantly upregulated in NRP2 depleted TAMs. This mir has been 
reported to attenuate phagocytosis as well modulate inflammatory cytokines in 
macrophages and DCs (251). Interestingly, several molecules like Elmo-3, Alox15, 
CD4, IgM, CD209 (DC-SIGN), OC-STAMP involved in phagocytic uptake or 
clearance of apoptotic cells were downregulated, although other molecules like 
Stabilin1, Marco that too can bind to and are important for the clearance of 
apoptotic cells were upregulated. CX3CL1 secreted from apoptotic cells bind to 
CX3CR1 expressed on macrophages and induce chemotaxis for efficient 
clearance of the apoptotic cells. We observed a significant downregulation in the 
expression of CX3CR1 in NRP2 depleted TAMs. Downregulation of phagocytic 
cargo-uptake related receptors and molecules may be either a secondary effect of 
impairment of phagosome maturation following NRP2 depletion, as it has already 
been reported that a defect in phagosome maturation can dampen the 
internalization process. Also, it may be possible that downregulation of the 
efferocytosis related receptors may be a tumor microenvironment specific effect. 
Known representative genes whose expression altered following NRP2 depletion 
in macrophages are shown in Fig. 4.16 A. In conclusion, the gene expression data 
indicated the potential involvement of genes present in macrophages, which are 
important for NRP2-mediated efficient clearance of apoptotic cells. Intriguingly, 
phagosomes containing different cargo often recruit functionally similar but distinct 
molecules for phagosome maturation or phagolysosome biogenesis and often 
follow different maturation kinetics. The exact molecular mechanism of how these 
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NRP2-regulated genes involve in the phagosome maturation is currently unknown 
and merits further investigation.  
NRP2 depletion alters genes in TAMs related to inflammation, 
immunosuppression, tissue remodeling, chemokines and cytokines 
Our analysis from IPA software, DAVID and KEGG pathways revealed many of 
the immunosuppressive genes and those associated with EMT and metastasis, 
like, IL-4, IL-10, TGF-α, IL-21R, IL-33, IL-34, IL-23a, IL-1β were downregulated in 
TAMs following NRP2 depletion. Genes associated with ECM remodeling like 
MMP9, MMP13, MMP11, MMP23, MMP25 were also downregulated. Among the 
inflammatory genes, we observed a mixed signature. There was an upregulation 
of IFN-β1, IL-12a, Gr-K, Gr-F, IL-15Ra, IL-1RL2, whereas IFN-γ, IL-12b, Gr-A, Gr-
B, Gr-C, IL23a were downregulated among others. It is known that efferocytosis 
upregulates the immunosuppressive genes in macrophages. Inefficient clearance 
of apoptotic cells reduces the immunosuppressive genes and induces the 
expression of inflammatory genes. For instance, cytosolic DNA from dead cells 
can trigger the expression of IFNβ. IL-12a expression is induced under 
inflammatory conditions and due to its low abundance, its induction is considered 
to be the rate limiting step in the production of biologically active IL-12. Gr-K has 
been reported to be upregulated in sepsis and acute airway inflammation, and 
plays a role in inflammatory responses in macrophages. Further, it can get 
activated in conditions where Gr-A activity is compromised. Additionally, Gr-K and 
Gr-F both have cytolytic potential and can be tumoricidal. These observations are 
in support of our hypothesis and indicate that NRP2 depletion affects efferocytosis. 
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This in turn downregulates the expression of immunosuppressive genes and 
upregulates the inflammatory genes. IL-12b subunit can homodimerize and bind 
to IL-12 receptor but does not mediate signaling and it therefore a strong 
antagonist for biologically active IL-12. We speculate the decrease in IL-12b 
transcript may be an effort to avoid formation of the antagonist (IL-12b)2 
homodimer. IL-23 (heterodimer of IL-23a and IL-12b) can also promote tumor 
progression by suppressing T and NK cells effector functions (252). Therefore, 
downregulation of IL-12a transcript may possibly be an effort to decrease the 
biologically active form of IL-23. Also, mir-24 that was significantly upregulated in 
NRP2 depleted TAMs has been reported to affect the expression of TNF-α, IL-6 
and IL-12b at the transcription level (251). These indicate an effect of NRP2 
depletion on dampening phagocytosis and a complex interplay among various 
molecules to affect the phenotype TAMs.  
Interestingly, several genes associated with the maintenance of stem cell niche 
and metastasis like MUC1, WISP1, Angptl2, CXCR4 were downregulated in NRP2 
depleted TAMs. TAMs are considered one of the important players in intratumoral 
vasculature. Interestingly, following NRP2 depletion, some of the genes 
associated with the endothelial cell like behavior, like, SOX7, Angptl2, Angptl7 
were downregulated. Angptl2 can regulate metastasis through CXCR4 signaling 
pathway and MMP13 mediated degradation of the collagen. It also has direct pro-
angiogenic activity. However, we did not observe any change in average vessel 
density in tumors following NRP2 depletion in macrophages. We also analyzed the 
chemokine gene profile in control versus test tumors. We detected that 
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chemokines like CXCL13, CCL25 that have been reported to promote migration of 
DC, activated T cells were upregulated in NRP2 depleted TAMs. Expression of 
CCL22 (known for attracting Th2, Treg or Th17 cells) and CXCL12 (may promote 
TAM differentiation) were downregulated in NRP2 deficient TAMs. 
In brief, these indicate that in NRP2 depleted condition, TAMs suppress 
immunosuppressive genes and upregulates several inflammatory pathways. 
Known representative genes pertaining to macrophage polarization are shown in 
Fig. 4.16 B.  
Effect of NRP2 depletion in macrophages on T cells 
We observed that NRP2 depletion affects the clearance of apoptotic cells in 
macrophages as well as TAMs in vitro. Our in vivo observations suggested NRP2 
depletion in macrophages resulted in an increased infiltration of cytotoxic CD8+ 
and CD4+ T cells (in 3 out of 5 tumors) into the tumor. We analyzed the 
transcriptome data in our quest to search for changes in expression of genes that 
could explain the increased infiltration of activated T cells into the tumors following 
NRP2 depletion in macrophages. As mentioned earlier, NRP2 depletion affected 
the expression pattern of several immunosuppressive genes, like IL-4, IL-10, TGF-
α, IL-21R, IL-33, IL-34. IL-4, IL-10, TGF-α can potentially induce the formation of 
Treg cells. TGF-α can also interfere with T cell activation, proliferation and 
migration to the tumor tissue. Also, IL-12α and IFN-β1 were upregulated in the 
NRP2 depleted TAMs which can potentially activate T cell responses. Additionally, 
our analysis revealed an increased expression of CXCL13 and CCL25 that can 
recruit effector T cells whereas molecules like CCL22, Sema-7A and Sema-3E that 
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can either recruit Treg cells or interfere with T cell migration or their activation were 
downregulated in the NRP2 deficient TAMs. Additionally, molecules like Foxp3, 
PDL2, TIGIT that can either induce immunosuppression in macrophages and 
indirectly dampen T cell response or provide co-inhibitory signal to T cells were 
downregulated following NRP2 depletion (253-255). Therefore, we believe that 
NRP2 deletion in macrophages affects the expression of several immune response 
genes that act in consort and facilitates the infiltration of cytotoxic CD8+ and CD4+ 
T cells. Further, we observed inefficient clearance of dead cells in tumors where 
NRP2 was depleted from macrophages. Apoptotic cells if not removed, form 
secondary necrosis and the nuclear and cellular contents leak outside as a result 
of loss of membrane integrity. This was observed from TUNEL staining where we 
found an increase in the number of necrotic zones in the tumors following NRP2 
depletion from macrophages. The leaked cellular contents from cells undergoing 
secondary necrosis can also potentially attract CD8+ T cells. Overall, we believe 
that the components of the necrotic cells and altered expression of several 
cytokines, chemokines and other signaling molecules following NRP2 depletion in 
macrophages act synergistically and result in robust infiltration of CD8+ T cells in 
to the tumors. Known representative genes that can potentially work in consort for 
T cell activation are shown in Fig. 4.16 B.  
Summary and Discussions 
Apoptosis is a highly orchestrated cell death modality and clearance of 
apoptotic cells by efferocytosis for removing aged or damaged cells in an 
immunologically silent manner is essential for maintenance of physiological 
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homeostasis. Impaired efferocytosis results in secondary necrosis and leakage of 
necrotic cell contents into the tissue milieu and can aberrantly activate adaptive 
immune responses. Efficient efferocytosis of cells infected with microbes (e.g. 
influenza virus, Mycobacterium tuberculosis) results in pathogen destruction. Cells 
infected with the pathogen can be taken up and degraded simultaneously by 
macrophages (230). Additionally, macrophages also efficiently remove the 
apoptotic or infected neutrophils that invade the site of injury or infection (256). 
This process of cleaning up further evokes non-inflammatory cascades, such as, 
production of IL-10, TGF-β in engulfing cells and polarizes the efferocytic 
macrophages towards an immunosuppressive phenotype and is important for 
resolution of inflammation and wound healing post infection or injury. Despite 
extensive research over the past decade, knowledge about the molecular 
pathways that link the processes of efferocytosis and immune suppression in 
macrophages is limited. Our data reveal a novel role of NRP2 in regulating 
efferocytosis in macrophages. We provide evidence to suggest that NRP2 
promotes rapid and efficient clearance of engulfed apoptotic cells and its absence 
significantly delays the overall clearance process. NRP2 is a cell surface receptor. 
Hence, the question arises, does it interact with any of the ‘find me’ or ‘eat me’ 
molecules expressed on the surface of dying cells and affect the uptake process. 
However, after initial incubation with apoptotic cells (0 min chase), our data 
suggest that NRP2 does not affect the uptake process. Of note, NRP2 depletion 
does not block the clearance of apoptotic cellular debris, but delays the overall 
clearance process. Macrophages were monitored for upto 12 hrs for their ability to 
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clear engulfed apoptotic debris in the presence and absence of NRP2. We 
observed that in absence of NRP2, the degradation and clearance of apoptotic 
cells was significantly delayed in the macrophages. This suggested that NRP2 
regulates the maturation of phagosomes containing apoptotic cells in 
macrophages.  Our earlier data suggested that depletion of NRP2 resulted in an 
accumulation of Rab5+ vesicles and a concomitant decrease in the number of 
Rab7+ positive vesicles in the cells. Although it is now accepted that the processes 
of endocytosis, phagocytosis and efferocytosis share similarities, each of these 
processes are distinct and may recruit unique effector molecules at each stage. 
Therefore, it is possible that NRP2 may interact with different effector molecule for 
efferosome maturation and apoptotic cell clearance. Further studies are required 
to investigate the molecular players that interact with NRP2 in apoptotic cell 
clearance process. Another important question is whether efferosome maturation 
and autophagy share a common mechanism. Recently, LC3 associated 
phagocytosis (LAP) has been proposed as an alternative pathway for clearance of 
apoptotic cells. We have previously reported a role for NRP2 in regulating 
autophagy in cancer cells. Whether NRP2 regulates efferocytosis through LAP 
needs further studies. Also, it is important to know if LC3 overlaps with Rab5 or 
Rab7 in phagosomes containing apoptotic cells and interact with each other in the 
presence and absence of NRP2.  
It is important to estimate the implications of our findings. Efficient 
efferocytosis and clearance of engulfed apoptotic cells are indispensable for the 
maintenance of cellular homeostasis. As mentioned earlier, defective efferocytosis 
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gives rise to pathological conditions like autoimmunity, systemic lupus 
erythematosus (SLE), atherosclerosis among others. Interestingly, delayed 
phagosome maturation arising either as a consequence of impaired fusion with 
lysosome or failure in the acquisition of degradative enzymes helps preserve 
antigenic epitopes and favors cross presentation. Since we observed that NRP2 
depletion significantly delays apoptotic cell clearance, it is plausible that its 
depletion or deficiency will increase the chance for cross presenting the apoptotic 
cell derived peptide and activate CD8+ T cell responses and aggravate 
inflammation related clinical disorders.  
Phagocytosis of cancer cells by APCs in the TME is a contentious topic. 
Cancer cells over-express ‘don’t eat me’ molecules to evade APC mediated uptake 
and presentation to the T cells. Additionally, TAMs have recently been shown to 
express PD-1 that negatively correlates with their phagocytic capacity of tumor 
cells. Further, blocking of interaction between PD-1 and PD-L1 increased 
phagocytosis and reduced tumor growth in a macrophage dependent manner. 
However, TAM mediated phagocytosis of tumor cells can act as a double-edged 
sword in tumor progression and metastasis. Most of the patients undergoing 
treatment for cancer, including Pancreatic Cancer receive either chemotherapy 
(CT) (such as Gemcitabine) or radiotherapy (RT). These conventional treatment 
modalities interact in a complex way with the dense stroma that is the hallmark 
feature of PC and can be detrimental. There are now evidences to show that there 
is increased infiltration of myeloid cells in to the TME following CT or RT that limits 
the anti-neoplastic efficacy and are associated with tumor protective function and 
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disease recurrence with more aggressive features. This can be attributed to 
increased apoptotic index in the TME following therapy and increased efferocytosis 
by the freshly recruited TAMs. This triggers anti-inflammatory cascades and elicit 
a misdirected tissue repair response, eventually resulting in further 
immunosuppression and tumor relapse. Blocking efferocytosis holds promise by 
increasing anti-tumor immune response. For example, Bavituximab, a PS targeting 
antibody is currently being assessed in multiple clinical trials and has shown 
considerable benefit (https://clinicaltrials.gov/ct2/show/NCT03139916)( 
http://www.peregrineinc.com/clinical-trials.html) (240, 257). We previously 
observed a role for NRP2 in regulating efferocytosis of apoptotic cells. Previous 
studies have briefly reported the presence of NRP2 expressing macrophages in 
lung carcinoma (human) and mouse tumor. In the current study, we detected 
NRP2 expressing TAMs in primary lesions of PDAC patients as well as in mouse 
PC tissue. We further observed that treatment of macrophages with conditioned 
media from human and mouse PC cell lines exhibited phagosomal maturation 
defect when challenged with E.coli in absence of NRP2, indicating a requirement 
for NRP2 in phagocytosis in TAMs.  Next, in our assessment of the ability of TAMs 
to efficiently clear apoptotic debris in presence and absence of NRP2, we observed 
that in comparison to the WT TAMs, NRP2 depleted macrophages failed to 
completely degrade and clear apoptotic cells even after 12 hrs. Interestingly, the 
effect was more robust in the presence of tumor cell derived conditioned media 
compared to MCSF treatment. Of note, we did not notice any uptake defect in 
NRP2 deficient TAMs. These results indicated that NRP2 is important for 
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phagosome maturation in TAMs and regulates the clearance of apoptotic cells by 
TAMs.  
       To test how delayed clearance of apoptotic tumor cells may affect PC growth, 
we used a subcutaneous tumor progression model. Genetic ablation of NRP2 in 
TAMs reduced tumor growth. However, we did not notice any changes in 
intratumoral macrophages following NRP2 depletion, indicating NRP2 is 
dispensable for TAM recruitment. Interestingly, when we implanted 2X106 cells, 
we observed a significant increase in the percentage of necrotic area in tumors 
where NRP2 was depleted in TAMs. This could be attributed to a rapid growth of 
the tumor cells and high apoptotic index and impaired efferocytosis by NRP2 
depleted TAMs and secondary necrosis resulting from the dying tumor cells. 
Macrophages are the major source of intratumoral angiogenesis. However, NRP2 
depletion in TAMs did not significantly affect intratumoral angiogenesis. Also, we 
did not see any increase in CD8+ T cells infiltration in test tumors. We do not know 
if this was because the time period we monitored the tumor progression was not 
optimal for noticing a change in CD8+ T cell infiltration.  
        Interestingly, when we repeated the experiment using 500,000 cells and 
monitored tumor growth, we once again observed a decrease in tumor growth rate 
following NRP2 depletion in TAMs. More importantly, growth curve for test group 
reached a plateau after day 17, indicating a cytostatic effect of NRP2 deletion in 
macrophages. Hence, it is conceivable that NRP2 depletion in macrophages can 
potentially harness tumor growth. TUNEL staining revealed an increased number 
of necrotic foci in tumors following NRP2 depletion in macrophages. We believe 
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the increase in the number of necrotic foci resulted from inefficient clearance of 
apoptotic tumor cells and eventual secondary necrosis that led to leakage of 
nuclear and cellular contents. NRP2 depletion did not affect macrophage 
recruitment to the site of the tumor, hence we conclude that the increase in the 
necrotic area is a consequence of inefficient apoptotic cell clearance in the TME. 
It is known that accumulation of apoptotic cells that eventually result in leakage of 
cellular contents due to secondary necrosis can potentially activate CD8+ T cells. 
Indeed, NRP2 depletion in TAMs significantly increased the infiltration of cytotoxic 
CD8+ T cells in test tumors (~3 fold). Interestingly, we did not observe any change 
any intratumoral angiogenesis following NRP2 depletion in TAMs. Stromal 
desmoplasia is a hallmark feature of PC and it has been shown to act as a physical 
barrier to therapy efficacy. High α-SMA has been associated with worse prognosis 
in PC. Although we did not observe any notable change in the α-SMA in test 
tumors, one must note that the subcutaneous tumor microenvironment does not 
mimic that of the natural PDAC (as found in orthotopic tumors). Further, pericytes 
often express α-SMA that can interfere with the conclusion.  
We have concluded from our earlier experiments that NRP2 regulates the 
clearance of E.coli, zymosan and apoptotic cells by modulating the phagosome 
maturation process. Whole transcriptome sequencing of TAMs in conjunction with 
pathway analysis revealed an altered expression of several Rab family proteins. 
For instance, Rab15, Rab3a, Rab6B, Rab34, Rab39, RabL3, Rab36, Rab13, 
Rab27B were affected following NRP2 depletion in macrophages. Some of these 
like, Rab36, Rab13, Rab27B have potent roles in retrograde transport, recycling 
215 
 
or exocytosis pathways. Several other genes associated with phagocytosis or 
phagosome/endosome maturation like, Tubb4a, TubA8, Rufy4a, Zap70 were 
deregulated suggesting a phagosomal maturation defect. Proteins like Rufy have 
a C-terminal FYVE domain for interaction with PI3P on the early phagosomes or 
endosomes and can interact with GTP-bound Rab5 and hence maybe a potential 
candidate for regulating the recruitment of downstream effector molecules for 
phagosome maturation. Interestingly, we detected elevated expression of genes 
encoding Rab7 GTPase activating proteins, TBC domain 1 member 15 and TBC 
domain 1 member 2. Increased expression of these proteins can potentially 
inactivate GTP-bound Rab7 recruited to the phagosome membrane and interfere 
with phagosomal maturation. Several Guanine Nucleotide Exchange Factors, that 
may be involved in actin cytoskeleton reorganization, like Rho GEF 15, Cdc42 GEF 
9, FYVE Rho GEF, RhoD among others were also differentially expressed. These 
indicate that NRP2 is important for endocytosis and phagocytosis pathways in 
macrophages. Interestingly, several molecules like Elmo-3, Alox15, CD4, IgM, 
CD209 (DC-SIGN), OC-STAMP involved in either phagocytosis or clearance of 
apoptotic cells were downregulated, although Stabilin1, Marco, two of the 
molecules involved in binding and recognizing apoptotic cells, were upregulated. 
Downregulation of efferocytosis related receptors and molecules may be either a 
secondary effect of impairment of phagosome maturation following NRP2 
depletion. It has already been reported that a defect in phagosome maturation can 
dampen the internalization process, although we did not observe any 
internalization defect in NRP2 depleted macrophages in vitro. However, it may be 
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possible that downregulation of the efferocytosis related receptors may be a tumor 
microenvironment specific effect. Taken together, this supports our observations 
that NRP2 is important for the efficient clearance of apoptotic cells by 
macrophages by favoring phagosome maturation and also indicates that apoptotic 
tumor cells were inefficiently removed by NRP2 depleted TAMs owing to either 
dampened uptake (may arise as a secondary effect) or a defect in the downstream 
events of phagosome maturation. Intriguingly, phagosomes containing different 
cargo often recruit functionally similar but distinct molecules for phagosome 
maturation or phagolysosome biogenesis and often follow different maturation 
kinetics. Enrichment and identification of differential recruitment of proteins during 
maturation is best observed following isolation of phagosome membranes. It may 
be possible that NRP2 interacts with a common adapter molecule and regulates 
the recruitment of several effector molecules at various stages of phagosome 
maturation. The exact molecular mechanism how NRP2 regulates the phagosome 
maturation is currently unknown; the differentially expressed genes from our RNA-
Seq data does not readily indicate how NRP2 regulates phagosome maturation at 
the molecular level and merits further investigation.  
The hallmark feature of efferocytosis is that it is immunologically silent and 
induces the expression of immunosuppressive genes in macrophages. Blockade 
of efferocytosis or inefficient clearance of apoptotic cells removes that suppressive 
effect and activates the inflammatory pathway. Our RNA sequencing analysis 
identified suppression of several immunosuppressive genes, for example, IL-4, IL-
10, TGFα, CCL22 were downregulated whereas inflammatory genes like IFN-β1, 
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IL-12a, Gr-K, Gr-F were upregulated. Additionally, we observed some chemokines 
or chemokine receptors like CCL25 or CXCL13 that can potentially recruit cytotoxic 
CD8+ or effector CD4+ T cells were upregulated in NRP2 depleted condition. Also, 
increase in IFN-β1, Il-12a may act to activate T cell response. A lot of effort is 
currently being given to harness checkpoint inhibitor molecules like CTLA-4, PDL-
2, PDL-1, PDL-1 which interfere with T cell activation and help maintain a local 
environment of immunosuppression in the TME. Interestingly, PDL-2 was 
downregulated in TAMs following NRP2 depletion. Additionally, molecules that can 
either activate T cell death, like FasL or indirectly interfere with T cell activity by 
promoting immunosuppression in macrophages (like TIGIT, Foxp3) were also 
downregulated. However, some of the altered genes showed a mixed signature. It 
is important to remember that TAMs are a complex population and often show a 
mixed phenotype, highlighting their plasticity. Taken together, we conclude that 
NRP2 depletion affects a wide array of molecules associated with the immune 
response that act in consort and result in CD8+ T cell activation. It is important to 
remember that the time point selected for RNA-seq (15 days post tumor 
implantation) provides us a snapshot of the changes occurring in TAM during that 
time point. Many important changes in gene profile that may reflect further 
deregulation of efferocytosis and therefore activation of M1-type inflammatory 
pathways in TAMs may have either happened before or would take place at later 
time points.  
Tumors manipulate the immune system in multiple ways, eventually 
shaping it to promote tumor growth and metastasis. One of the key mechanisms 
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by which this is achieved is through suppression of effector and cytotoxic T cell 
recruitment to the tumor bed and their activation, and through recruitment of 
suppressor T cells. In summary, based on our current findings that NRP2 depletion 
in macrophages suppresses the immunosuppressive genes robustly increases 
CD8+ T cell infiltration, we propose NRP2 may be a potential candidate for 
therapeutic intervention in treating solid tumors, including PC. However, 
considering targeting NRP2 in TAMs to dampen efferocytosis and activate anti-
tumor immune response as a potential strategy for treating cancer, one must weigh 
the risks associated with necrotic cell death and leakage of necrotic cellular 
components, hyper activation of T cells, autoimmunity and tissue damage. For 
example, impaired efferocytosis of apoptotic cells in post-partum condition results 
in tissue scarring and inflammation and interferes with lactation ability. Also, 
inflammation resulting from blockade of NRP2 mediated efferocytosis may 
adversely promote tumor associated inflammation and aid in tumor progression. 
Therefore, it is important to identify the optimal therapeutic window for targeting 
efferocytosis in cancer.   
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Fig. 4.1 NRP2 is expressed by tumor infiltrating macrophages in pancreatic 
cancer. (A) Representative confocal image showing the presence of NRP2 
expressing TAM in human PDAC tissue. The first panel shows only NRP2 positive 
cells in the tumor section (red). The second panel shows CD68+ macrophages 
(green). The third panel represents merged image showing NRP2+CD68+ 
macrophage in the tumor tissue. Scale bar, 50µm. Inset shows magnified image 
of a single macrophage. Arrows indicate NRP2+CD68+ macrophage while * 
indicate NRP2 expressing non-macrophage type cells. Dapi was used to stain the 
nucleus. (B) Representative confocal image showing the presence of NRP2 
expressing F4/80+ macrophages in mouse pancreatic tumor. The first panel shows 
cells that stained positive for NRP2 (green). The second panel represents F4/80+ 
cells (red). The third panel represents merged image showing NRP2+F4/80+ 
macrophages in the tumor section. Scale bars, 20µm. Inset showing magnified 
image of an individual NRP2+ macrophage. Arrows indicate NRP2+F4/80+ cells 
while * indicate NRP2 expressing other cell types in the tumor section. 
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Fig. 4.2 Expression of NRP2 in human and mouse TAMs generated in vitro. 
(A-C) Immunoblot analyses showing NRP2 expression in TAMs generated in vitro. 
Freshly isolated human monocytes or bone marrow cells from WT mice were 
differentiated to TAMs with CM from Panc-1 (human) or UNKC-6141 or KPC cells 
(mouse) for 7days. Significant NRP2 expression was observed in both human and 
mouse TAMs generated in vitro.  
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Fig. 4.3 NRP2 regulates phagosome maturation in TAMs in vitro. Human 
macrophages treated with CM from Panc-1 cells were used for phagocytosis assay 
with pHrodo E.coli bioparticles. Phagosome maturation was scored from visible 
red puncta under the microscope. (A) Representative confocal microscopy image 
showing NRP2 depletion impaired phagosome maturation in Panc-1 CM treated 
macrophages. Inset shows magnified image of an individual cell. Scale bar, 10µm. 
(B) Phagosome maturation was quantified as total cellular fluorescence using 
Image J software and represented in a bar graph. (C) western blot showing NRP2 
depletion. (D,G) Mouse bone marrow derived macrophages treated with CM from 
UNKC-6141 or KPC cells were exposed to pHrodo E.coli bioparticles. Phagosome 
maturation was assessed from the intensity of visible red puncta under the 
microscope. Representative confocal microscopy image is shown. Inset shows 
magnified image of an individual cell. Scale bar, 20µm. (E,H) Phagosome 
maturation was quantified as total cellular fluorescence using Image J software 
and represented in a bar graph. All values as mean ± SEM. Dapi was used for 
staining the nucleus in all the experiments. Student t test was used for comparison 
between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. ns=not significant. 
(C,F, I) Western Blots for NRP2 depletion for each experiment is shown.  
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Fig. 4.4 NRP2 regulates efferocytosis of apoptotic cells in bone marrow 
derived macrophages. Efferocytosis assay to assess the effect of NRP2 
depletion on the ability of macrophages to mature the efferosomes and degrade 
the apoptotic cells. (A) A schematic diagram showing the experimental design. (B) 
Bone marrow cells isolated from NRP2fl/flCSF1R-iCre mice were cultured for 7days 
with M-CSF. Macrophages were then challenged with apoptotic Jurkat cells for 1hr 
(pulse). Non-engulfed or loosely adherent apoptotic cells were removed and 
macrophages were then microscopically assessed for their ability to degrade the 
apoptotic cell cargo for the chase time points= 0hr, 2hr, 6hr, 12hr. Scale bars, 
10µm. Magnified images within the insets show single cell containing apoptotic 
body at each indicated time point for the panels. (C) Intensity of cellular 
fluorescence (red) was analyzed using Image J software and used as a measure 
for the ability of the macrophages for efferosome maturation and to degrade the 
apoptotic cargo. Cells were analyzed at the time points indicated in the graph 
abscissa and results represented as bar graphs. Values are mean ± SEM. (D) 
Immunoblot to show knock out of NRP2 following addition of (Z)-4-Hydroxy 
Tamoxifen. Dapi was used for staining the nucleus in all experiments. Student t 
test was used for comparison between 2 groups of cells. *P < .05; **P < .005; ***P 
< .0005. ns=non-significant. 
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Fig. 4.5 NRP2 regulates efferocytosis of apoptotic cells in peritoneal 
macrophages. Efferocytosis assay to assess the effect of NRP2 depletion on the 
ability of macrophages to mature the efferosomes and degrade the apoptotic cells. 
(A) Peritoneal macrophages isolated from NRP2fl/flCSF1R-iCre mice were cultured 
for 3 days with M-CSF. Macrophages were then challenged with apoptotic Jurkat 
cells for 1hr (pulse). Non-engulfed or loosely adherent apoptotic cells were 
removed and macrophages were then microscopically assessed for their ability to 
degrade the apoptotic cell cargo for the chase time points= 0hr, 2hr, 6hr, 8hr. Scale 
bars, 10µm. Magnified images within the insets show single cell containing 
apoptotic body at each indicated time point for the panels. (B) Intensity of cellular 
fluorescence (red) was analyzed using Image J software and used as a measure 
for the ability of the macrophages for efferosome maturation and to degrade the 
apoptotic cargo. Cells were analyzed at the time points indicated in the graph 
abscissa and results represented as bar graphs. Values are mean ± SEM. (C) 
Immunoblot to show knock out of NRP2 in peritoneal macrophages following 
addition of (Z)-4-Hydroxy Tamoxifen. Dapi was used for staining the nucleus in all 
experiments. Student t test was used for comparison between 2 groups of cells. 
*P < .05; **P < .005; ***P < .0005. ns=non-significant. 
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Fig. 4.6 NRP2 regulates the clearance of apoptotic cells in TAMs in vitro. 
Efferocytosis assay to assess the effect of NRP2 depletion on the ability of TAMs 
to mature the efferosomes and degrade the apoptotic cells. (A) bone marrow cells 
isolated from NRP2fl/flCSF1R-iCre mice were cultured for 7 days with CM from 
UNKC-6141 cells. Macrophages were then challenged with apoptotic Jurkat cells 
for 1hr (pulse). Non-engulfed or loosely adherent apoptotic cells were removed 
and macrophages were then microscopically assessed for their ability to degrade 
the apoptotic cell cargo for the chase time points= 0hr, 2hr, 6hr, 12hr. Scale bars, 
10µm. Magnified images within the insets show single cell containing apoptotic 
body at each indicated time point for the panels. (B) Intensity of cellular 
fluorescence (red) was analyzed using Image J software and used as a measure 
for the ability of the macrophages for efferosome maturation and to degrade the 
apoptotic cargo. Cells were analyzed at the time points indicated in the graph 
abscissa and results represented as bar graphs. Values are mean ± SEM. (C) 
Immunoblot to show knock out of NRP2 following addition of (Z)-4-Hydroxy 
Tamoxifen. Dapi was used for staining the nucleus in all experiments. Student t 
test was used for comparison between 2 groups of cells. *P < .05; **P < .005; ***P 
< .0005. ns=non-significant. 
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Fig. 4.7 Scheme of subcutaneous tumor growth model. Schematic diagram for 
subcutaneous tumor growth model. UNKC-6141 cells were mixed with Matrigel 
and subcutaneously implanted into the right flank of NRP2fl/flCSF1R-iCre mice. 
Once the tumors became palpable, animals were randomly divided into control and 
test groups (n=5). The test animals received daily intraperitoneal injection of 
Tamoxifen (20mg/kg body weight) to knock out NRP2 from the macrophages. 
Tumor growth was monitored for time periods indicated in Fig. 4.8 and Fig. 4.9.  
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Fig. 4.8 NRP2 in macrophages affects tumor progression. (A) Representative 
image of the harvested tumors from the control and Tamoxifen treated mice, 
showing moderate decrease in the test group tumors following NRP2 depletion in 
macrophages. (B) Tumor growth was monitored regularly for the indicated time 
period and represented as a line graph. * indicates p=0.05. (C) Scatter plot 
comparing the volume of the control and test tumors after they were harvested. (D) 
Graphical representation of weight of harvested tumors. (E) Western Blot showing 
NRP2 was completely knocked out from the bone marrow macrophages following 
Tamoxifen injection into the test animals. (F) graph showing weight of animals 
before and at the end of the study.  
234 
 
Fig. 4.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
A B 
C D 
F E 
235 
 
Fig. 4.9 Depletion of NRP2 in macrophages increases the necrotic area in 
tumors. (A) Representative image H&E images from control and test tumors 
showing increase in necrotic area following NRP2 depletion in macrophages. (B) 
Necrotic areas were marked using Image J software and the areas calculated. 
Result represented as box plot. Values are mean ± SEM. * indicates p=0.05. 
236 
 
Fig. 4.9 
 
 
 
  
 
 
 
 
 
 
A 
B 
237 
 
Fig. 4.10 Effect of macrophage NRP2 depletion on TAM recruitment, 
angiogenesis and CD8+ T cell infiltration. (A) representative confocal image of 
F4/80+ macrophages (red) infiltrating control (top) and test tumors (bottom). The 
first column shows only F4/80+ staining. The second column shows DAPI staining 
of the tissue. The third column represents merged picture for F4/80+ cells in the 
tissue section. Images acquired at 20X magnification. Dapi was used for nuclear 
staining. Inset shows individual macrophage. (B) The number of F4/80+ 
macrophages per field were counted for 10 random fields using Image J software 
and represented as a box plot. (C) Representative images of 
immunohistochemistry showing CD8+ T cell infiltration (brown) in control and test 
tumors. Image scale, 20X magnification. (D) Number of CD8+ T cells per field was 
counted using Image J software, for 10 random fields and represented as a vertical 
scatter plot. (E) Representative immunohistochemistry image showing CD31+ 
vessels in control and test tumor. Image scale, 20X magnification. (F) Number of 
CD31+ vessels per field was counted (vessel density) using Image J software, for 
10 random fields and represented as a vertical scatter plot. All values are mean± 
SEM. Student t test was used for comparison between control and test. *P < .05; 
**P < .005; ***P < .0005. ns=non-significant. 
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Fig. 4.11 NRP2 in macrophages regulates tumor growth. 500,000 UNKC-6141 
cells were mixed with Matrigel and subcutaneously implanted into the right flank of 
NRP2fl/flCSF1R-iCre mice. Once the tumors became palpable, animals were 
randomly divided into control and test groups (n=5). The test animals received 
daily intraperitoneal injection of Tamoxifen (20mg/kg body weight) to knock out 
NRP2 from the macrophages. Tumor progression was monitored for 25days. (A) 
Representative image of the harvested tumors from the control and Tamoxifen 
treated mice, showing moderate decrease in the test group tumors following NRP2 
depletion in macrophages. (B) Tumor growth was monitored regularly for the 
indicated time period and represented as a line graph. * indicates p=0.05. (C) 
Scatter plot comparing the volume of the control and test tumors after they were 
harvested. (D) Graphical representation of weight of harvested tumors. (E) TUNEL 
staining showing increased number of apoptotic or necrotic cells in tumors 
following NRP2 depletion in myeloid cells. (F) Graphical representation of 
increased number of apoptotic or necrotic cells in tumors deficient in NRP2 in 
myeloid cells. (G) Western Blot showing NRP2 was completely deleted from 
macrophages following Tamoxifen administration. (H) graph showing NRP2 was 
knocked out from intratumoral TAMs following Tamoxifen administration. 
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Fig. 4.12. Effect of NRP2 depletion in macrophages on TAM recruitment, 
angiogenesis and α-SMA. (A) Representative confocal microscopy image 
showing NRP2 does not have any role in the migration of macrophages (F4/80+, 
red) to the tumor. The first column shows only F4/80 staining in red, in control 
(upper) and test (bottom) tissue. The second column represents only DAPI staining 
for nucleus in control (upper) and test (bottom) tissue. The third column shows 
merged images with F4/80 and DAPI staining, for both control (upper) and test 
(bottom) tumors. Scale bar, 20µm. Inset shows magnified image of a single F4/80+ 
macrophage. (B) the number of F4/80+ cells per field (for 10 random field, 20X 
magnification) were counted using Image J software and represented graphically 
in a scatter plot. (C) Representative immunohistochemistry image showing CD31+ 
vessels in the control and test tumors. (D) The number of CD31+ vessels per field 
were counted (20X magnification, 10 random fields) using Image J software and 
represented as average vessel density in a vertical scatter plot. (E) Representative 
image showing α-SMA in control and test tumors. (F) Graphical representation of 
the result. All values are represented as mean± SEM. Student t test was used to 
compare between the control and test tumors. ns= not significant. 
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Fig. 4.13 NRP2 depletion in macrophages affects T cell response in tumor. 
(A) Representative images of immunohistochemistry showing significantly higher 
CD8+ T cell infiltration in test tumors in comparison to control tumor. Image scale, 
20X magnification. (B) Number of CD8+ T cells per field was counted using Image 
J software, for 10 random fields and represented as a vertical scatter plot. (C) 
Representative image showing Granzyme B positive cells in tumor. (D) Graphical 
representation of relative numbers of Granzyme positive cells per field in control 
and test tumors. (E) Representative confocal microscopy image for CD4+ T cell 
infiltration (red) in the control and test tumors. Scale bar 20µm. Inset shows 
magnified image of individual CD4+ T cell. Dapi was used to stain the nucleus. (F) 
Number of CD4+ T cells per field was counted using Image J software and 
represented in a scatter plot. All values are mean± SEM. Student t test was used 
for comparison between control and test. *P < .05; **P < .005; ***P < .0005. 
ns=non-significant.  
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Fig. 4.14 Transcriptome analysis from CD11b+ cells by RNA-Sequencing 
analysis. (A) Schematic diagram showing the experimental design for the study. 
(B) Graphical representation of the volume of the harvested tumors. (C) Graphical 
representation of weight of excised tumors. (D) Pie chart showing number of genes 
(upregulated and downregulated) whose expression altered by atleast log2 fold 
change 1 following NRP2 depletion in macrophages.  
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Fig. 4.15 Analysis of differentially expressed genes using Ingenuity Pathway 
Analysis and DAVID functional annotation bioinformatics microarray 
analysis. (A) Representative canonical pathways enriched in IPA analysis. (B) 
Functional annotation clusters for the differentially expressed genes from DAVID 
database. (C) Representative functional annotation clusters related to immune 
response phagocytosis from DAVID database analyses.  
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Fig. 4.16. Representative genes for phagocytosis pathway (A) and immune 
response related functions (B) are shown. (C) Representative genes encoding 
wound healing and immunosuppressive molecules in macrophages, that were 
altered following NRP2 depletion.   
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5.1 Central theme of dissertation and approach 
The central theme of the dissertation is to identify the role of NRP2 in macrophages 
and how it affects the pro-tumorigenic activities of TAMs in PC. Others and we 
have shown NRP2 is expressed in macrophages and TAMs. However, the exact 
function of NRP2 in macrophages and the signaling pathways it governs is still 
elusive. To clearly understand the effect of NRP2 in macrophages, we have used 
siRNA approach in human monocyte derived macrophages as well as genetically 
depleted NRP2 in inducible manner in mouse macrophages in vitro as well as in 
vivo studies. We also tested the effect of NRP2 depletion in TAMs in tumor 
progression, using a subcutaneous PC model, to identify the role of NRP2 in tumor 
progression and identify novel treatment modality for PC.  
5.2 Current understanding 
In summary, data presented in this dissertation indicate that the expression of 
NRP2 in macrophages is essential for phagocytosis. We show that NRP2 
promotes the degradation and clearance of microbes (E.coli, zymosan) by 
promoting the maturation of early to late phagosomes. This was attributed to an 
increase in Rab5+ vesicles and a concomitant decrease in Rab7+ late 
endosomes/phagosomes in absence of NRP2. We further show that NRP2 is 
important for efferocytosis of apoptotic cells, a process although similar, but distinct 
from phagocytosis. The process of efficient cleaning up by macrophages is 
important for maintenance of physiological and immunological homeostasis, 
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however, it can also act as a double-edged sword in malignancies. Efferocytosis 
of dying tumor cells in the TME polarizes the macrophages towards an 
immunosuppressive phenotype and triggers non-inflammatory signaling cascades, 
such as, production of TGF-β, IL-10. This helps maintain an overall 
immunosuppressed environment in the TME by silencing effective T cell response, 
and creates a niche for tumor survival, growth and metastasis. Most of the patients 
undergoing treatment for cancer, including PC, receive either CT or RT as 
conventional treatment modalities. Intriguingly, these treatments result in 
increased recruitment of TAMs and trigger a TAM-mediated misdirected tissue 
repair response and immunosuppression by increasing efferocytosis of apoptotic 
tumor cells by TAMs. Pharmacological blockade of efferocytosis has been shown 
to reduce tumor burden by activating inflammatory responses in macrophages and 
activating T cell responses. We observed a slower tumor growth following 
depletion of NRP2 in macrophages. We attribute this to delayed clearance of dying 
tumor cells in the TME and subsequent activation of tumoricidal CD8+T cells in 
absence of NRP2 in TAMs. Thus, this study led to the identification of NRP2 in 
TAMs as a potential therapeutic strategy for treatment of PC and other cancers in 
the future.  
5.3 Future Directions 
There are a few open ends to this study that warrant further investigation. The next 
step for this work would be to understand the following: 
How NRP2 regulates phagosome maturation at the molecular level: We have 
previously shown that NRP2 regulates maturation of early to late phagosomes and 
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that in its absence there is an increase in the number of Rab5+ early 
endosomes/phagosomes and a concomitant decrease in the number of Rab7+ late 
endosomes/phagosomes. This indicated a defect in the switch from Rab5 to Rab5, 
a step that is essential for phagosomes (and endosome) maturation. Although 
details about phagosome maturation is currently limited, it is believed that first 
Dynamin is recruited to the phagosome membrane, which then interacts with 
Vps34 (a PI3 Kinase) and helps recruit Rab5 to the phagosome surface. Rab5, is 
activated by Gapex-5 (Rab5 GEF), and further promotes Vps34 activation. Vps34 
then generates PtdIns(3)P on the phagosome surface where the vacuolar fusion 
protein complex, Mon1A-Ccz1, is recruited. This complex recruits Rab7 and act as 
its effector. Rab7 next interacts with homotypic fusion and vacuole protein sorting 
(HOPS) complex to facilitate phagoslysosome generation. Since our data suggest 
NRP2 regulates the switch from Rab5 to Rab7, we hypothesize that NRP2 regulate 
the steps downstream of Rab5 recruitment, such as activation of Rab5, Vps34 or 
membrane recruitment of the Mon1a-Ccz1 complex. Additionally, differentially 
expressed genes from our RNA-Sequencing analyses revealed several molecules 
involved in either phagosome maturation, endocytic recycling, exocytosis were 
affected following NRP2 depletion. These need to be investigated to understand 
how NRP2 mechanistically regulate phagosome maturation.  
Does NRP2 activate LAP pathway for clearance of apoptotic cells: LC3 associated 
phagocytosis has recently been shown to be important for clearance of fungal 
particles as well as engulfed apoptotic cellular debris in macrophages. We have 
previously reported that NRP2 regulates autophagy in cancer cells. Whether NRP2 
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promotes clearance of dead cells through activation of LAP pathway needs further 
investigation.  
Does delayed phagosome maturation or efferocytic clearance in absence of NRP2 
promote cross presentation: Our results indicated that NRP2 promotes the 
maturation of phagosomes. In NRP2 depleted conditions, phagosome maturation 
is delayed which subsequently results in significantly delayed clearance of 
phagocytosed cargo (E.coli, zymosan, apoptotic cells). It is now well understood 
that delayed phagosome maturation helps preserve antigenic peptides against 
degradative enzymes in the phagolysosome and favors antigen loading to the 
MHC complexes and subsequent presentation to the T cells. This is of particular 
importance in case of solid tumors where following NRP2 depletion in 
macrophages, we observed a robust infiltration of cytotoxic CD8+ T cells. It is 
plausible that delayed phagosome maturation in NRP2 depleted TAMs augmented 
cross presentation of tumor cell derived antigens to the CD8+ T cells. This needs 
to be tested in more details in the future. 
Effect of NRP2 on PDAC metastasis: Previous studies have shown efferocytosis 
increases the risk for metastasis in a model of post-partum breast cancer (ppBC) 
by 10-fold. Pharmacologically blocking efferocytosis significantly reduced the 
metastasis in ppBC as well as therapy induced metastasis in tumor bearing 
animals. Since our current findings suggest a role for NRP2 in efferocytosis, and 
also it can affect tumor growth, the next step for the study would be to identify the 
role of NRP2 in TAMs on metastasis in PDAC. One of the limitations of the 
subcutaneous tumor progression model used in the current study is that it does 
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not mimic the natural PDAC TME. Orthotopically implanted tumors closely 
resemble the natural pattern of human PDAC development and progression. To 
test if blocking NRP2 mediated efferocytosis affects distant metastasis, we will 
orthotopically implant GFP- expressing UNKC-6141 clone into CSF1R-
iCre;NRP2f/f mice. UNKC-6141 cells have previously been shown to develop 
metastatic lesions in the liver, spleen, small intestines and mesenteric lymph nodes 
within 1 month of implantation. We have observed in our mouse model, that tumors 
are established within 6-7 days of implantation. Once the tumors are established, 
NRP2 will be genetically knocked out from macrophages by daily intraperitoneal 
injection of Tamoxifen (75mg/kg body weight). Tumors will be allowed to grow for 
1 month and then excised; spleen, liver, intestine and lungs will be harvested for 
metastatic foci. Metastasis was assessed by monitored by in vivo optical imaging 
for GFP expression using a Xenogen-IVIS cooled CCD optical system.  
It is important to note that blockade of efferocytosis may increase inflammation that 
may potentially augment tumor progression and metastasis. Therefore, it is 
extremely important to optimize at what stage of the tumor NRP2 may be targeted 
for therapeutic efficacy. 
Correlation between NRP2 expression in TAMs and PDAC stage:  
In the current study, we tested a small cohort of patients (obtained from UNMC 
Pancreatic Cancer Rapid Autopsy Program), who died of PDAC with no prior 
history of treatment. We observed a high infiltration of NRP2 expressing 
macrophages in almost all of the tissues. Treatment with either radiation, 
chemotherapy or any other adjuvant therapy is known to modify the tissue 
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architecture and results in recruitment of myeloid cells to orchestrate tissue repair 
in response to therapy induced damage. Further, following any type of therapy, 
apoptotic index in the TME is high and the freshly recruited macrophages efficiently 
remove the dead tumor cells. This process has been reported to give rise to further 
immune suppression in post-partum breast cancer. Based on our current data that 
NRP2 regulates efferocytosis by macrophages as well as TAMs, and that it can 
regulate T cell responses, it will be interesting to see if there is any correlation 
between NRP2 expression in macrophages or their relative numbers in the TME 
with different stage of PDAC, metastasis or overall survival post therapy.  
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